The role of miRNAs in resistance to HER2 targeted therapies by Howe, Karen
1 
 
The role of miRNAs in resistance to 
HER2 targeted therapies 
 
 
A thesis submitted for the degree of PhD 
by Karen Howe, B.A 
September 2015 
 
 
The work in this thesis was carried out under the supervision of 
Dr. Norma O’Donovan 
School of Biotechnology 
Dublin City University 
& 
Prof. John Crown 
St. Vincent's University Hospital 
2 
 
I hereby certify that this material, which I now submit for assessment on the programme 
of study leading to the award of PhD is entirely my own work, that I have exercised 
reasonable care to ensure that the work is original, and does not to the best of my 
knowledge breach any law of copyright, and has not been taken from the work of others 
save and to the extent that such work has been cited and acknowledged within the text 
of my work. 
 
Signed:   
 
(Candidate) ID No.: 10113681 
 
Date: 02
nd
 September 2015 
 
 
 
 
 
  
3 
 
Table of Contents 
Acknowledgements ..........................................................................................................8 
Abbreviations ..................................................................................................................10 
Communications arising from this work.........................................................................13 
Abstract ...........................................................................................................................14 
Chapter One .................................................................................................................. 15 
Introduction ................................................................................................................... 15 
1.1. Introduction ....................................................................................................... 16 
1.2. Diagnosis of breast cancer ................................................................................ 18 
1.3. Classification of breast cancer .......................................................................... 18 
1.4. Breast cancer treatment strategies ..................................................................... 23 
 1.4.1.Conventional therapies............................................................................. 23 
 1.4.2.Targeted therapies .................................................................................... 24 
1.5. HER2 positive breast cancer ............................................................................. 25 
1.6. Current treatments for HER2 positive breast cancer ........................................ 31 
      1.6.1  Trastuzumab- monoclonal antibody ................................................................ 32 
             1.6.1.1      Discovery and development of trastuzumab ...................................... 32 
             1.6.1.2    Drug structure ...................................................................................... 34 
             1.6.1.3    Mechanism of Action .......................................................................... 34 
             1.6.1.4    Mechanisms of Resistance .................................................................. 40 
             1.6.1.5    Biomarkers of trastuzumab resistance ................................................. 42 
      1.6.2   Lapatinib- Tyrosine Kinase Inhibitor ............................................................. 42 
             1.6.2.1    Development and Discovery of Lapatinib ........................................... 42 
             1.6.2.2   Drug Structure ...................................................................................... 43 
             1.6.2.3    Mechanism of Action........................................................................... 44 
             1.6.2.4    Lapatinib and trastuzumab .................................................................. 46 
             1.6.2.5    Mechanisms of Resistance .................................................................. 48 
1.7. microRNAs ....................................................................................................... 49 
        1.7.1 Introduction ................................................................................................... 49 
        1.7.2 miRNA biogenesis ........................................................................................ 50 
        1.7.3 miRNA function ........................................................................................... 51 
        1.7.4 Roles of miRNA ........................................................................................... 54 
4 
 
        1.7.5 miRNAs and HER2 positive breast cancer ................................................... 55 
        1.7.6 miRNAs  and trastuzumab resistance ........................................................... 56 
        1.7.7 microRNAs and Lapatinib resistance ........................................................... 58 
1.8. Circulating miRNAs ......................................................................................... 59 
1.9. Cancer stem cells (CSCs).................................................................................. 61 
1.10. Study Aims........................................................................................................ 63 
Chapter Two .................................................................................................................. 64 
Materials & Methods .................................................................................................... 64 
2.1. Cell lines, cell culture and reagents .................................................................. 65 
2.2. Proliferation assays ........................................................................................... 67 
2.3. microRNA extraction ........................................................................................ 67 
2.4. Agarose gels ...................................................................................................... 68 
2.5. TLDA data analysis .......................................................................................... 68 
2.6. miRNA reverse transcriptase reaction (RT-PCR) ............................................. 70 
2.7. Gene expression reverse transcriptase reactions ............................................... 71 
2.8. Real time quantitative reverse transcription polymerase chain reaction (qRT-
PCR) ...........................................................................................................................72 
2.9. MiRWalk- Target prediction & validation ....................................................... 74 
2.10. Lentiviral stable transduction ............................................................................ 75 
2.11. Wound scratch migration assay ........................................................................ 76 
2.12. Doubling time assays ........................................................................................ 76 
2.13. Preparation of cell lysates ................................................................................. 77 
2.14. Western blotting ................................................................................................ 77 
2.15. miRNA extraction from conditioned media ..................................................... 80 
2.16. miRCURY RNA isolation kit- Biofluids .......................................................... 80 
2.17. ALDEFLOUR assay ......................................................................................... 81 
2.18. Establishment of primary mammosphere assays from cell lines ...................... 82 
2.19. Assessment of self-renewal – secondary mammosphere generation ................ 84 
2.20. Preparation of cell culture blocks as block donors ........................................... 85 
2.21. Sectioning and coring of cell culture donor blocks .......................................... 86 
2.22. De-paraffinisation and H & E staining of sections ........................................... 86 
2.23. HER2 Immunohistochemistry .......................................................................... 87 
2.24. Formalin Fixed Paraffin Embedded (FFPE) - miRNA extraction .................... 89 
5 
 
2.25. RNA evaluation ................................................................................................ 90 
2.26. qRT-PCR analysis ............................................................................................. 91 
2.27. Patient population ............................................................................................. 91 
2.28. Statistical analysis ............................................................................................. 91 
Chapter Three ............................................................................................................... 92 
Characterisation of acquired trastuzumab and lapatinib resistant cell lines .......... 92 
3.1. Introduction ....................................................................................................... 93 
3.2. Sensitivities of SKBR3-P and SKBR3-T cells to trastuzumab and lapatinib ... 93 
3.3. Doubling times .................................................................................................. 96 
3.4. Migratory properties of the acquired resistant cell lines ................................... 97 
3.5. Sensitivity of BT474-Tr acquired trastuzumab resistance cell line model ....... 99 
3.6. HCC-1954-L acquired lapatinib resistance cell line model ............................ 100 
3.7. Microarray data analysis of the SKBR3-T and SKBR3-L cell lines .............. 102 
3.8. ALDEFLUOR analysis of SKBR3-P & SKBR3-L cell lines ......................... 104 
3.9. Summary ......................................................................................................... 107 
Chapter Four ............................................................................................................... 109 
miRNA expression in trastuzumab and lapatinib resistant cell lines .................... 109 
4.1. Introduction ..................................................................................................... 110 
4.2. miRNA expression analysis (Taqman Low Density arrays)........................... 110 
4.3. RNA extraction ............................................................................................... 112 
4.4. qRT-PCR validation of miRNA targets in trastuzumab and lapatinib resistant 
cells .........................................................................................................................113 
4.5. Validation of miRNA targets in the BT474-Tr acquired trastuzumab resistance 
cell line model ............................................................................................................... 116 
4.6. Validation of miRNA targets in the HCC-1954-L acquired lapatinib resistance 
cell line model ............................................................................................................... 116 
4.7. Analysis of miRNA targets in a cell line panel of innate trastuzumab and 
lapatinib resistance ........................................................................................................ 117 
4.8. Short-term trastuzumab treatment of SKBR3-P cell line ............................... 119 
4.9. Target prediction for microRNAs ................................................................... 121 
4.10. Summary ......................................................................................................... 125 
Chapter Five ................................................................................................................ 128 
miR-9 and retinoic acid receptors in trastuzumab and lapatinib resistant cells... 128 
5.1 Introduction ..................................................................................................... 129 
6 
 
5.2 Identification of potential miR-9 targets ......................................................... 129 
5.3 All-trans retinoic acid (ATRA) treatment ...................................................... 130 
    5.2.1    SKBR3-P, SKBR3-T and SKBR3-L cell lines .................................... 130 
  5.2.2    Other cell line models –BT-474, HCC-1954 and EFM-192A............. 132 
5.4 All-trans retinoic acid (ATRA) and trastuzumab combination treatment ...... 134 
 5.4.1   SKBR3-P, SKBR3-T and SKBR3-L ................................................... 134 
 5.4.2    Other cell line models –BT-474, HCC-1954 and EFM-192A............. 136 
5.5 All-trans retinoic acid (ATRA) treatment - Lapatinib combinations ............. 138 
 5.5.1     SKBR3, SKBR3-T and SKBR3-L cell lines ...................................... 138 
 5.5.2     Other cell line models –BT-474, HCC-1954 and EFM-192A ............ 140 
5.6 RARα expression analysis .............................................................................. 143 
 5.6.1    RARα mRNA expression .................................................................... 143 
 5.6.2   RARα protein expression ..................................................................... 144 
5.7 RARβ, RARγ and RxRα protein expression ................................................... 145 
5.8 24 hour ATRA treatment and the effect on the retinoic acid receptors .......... 150 
5.9 Summary ......................................................................................................... 153 
Chapter Six .................................................................................................................. 155 
The role of miR-221 & -222 in resistance, migration and ‘stemness’ .................... 155 
6.1 Introduction ..................................................................................................... 156 
6.2 Characterisation of the stable transfected SKBR3-P cell line ........................ 156 
 6.2.1    Confirmation of transfection in the SKBR3-P cell line ....................... 156 
 6.2.2     Effect of miR-221 and -222 over-expression on morphology and    
doubling time ................................................................................................................ 158 
 6.2.3     Effect of miR-221 and -222 on trastuzumab sensitivity ..................... 160 
 6.2.4    Effect of miR-221 and -222 on migration........................................... 161 
6.3 Target Prediction for miR-221 and miR-222 .................................................. 165 
6.4 miR-221 and -222 and their involvement in stemness .................................... 168 
6.5 Summary ......................................................................................................... 171 
Chapter Seven ............................................................................................................. 173 
miRNA expression in HER2 positive breast tumours ............................................. 173 
7.1 Introduction ..................................................................................................... 174 
7.2 Assessment of FFPE miRNA extraction kits .................................................. 174 
 7.2.1    Cell culture donor block preparation ................................................... 174 
7 
 
 7.2.2    Comparison of miRNA extraction methods ........................................ 175 
7.3 Primary tumour miRNA analysis in a FFPE HER2 positive breast cancer 
cohort .........................................................................................................................181 
 7.3.1   Patient characteristics........................................................................... 182 
 7.3.2.  HER2 immunohistochemistry and miRNA extraction ........................ 183 
 7.3.3.   qRT-PCR analysis ............................................................................... 185 
7.4 Conditioned media study ................................................................................ 187 
 7.4.1   miRNA analysis from conditioned media............................................ 187 
7.5 miRNA analysis from serum samples............................................................. 191 
7.6 Summary ......................................................................................................... 194 
Chapter Eight .............................................................................................................. 196 
Discussion .....................................................................................................................196 
8.1. Introduction ..................................................................................................... 197 
8.2. Characterisation of acquired trastuzumab and lapatinib resistant cell lines ... 198 
8.3. microRNA expression analysis ....................................................................... 202 
 8.3.1.   Cell line analysis ................................................................................. 202 
 8.3.2.   Comparison of FFPE miRNA extraction kits ..................................... 205 
 8.3.3.    miRNA analysis in the HER2 positive FFPE tumour samples .......... 207 
 8.3.4.   miRNA analysis in conditioned media ............................................... 209 
 8.3.5.   miRNA analysis in patient sera........................................................... 210 
8.4. Evidence of miRNA value in resistance ......................................................... 211 
8.5. Target prediction for miRNAs ........................................................................ 214 
 8.5.1    miR-9 and Retinoic acid receptor alpha.............................................. 215 
 8.5.2    ATRA response, estrogen receptor status and RARα amplification ... 219 
 8.5.3     miR-221 and -222 expression ............................................................. 221 
 8.5.4    miR-221 and -222 expression and ‘stemness’ .................................... 225 
8.6. Summary and conclusions .............................................................................. 228 
Chapter Nine ............................................................................................................... 229 
Bibliography.................................................................................................................227 
 
 
8 
 
Acknowledgments 
Firstly, I wish to offer my utmost thanks to my supervisor, Dr. Norma O’Donovan. 
Without her support and guidance over the course of my PhD this body of work 
wouldn’t exist. I have learned invaluable lessons not only in a professional capacity but 
in a personal one. To Prof. John Crown, I wish to thank you for the opportunity of this 
PhD, for the CCRT funding towards the end and for the insight in to clinical world of 
oncology. 
 
Secondly, I wish to thank the members of Dr. O’ Donovan laboratory. From post-docs 
to research assistants, their help, advice and numerous puns certainly made the years 
pass with a smile. 
 
A huge thanks to my NICB family, you know who ye are. A special mention to a few 
special people; 
 To Alex and Denis who taught me so much in the start and were always 
approachable for any advice or laughs. 
 To Laura and Joanne, who passed on their tricks of the trades and reminded me 
to keep my head up in tough times.  
 To Naomi, who became our stand in supervisor and dealt with all the craziness 
of the O’Donovan lab. 
 To the coffee gang. Every morning was made easier to get to work with the 
knowledge there would be brekkie, tea and laughs. 
 To Sandra and Erica, the two wisest and craziest postdocs that kept the mood 
light through the long nights and sad science times. To the numerous jaeger-
bombs and kebabs along the way it was a pleasure to become long lasting 
friends with both of you.  
 To Deirdre and Trish. I am so honoured to have met such fabulous friends. 
During the PhD, there were certainly tough times for us all and together I think 
we got through it. This degree is a test of endurance and sanity and without such 
great friends I do not think it would have been possible. Thank you for all the 
Geordie shore nights, the vintage soirees and epic amounts of laughter. 
9 
 
To my “outside PhD” mates, Karl, Robbie and Emma. Thank you for understanding that 
the PhD takes away from drinking times but also I sometimes needed to get away from 
it all and have fun.  
 
This work would never have finished had it not been for Darren. I wish to thank him 
from the bottom of my heart for his wisdom as a scientist and for being my partner in 
crime. You helped me from start to finish. The last year of the PhD was extremely 
trying and difficult especially when we had an ocean between us but thank you for 
giving me advice and calming me down through the weepy skype calls. Thank you for 
always trying, maybe not always succeeding in cheering me up even when I couldn’t 
see the light at the end of the tunnel. Thank you for sticking by me until the end. 
 
On a very personal note, a thank you cannot cover the gratefulness and appreciation for 
my family over the last four years. To my dear parents, thank you for always supporting 
me in my choice to remain a student that little bit longer. For all the personal and 
monetary support throughout this journey and for being there when I just needed a hug. 
We have certainly had it hard throughout the last few years and there have been ups and 
downs but we managed to survive and come out the other end.  
 
To my dearest and only sister, we are certainly cut from different cloths but I wouldn’t 
change you for the world. Thank you for doing my minion work during the summers, 
for cooking for me when I was a hangry bear and for letting my nest on your floor in the 
final few weeks of this PhD. I can only hope I can give you the same support, perhaps 
not floor space, in your PhD.  
 
To my second Mammy, Jella, who has been my one of my biggest supporters 
throughout my life. Without your love and guidance along with my parents I wouldn’t 
be the person I am today. 
 
10 
 
Abbreviations 
5FU fluorouracil  
5-HT 5-hydroxytryptamine 
ADCC antibody dependent cell cytoxicity 
Ago argonaute family protein  
AI aromatase inhibitor 
AIF apoptosis inducing factor  
AKT protein kinase B 
ALDH1 aldehyde dehydrogenase 1 
AMPK 5' AMP-activated protein kinase 
ATG5  autophagy related protein 5 
ATG8 autophagy related protein 8 
ATRA All-trans retinoic acid 
BAAA BODIPY-aminoacetaldehyde  
BCA bicinchoninic acid 
BID BH3 interacting-domain death agonist 
BIM Bcl-2 interacting mediator of cell death 
BRCA1 breast cancer 1, early onset 
BRCA2 breast cancer 2, early onset 
BTC β-cellulin 
CCDB Cell culture donor blocks 
CD49f integrin subunit α6 
CDK cyclin dependent kinase  
CDKN1A/p21
Cip1
 Cyclin-dependent kinase inhibitor 1A  
CDKN1B /p27 
kip1 
 Cyclin-dependent kinase inhibitor 1B 
CDKs cyclin dependent kinases  
CHO Chinese hamster ovary 
CISH chromogenic in situ hybridisation 
CmiRNA Circulating miRNAs 
CML chronic myelogenous leukemia 
CNS central nervous system 
COX2 cyclooxygenase-2 
CT computerised tomography 
DAG diacylglycerol 
DCM dilated cardiomyopathy 
DDFS distant disease free survival  
DEAB Diethylaminobenzaldehyde 
DFS disease free survival 
ECD Extracellular domain 
EGF epidermal growth factor (EGF 
EMT epithelial-to-mesenchymal transition 
EpCAM epithelial cell adhesion molecule  
ER α estrogen receptor α  
11 
 
  
EREG Epiregulin 
ERK 1/2 extracellular signal-related kinase 1/2 
ESA epithelial surface antigen  
FAK focal adhesion kinase 
FBS Fetal bovine serum 
FDA Us Food & Drug Administration 
FISH fluorescent in situ hybridisation 
GADPH glyceraldehyde-3-phosphoate dehydrogenase 
G-CSF granulocyte-colony stimulating factor 
GFP green fluorescent protein 
GRB2 growth factor receptor bound protein 2 
GRB7 Growth factor receptor bound protein 7  
HB-EGF heparin-binding EGF-like growth factor 
HER2 human epidermal growth factor 2 
HGF hepatocyte growth factor  
HR Hormone receptor 
HSP90 heat shock protein 90  
IAP inhibitor of apoptosis  
IBC inflammatory breast cancer 
IGF insulin-like growth factor  
IGF-1R insulin-like growth factor 1 receptor 
IGFBP2 insulin-like growth factor binding protein 2  
IL-8 interleukin-8  
IP3 inositol triphosphate  
MAPK mitogen activated protein kinase 
MBC metastatic breast cancer 
MCL-1 myeloid cell leukemia 1 
MEK MAPK kinase 
MFE mammosphere formation efficiency  
miRNP miRNA-containing ribonucleo-protein particle  
MREs miRNA-Recognition Elements 
mTOR mammalian target of rapamycin  
mTORC1 mammalian target of rapamycin complex 1  
MUC4 membrane associated glycoprotein  
NK cells natural killer cells 
NmU neuromedin 
NPC nasopharyngeal carcinoma 
NPM1 nucleophosmin 1 
NRG neuregulin 
NSCLC non-small cell lung cancer 
ORR overall response rate 
OS overall survival 
p4E-BP1 phosphorylated 4E binding protein  
PARP Poly (ADP-ribose) polymerase 
PBS Phosphate buffered saline 
12 
 
PCD4 protein programmed cell death 4 
pCR pathological complete response 
pCSCs putative cancer stem cells 
PFGF platelet-derived growth factor receptor 
PFS progression free survival  
PI3K phosphatidylinositol-3 kinase 
PKC protein kinase C 
PLCγ phosphodiesterase phospholipase Cγ 
PPM1H protein phosphatase, Mg2+/Mn2+ dependent, 1H  
PR progesterone receptor 
PTEN  phosphatase and tensin homolog deleted on chromosome 10 
qRT-PCR quantitative real time polymerase chain reaction 
RAR α, β, γ Retinoic acid receptor alpha, beta, gamma 
Rb Retinoblastoma 
RISC RNA induced silencing complex  
RNApol II RNA polymerase II 
RTK Receptor tyrosine kinase 
RxR α, β, γ Retinoid X Receptor alpha, beta, gamma 
SDS sequence detection systems 
snoRNAs small nucleolar non-coding RNA  
SOCS1 suppressor of cytokine signalling 
SOS son of sevens 
T-DM1 ado-trastuzumab emtansine   
TGF1 transforming growth factor 1  
TGFα transforming growth factor alpha 
TKI tyrosine kinase inhibitor 
TLDA Taqman Low Density Array 
TNBC Triple negative breast cancer 
TRAF4 TNF-receptor associated factor 4  
TRAIL tumour necrosis factor-related apoptosis-inducing ligand 
TSC1/2 tuberous sclerosis complex 1/2 
TSP-1 thrombospondin  
UTR untranslated region  
VEGF vascular endothelial growth factor  
XIAP X-linked inhibitor of apoptosis 
 
 
 
 
 
 
13 
 
Communications arising from this work 
Book Chapter 
 Neil A. O’Brien, Alexandra Canonici, Karen Howe, Martina SJ McDermott, 
Denis M. Collins, Brigid C. Browne, John Crown and Norma O’Donovan. 
HER2 targeted therapies. eBook series Frontiers in Anticancer Drug 
Discovery.  
 
Published Abstracts 
 Poster - Altered expression of miRNAs in acquired trastuzumab resistance. 
AACR 2014, San Diego, CA 4
th
 – 9th April 2014. 
 Poster - miR-221 and -222 in acquired and innate trastuzumab resistant cell 
lines. IACR 2014, Galway, Ireland. Feb 2014. 
 Oral Presentation- miR-221 and -222; Do they play a role in trastuzumab 
resistance? School of Biotechnology Research Day, DCU. 7
th
 Feb 2014 
 Oral Presentation – microRNAs in trastuzumab and lapatinib resistant breast 
cancer cells. 1
st
 Dublin microRNA Day, May 2013 
 Poster- microRNA- 224, - 375 and -9 in trastuzumab and lapatinib acquired 
resistant HER2 positive breast cancer cells. 24th EORTC-NCI-AACR 
Symposium on ‘Molecular Targets and Cancer Therapeutics’, Dublin 6-9 Nov 
2012 
 Poster - microRNA expression analysis in trastuzumab and lapatinib resistant 
HER2 positive breast cancer cells. Biotechnology in Action 2012, 4-6 
September 2012. The Helix, Dublin City University. 
 Poster Discussion - microRNA-9 and -224 in trastuzumab resistant HER2 
positive breast cancer cells.  ESMO Congress, Vienna, Austria 28
th
 Sep – 2nd  
October 2012 
 Poster - microRNA expression analysis in trastuzumab resistant HER2 positive 
breast cancer cells. 2012 IACR annual meeting, Belfast, Ireland, 1-2 March 
2012 
Awards 
 EACR Travel Fellowship May 2014 
 Roche Researcher of the Year Feb 2014 
 NCI Molecular Prevention Course (Health Research Board (HRB)) Aug 2013 
14 
 
Abstract 
The role of miRNAs in resistance to HER2 targeted therapies 
Karen Howe 
 
Trastuzumab, a monoclonal antibody, and lapatinib, a tyrosine kinase inhibitor are 
approved treatments for HER2 positive breast cancer; however, patients that initially 
respond frequently develop resistance. The aims of this study were to investigate 
microRNA expression in acquired and/or innate trastuzumab and lapatinib resistant cell 
lines, and in a cohort of HER2 positive breast cancer patients. 
 
Four miRNAs were identified as altered in the acquired trastuzumab resistant cell lines;. 
miR-221, -222, -224 and -9. miR-221 and -224 are also involved in innate trastuzumab 
resistance. miR-221, -224, -30e-3p, -550, -92a and -9 are altered in acquired lapatinib 
resistant cells lines and miR-221 is associated with innate lapatinib resistance. These 
microRNAs are potential predictive biomarkers of innate and/or acquired resistance to 
HER2 targeted therapies. 
 
All-trans retinoic acid (ATRA) treatment alone or in combination with trastuzumab or 
lapatinib may overcome resistance in some HER2 positive breast tumours. Co-
amplification of retinoic acid receptor alpha (RARα) with HER2 may be a potential 
biomarker to predict benefit from combined ATRA and HER2 targeted therapies. 
 
Over-expression of miR-221 and -222 in the SKBR3-P cell line does not confer 
resistance to trastuzumab. However, they increase the migratory potential of the 
SKBR3-P cell line. We identified miR-221, -222 and -9 expression is higher and miR-
224 is lower in patients who did not achieve a durable complete response (non-DCR) 
compared to the DCR cohort. This miRNA profile may be predictive for acquired 
trastuzumab resistance.  
 
This is the first report of the involvement of miR-222, -224 and miR-9 in innate and 
acquired trastuzumab and/or lapatinib resistance in HER2 positive breast cancer. These 
miRNAs represent potential biomarkers of resistance and ATRA treatment may be a 
potential therapeutic strategy to overcome resistance, in some cases.  
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1.1. Introduction  
Cancer is the abnormal growth of cells caused by multiple changes in gene expression 
leading to a dysregulated balance of cell proliferation and cell death ultimately evolving 
into a population of cells that can invade and metastasise to distant sites causing 
significant morbidity and, if untreated, death of the patient [1]. Breast cancer is cancer 
of the breast tissue and generally affects the ducts and lobules and can spread to distant 
sites via the lymph system (Figure 1-1) [2].  
 
 
 
 
 
 
 
 
 
Figure 1-1: Overview of the anatomy of the breast [2]. 
 
Cancer is the second leading cause of death in Ireland. Breast cancer is the most 
prevalent form of invasive cancer, (excluding non-melanoma skin cancer) (2010-2012) 
as shown in Figure 1-2. The average incidence rate of female breast cancer is 122.7 
women per 100,000 cases of breast cancer [3]. However, regular screening campaigns 
have increased the total number of reported cases since 2000. This and advances in 
treatment have led to improved prognosis and improved survival rates (>80% net 
survival). 
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Figure 1-2: Relative frequency of the main invasive cancers diagnosed during 2010-
2012 in females, in Ireland [3]. 
 
The causes of most cancers are unknown but there are some clues as to who may be at a 
higher risk of developing breast cancer. According to the Mayo Clinic risk factors 
include; age, being female, previous personal or family history of breast cancer, obesity, 
women who have never been pregnant or women who have undergone postmenopausal 
hormone therapies and UV radiation to name but a few. Family history and genomic 
changes are the strongest determinants of risk [4]. History of breast cancer in a person’s 
family and mutations in genes known to be involved in cancer e.g. p53 and in breast 
cancer susceptibility genes breast cancer 1 and 2, early onset gene (BRCA1 and 
BRCA2) are often linked with the development of breast cancer [5].  
18 
 
1.2. Diagnosis of breast cancer 
 Initial identification of breast cancer can vary in each case with symptoms ranging from 
detection of lump(s), changes in the skin, nipple and size and shape of breast, unusual 
swelling and any pain in the general area [6]. Once recognised, further testing is carried 
out including a physical examination, imaging tests including x-rays and Computerized 
tomography (CT) scans, blood tests, biopsies, immunohistochemistry and surgical 
reports if the tumour has been excised [6]. Classification of cancer histology, stage, 
grade, estrogen receptor α (ER) and human epidermal growth factor 2 (HER2) receptor 
status and whether cancerous cells have spread to the lymphatic system are extremely 
important determinants for prognosis and response to treatment plans [7].  
 
1.3. Classification of breast cancer 
Originally, cancer was typed according to the location that the cancerous cells occurred 
in e.g. breast, pancreatic, lung cancer.  In the pre- molecular era, breast cancer was 
classified according to the histological/cellular type of tumour e.g. ductal, lobular, 
nipple or Paget’s and whether it was in situ, invasive or inflammatory [8].  In the last 
decade with the introduction of high throughput micro arrays, breast cancer typing has 
taken a dramatic change. Perou et al. initiated the post molecular era by systematic 
investigation into a new classification system for breast cancer [9]. They examined gene 
expression patterns in tumour samples and found that specific genes expression patterns 
were associated with certain types of cancers. Perou et al. termed these the “intrinsic 
subtypes” as they are a representation of the intrinsic properties of these cancers [9]. 
Four subtypes with individual molecular features were distinguished to classify breast 
cancer (Table 1-1) [10]. 
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Basal-like breast cancers are distinguished by their lack of ER, progesterone receptor 
(PR) and HER2  and are therefore termed triple negative tumours [11, 12]. However, 
not all basal-like breast cancers follow this “triple negative” behaviour as approx 25% 
do not concur with this classification [13]. These particular types of cancers contain 
high expression levels of cytokeratins 5 and 17, laminins, fatty acid binding protein 7 
and growth factor receptors including epidermal growth factor (EGF), c-kit, hepatocyte 
growth factor (HGF) and insulin-like growth factor (IGF) [10, 11]. These tumours also 
contain high frequency of mutated p53 (tumour suppressor gene) and generally are 
associated with poor prognosis and weakened sensitivity to systemic therapy [14]. In 
2007, it was found that retinoblastoma (Rb) protein was mutated in basal-like breast 
cancers [15] and that this along with the p53 mutation was the cause for the high rate of 
proliferation seen within this cancer subtype [13]. Another mutation that is commonly 
linked to basal-like cancer phenotype is the BRCA1 gene mutation [11, 16]. BRCA1 is 
a tumour suppressor gene that is involved in DNA repair, cell cycle and chromosome 
stability [17]. Women who have a deleterious mutation in the BRCA1 gene and develop 
breast cancer will most likely be diagnosed with the basal-like breast cancer subtype 
[13]. Overall, basal-like cancers are associated with shorter overall survival time and 
relapse-free survival [10]. 
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Table 1-1: Microarray based classification of breast cancer subtypes including 
characteristic genes, immunohistochemistry (IHC) markers and clinical features. 
Abbreviations: ER- estrogen receptor, PR- progesterone receptor, HER2- human 
epidermal growth factor receptor 2, GRB7- growth factor receptor bound protein 7. 
Information adapted from [10, 18]. 
 
 
 
Sub-type IHC Markers Clinical features 
Basal-like 
ER-/PR-/HER2- and genes 
characteristic of basal 
epithelial cells and  epithelial 
cytokeratins 5/6 
High grade, strong 
association with BRCA1 
mutation carriers, high risk 
of recurrence, responsive to 
chemotherapy and no known 
targeted treatment 
Luminal 
Subtype A 
ER+ and or PR+/ HER- and 
GATA binding protein 3, X-
box binding protein 1, 
Trefoil factor, FOXA-1 and 
LIV-1 and luminal 
cytokeratins 8/18 and Ki-67 
(Low) 
Low grade, most common 
form of breast cancer, low 
risk of recurrence, responsive 
to endocrine therapy and 
some are less responsive to 
chemotherapy 
Luminal 
Subtype B 
ER+ and/or PR+/ HER2+, 
luminal cytokeratins 8/18 
and Ki-67 (High) 
Varies in grade and response 
to chemotherapy, responsive 
to endocrine therapy. If 
HER2+  is responsive to 
anti-HER2 strategies 
Normal-Like 
Similar genes as found in 
basal epithelial cells and 
adipose tissue 
Samples are generally 
contaminated with normal 
breast tissue 
 
ERBB2+/ 
HER2+ 
ER-/PR-/HER2+ and high 
expression of genes on the 
17q2FF4 amplicon incl; 
HER2, GRB7 
High grade, involved in 
axillary lymph nodes at 
presentation, high risk of 
recurrence, responsive to 
chemotherapy, targeted 
therapies include 
trastuzumab (monoclonal 
antibody) & tyrosine kinase 
inhibitor lapatinib 
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Luminal breast cancers are generally cancers that originate from the luminal epithelial 
cells within the mammary gland [19] and were originally characterised by their high 
expression of the ER [9]. This subtype is classified as hormone receptor positive due to 
the expression of ER and PR [13].  In 2001, Sorlie et al. discovered that this luminal ER 
positive group could be divided into three subgroups- luminal A, B and C [10]. Luminal 
A cancers were distinguished by their high expression levels of the ER gene, low 
expression of HER2 and proliferation- associated gene Ki-67 and transcription factors 
(Table 1-1) [10].  Cancers of this subtype are generally associated with good prognosis 
and longest overall survival times [10] and are sensitive to therapy [11].  
 
Luminal B and C cancers are often grouped together as they are both distinguished by 
intermediate levels of ER in comparison to the luminal A cancers [10].  In contrast to 
luminal A subtype, luminal B subtypes have lower expression of ER, higher expression 
of HER2, higher expression of Ki-67 and contain p53 mutations [13]. Due to this, 
luminal B breast cancers are generally of a higher grade and are insensitive to 
treatments [11].   
 
Normal-like breast cancers are hard to distinguish as they share common factors with 
normal breast tissue as their name suggests. Classification of this group came after 
hierarchical clustering determined that it included genes that are expressed by adipose 
tissue and genes associated with basal epithelial cells (Figure 1-3) [10]. This normal-
like breast subtype also clustered with the luminal A subtype due to their moderate 
expression of luminal epithelial genes [13]. Normal-like breast cancers are associated 
with moderate relapse free and overall survival rates [9].  
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Figure 1-3: Statistical analysis and hierarchical clustering of 115 tumour tissues and 7 
non-malignant tissues determined using the intrinsic gene set as per Perou et al. [9]. (A) 
Shows the entire cluster. C-G represents gene clusters grouping similar genes together. 
Gene clusters representing the ERBB2/HER2 oncogene and related genes (C), luminal 
subtype B (D), basal subtype (E), normal breast like subtype (F) and the ER positive 
luminal subtype A (G). Figure taken from [13].  
 
 
HER2 positive breast cancers are distinguished by their over-expression of several 
genes on the HER2 amplicon at 17q22.24 including; HER2, GRB7, TGFβ1-induced 
anti-apoptotic factor 1 and TNF-receptor associated factor 4 (TRAF4) [20] and their 
lack of expression of ER [18]. HER2 tumours have also been correlated with shorter 
survival times, high levels of recurrence, poor prognosis and have more involved lymph 
nodes [18]. This subtype will be dealt with in more details in section 1.4. 
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1.4. Breast cancer treatment strategies 
Breast cancer treatment options include conventional therapies such as surgery, 
radiotherapy, chemotherapy, hormone therapy and targeted therapy. Determining the 
breast cancer subtype is crucial as different therapies are available for each subtype and 
they are often linked to prognosis, aggressive behaviour of tumour, survival and drug 
resistance. 
1.4.1. Conventional therapies 
Surgery is the first step in treatment for most patients with early stage breast cancer, 
where the type of cancer and location of the tumour are deciding factors in the type of 
surgery carried out. Breast conserving therapy (lumpectomy) is used in the treatment of 
primary breast cancer that is small in size. A total mastectomy is carried out when the 
tumour has spread into other areas or is advanced, and in some of these cases 
chemotherapy may be given to shrink the size of the tumour prior to surgery. Lymph 
nodes are removed as a means of determining the extent of the cancer and if cancer is 
present in these nodes it confirms the cancer has metastasised and that further adjuvant 
treatment (hormonal or chemotherapy) is needed. Removal of the lymph nodes is not a 
curative measure but it is used to inform treatment decisions [21].  
 
Radiation therapy is often part of a patient’s treatment plan when diagnosed with 
primary breast cancer. It is normally the next step in treatment after surgery to ensure 
there are no remaining cancer cells around the excised tumour [21]. The principle of 
radiation therapy is using x-rays, gamma rays and charged particles to damage DNA 
directly or by the creation of charged particles (free radicals) within cells and therefore 
damaging the DNA [22]. 
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Chemotherapy can given to early stage breast cancer patients post-surgery to minimise 
the risk of recurrence (adjuvant treatment), however, it can also be given to patients 
with metastatic breast cancer to either shrink the tumour or to improve the patient’s 
prolonged survival and quality of life. In early stage breast cancer, chemotherapy is 
normally given in combinations to patients, as this reduces the risk of resistance e.g.; 
[21].  
1.4.2. Targeted therapies 
Hormone therapy is used for breast cancers that are positive for the ER and PR. 
Tamoxifen is a non-steroidal anti-estrogen that also acts upon the ER to inhibit 
proliferation of breast cancer cells [21]. Aromatase inhibitors are used to block the 
production of estrogen and therefore prevent proliferation of breast cancer cells. There 
are irreversible and reversible inhibitors that either bind irreversibly or reversibly to 
aromatase. Antibody based therapies are a new generation of ‘targeted therapies’ that 
are specific to a molecular target that plays a vital role in tumour growth. Trastuzumab 
and pertuzumab are monoclonal antibodies and are examples of antibodies approved for 
the treatment of HER2 positive early stage and metastatic breast cancer by the U.S. 
Food and Drug Administration (FDA)  in 1998 [23] and 2012 [24], respectively. As 
initial response rates with trastuzumab were low [25], small molecule inhibitors tyrosine 
kinase inhibitors (TKIs) were developed. Lapatinib is a first generation TKI, which 
targets both HER1 (EGFR) and HER2 and is approved for the treatment of metastatic 
HER2 positive breast cancer [26]. Second generation TKIs include neratinib (HKI-272) 
which targets HER1 and HER2 [27] and afatinib (BIBW-2992) [28] which targets all 
HER family members [29] and they are currently in clinical trials. More recently, ado-
trastuzumab emtansine (T-DM1) (Kadcyla
TM
, Genentech) is an antibody-drug conjugate 
which is FDA approved for the treatment of HER2 positive breast cancer. It is 
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composed of the HER2 monoclonal antibody trastuzumab linked, via 4-(3-mercapto-2, 
5-dioxo-1-pyrrolidinylmethyl)-cylohexanecarboxylic acid (MCC), to the cytotoxic 
chemotherapy drug emtansine. In 2013, the FDA approved T-DM1 for the treatment of 
HER2-positive, metastatic breast cancer [30]. 
  
1.5. HER2 positive breast cancer 
In 1981, HER2, originally designated neu was discovered in rat neuroblastomas that had 
undergone chemical induction and were found to have oncogenic properties [31].  
neu/HER2 was described as 50% homologous to an epidermal growth factor receptor 
(EGFR) that was at the time unknown and contained 80% similarity to tyrosine kinases 
[32]. Schechter et al. discovered that neu/HER2 belongs to a family of EGF-like 
receptors that contain tyrosine kinase domains [33]. In 1987, Slamon et al. discovered 
that this gene is over-expressed and amplified in invasive breast cancer [34] and that 
this alteration of HER2 appears in approx 25-30% of breast and ovarian cancer [35]. 
Further studies confirmed that neu/HER2 is a prognostic factor as it was related to 
shortened disease free and overall survival among patients with amplified HER2 [34]. It 
is also a predictive factor in determining response to conventional cancer therapies [36]. 
In 2000, the HER2/ERBB2 positive subgroup was confirmed as a subtype of breast 
cancer in the microarray study carried out by Perou et al. [9]. This group is identified by 
high expression of the HER2 proto-oncogene that is located on the 17q22.24 amplicon 
along with other genes that are present at this region including GRB7 [10]. HER2 is 
over expressed or amplified in approximately 25% of breast cancer cancers [34] and is 
also identified by its low or non-expression of ER and PR. Diagnosis of this subtype of 
breast cancer in patients requires testing that measures the amplification of genes by  
fluorescent in situ hybridisation (FISH) or chromogenic in situ hybridisation (CISH) 
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[37]. HER2 over-expression induces increased proliferation, apoptosis suppression and 
increased formation of solid structures [38] and also increases the invasive potential of 
cells [39, 40]. Due to these factors, tumours of this subtype have a poor prognosis and 
are related to a shorter survival rate [18]. However, these subtypes are quite responsive 
to chemotherapy and trastuzumab (Herceptin
TM
) [18]. 
 
In order to understand the HER2 positive subtype of breast cancer, the structure, 
mechanism of action and signalling pathways of the HER family needs to be explored. 
In 1984, this proto-oncogene was classified further by Schechter et al. [33] as being a 
185-kilodalton glycoprotein that is associated with tyrosine kinase activity. HER2 is a 
member of the EGFR family  [41]. This family is comprised of HER1 (EGFR/ErbB1), 
HER2 (ErbB2/neu), HER3 (ErbB3) and HER4 (ErbB4).  This family are class I receptor 
tyrosine kinases (RTKs) [33]. These types of RTKs have specific structural features 
including an extracellular binding, transmembrane and an intracellular domain (Figure 
1-4) [42].  
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Figure 1-4: Structure of Class I Receptor Tyrosine Kinases showing the extracellular 
cysteine rich region and the intracellular tyrosine kinase region. 
 
RTK domains have very specified roles. The extracellular domain is a region that 
contains two cysteine rich domains where ligands bind to induce a response [43]. 
ligands include transforming growth factor alpha (TGFα), EGF  and amphiregulin (AR) 
for HER1 only. HER2 does not directly interact with ligands. Ligands for HER3 include 
neuregulin 1 and 2 (NRG1 and NRG2) Ligands for HER4 are NRG3 and NRG4. HER1 
and HER4 share ligands including β-cellulin (BTC), heparin-binding EGF-like growth 
factor (HB-EGF) and epiregulin (EREG) (Figure 1-5). 
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Figure 1-5: Ligands that bind to specific HER family members. Adapted from [44]. 
 
The intracellular domain contains the tyrosine kinase region and a carboxyl tail region 
where the phosphorylation sites reside [42]. This family of receptors are monomeric and 
upon ligand binding undergo dimerisation with other family members and can form 
either homo- or hetero-dimers depending on the dimerisation partner [37]. Once in 
dimer formation, the tyrosine residues in the intracellular domains cross-phosphorylate, 
activating the kinase domain leading to phosphorylation of substrates including 
signalling intermediates in the phosphatidylinositol-3 kinase/AKT (PI3K/AKT), 
Ras/mitogen activated protein kinase (Ras/MAPK) and phosphodiesterase 
phospholipase Cγ/protein kinase C (PLCγ/PKC) pathways (Figure 1-6). HER2 has no 
known ligand and is activated only upon dimerisation with another HER2 receptor or 
other family members that have been activated by their specific ligands [37]. HER2 is 
the favoured dimerisation partner within this family and it also holds the strongest 
kinase activity and a lower ligand dissociation creating a strong prolonged signal [45].   
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Figure 1-6: Overview of the HER-induced pathways. Ligand binding induces 
dimerisation between HER family members and induces tyrosine kinase properties of its 
intracellular domain resulting in activation of many downstream signalling cascades 
including; PI3K/AKT, Ras/MAPK and PLC/PKC pathway inducing cell proliferation, 
migration and survival. Adapted from [46]. 
 
These signalling pathways are the key to cell proliferation and survival as shown in 
(Figure 1-6). The PI3K/AKT pathway plays a role in cell growth and survival [37].  
Briefly, PI3K is a protein which contains SH2 and SH3 domains which are activated 
upon binding to the RTK domains of HER receptors [47]. Once neu/HER2 is activated 
via dimerisation with HER3 in turn PI3K is activated [48]. This pathway involves the 
production of lipids (PIP2 and PIP3) which in turn activate protein kinase B (AKT), 
which is an inhibitor of the pro-apoptotic protein BAD which is involved in the 
promotion of apoptosis [37]. Inhibition of this protein therefore promotes cell survival. 
Regulation of this pathway is crucial in the balance of pro- and anti-apoptotic proteins 
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and determining cell survival and proliferation or cell death [49]. Phosphatase and 
tensin homolog deleted on chromosome 10 (PTEN) is a known tumour suppressor 
protein and is a key regulator of this pathway [50]. PTEN dephosphorylates the lipids 
that initially activate AKT and therefore drive apoptosis. AKT can also activate the 
mammalian target of rapamycin (mTOR) pathway via phosphorylation of tuberous 
sclerosis complex 1/2 (TSC1/2), a pathway which is involved in cell growth and 
proliferation [49]. This pathway regulates mRNA translation, ribosome biogenesis and 
nutrient metabolism and is crucial in cellular growth [49]. 
 
The Ras/MAPK pathway is frequently mutated in cancers. Briefly, activation of RTKs 
induces the recruitment of proteins that can further activate downstream signalling 
cascades. One such recruit is the growth factor receptor bound protein 2 (GRB2) which 
in turn recruits son of sevens (SOS) which regulates the Ras protein and downstream 
kinases including MAPK, MAPK kinase (MEK) and extracellular signal-related kinase 
1/2 (ERK 1/2) [49]. Ras belongs to a family of small GTPases which when bound to 
SOS (guanine nucleotide exchange factor) undergoes dissociation to generate a Ras-
GTP complex which activates a serine-threonine kinase, Raf-1 which phosphorylates 
MEK (threonine-tyrosine kinase), which in turn activates MAP kinase [51, 52]. This 
signalling cascade controls cell differentiation, cell proliferation and cell death [53], 
therefore disruption of this pathway can interrupt cellular control leading to cellular 
dysfunction. 
 
Another pathway that is important in the HER kinase signalling cascade is the 
PLCγ/PKC pathway. RTKs bind PLCγ via Src 2 homology domains (SH2 domains) 
[54]. SH2 domains are involved in many important signalling pathways and protein-
31 
 
protein interactions and function as adaptors for these reactions [55]. Phosphorylation of 
PLCγ upon binding with the active HER2 dimer via these SH2 domains induces 
hydrolysation of PIP2 producing the second messengers inositol triphosphate (IP3) and 
diacylglycerol (DAG) [56]. These second messengers induce increased intracellular 
calcium concentration, which together with DAG activates PKC [56]. PKC initiates the 
MAPK pathway and therefore the expression of cyclin D, an important factor governing 
cell cycle progression from the G1 to S phase [57]. Cyclin D phosphorylates the tumour 
suppressor protein Rb [56] and is a key regulator of the cell cycle progression from G1 
to S stage via phosphorylation of cyclin dependent kinases (CDKs), thus mediating cell 
proliferation [58].  
 
1.6. Current treatments for HER2 positive breast cancer 
Due to the nature of HER2 and its over-expression in breast cancer, its prognostic 
characteristics and its pathogenic and aggressive qualities, it has become a prime target 
for targeted therapies. There are important factors that have been taken into account 
when developing a HER2 targeted therapy including; the levels of HER2 in human 
cancer cells is much higher in relation to normal cells which suggests that the level of 
toxicity associated with anti-cancer drugs may be limited, levels of the receptor 
correlate with the pathogenesis, prognosis and disease free survival rate of HER2 breast 
cancer. HER2, due to its amplification/over-expression, is present in a high percentage 
of tumour cells and is found in the primary tumour site and metastatic sites indicating 
that targeted therapy would target most cancerous cells and all disease sites [59-61].  
Monoclonal antibodies and TKIs are the two main types of anti-HER2 treatments that 
have been developed and are generally used in combination with chemotherapy (Figure 
1-7) 
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Figure 1-7: Inhibition of HER-2 signalling: Trastuzumab binds the extracellular domain 
of HER-2 dimers and reduces HER-2 signalling. The tyrosine kinase inhibitors (TKIs) 
include; lapatinib which reversibly inhibits the tyrosine kinase domain of HER-2 and 
EGFR; whereas neratinib, afatinib and dacomitinib are irreversible pan-Her inhibitors 
[62]. 
 
1.6.1 Trastuzumab- monoclonal antibody 
1.6.1.1   Discovery and development of trastuzumab 
The discovery and development of trastuzumab spans 2 decades and it is the most 
successful monoclonal antibody discovery for the treatment of breast cancer. It 
originally stemmed from two pivotal discoveries in the 1980s; the identification of  185 
kDa phosphoprotein called neu [63] and the discovery that neu, or HER2 as it is now 
referred to, was up-regulated in 20-30% of human primary breast cancers [34]. 
Researchers saw this change as an attractive target for the development of possible new 
treatments. Several groups including researchers at Genentech developed murine 
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monoclonal antibodies directed against the extracellular domain (ECD) of HER2, 
p185
HER2 
[64, 65]. Ultimately, Genentech Inc discovered a potent murine monoclonal 
antibody, muMAb 4D5 which significantly inhibited cell growth of HER2 over-
expressing cell lines but had little effect on HER2 normal cell lines [66]. Tumour cell 
sensitivity to tumour necrosis factor was enhanced upon treatment with the 4D5 
antibody [64, 67]. Further demonstration of this new antibody’s efficacy came from its 
activity against human breast cancer xenografts [68]. Due to these potent anti-tumour 
effects, the 4D5 murine monoclonal antibody was chosen for further clinical 
development.    
 
However, due to its murine origin the antibody was humanised to overcome the limiting 
factor of an anti-globulin response during therapy [69]. Utilising gene conversion and 
site-directed mutagenesis, Carter et al., subcloned the hypervariable region of the 
muMAb 4D5 into plasmids encoding the IgG1 constant region and a human κ light 
chain to generate eight chimeric antibodies [70]. One variant, humAb4d5-8 bound three 
times more tightly to the ECD of p185
HER2
 than the muMAb 4D5 and had anti-
proliferative effects on the HER2 over-expressing cell line, SKBR3 [70]. Interestingly, 
humAb4D5-8 also mediated an antibody dependent cell cytoxicity (ADCC) response 
against SKBR3 cells in the presence of human effector cells whereas the murine variant 
does not [70]. This vector was then transduced into Chinese hamster ovary (CHO) cells 
that are used in large scale production and was further purified [71]. Overall, this 
humanised monoclonal antibody, called trastuzumab (Herceptin
TM
), is 95% human and 
5% murine and is specific for HER2 [71]. In 1998, this monoclonal antibody received 
approval for use in the treatment of metastatic breast cancer, alone or in combination 
with chemotherapy [72]. In 2006, trastuzumab was approved for treatment of early 
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breast cancer (postoperative or adjuvant setting) in combination with chemotherapy 
[73]. 
1.6.1.2   Drug structure 
Trastuzumab is an immunoglobin G (IgG1) monoclonal antibody composed of 1,328 
amino acids and has a molecular weight of approximately 148 kDa [74]. It consists of 
two antigen specific sites derived from the murine 4D5, the human variable region and 
an IgG1 conserved Fc portion (Figure 1-8) [70, 75]. 
 
 
 
 
 
 
 
 
Figure 1-8: Overall structure of Trastuzumab monoclonal antibody. It is composed of a 
human IgG1 antibody (95%) which has two antigen specific epitopes for HER2. 
Reproduced from Ross et al. [76]. 
1.6.1.3   Mechanism of Action 
Several mechanisms of action have been proposed for trastuzumab. The prevailing 
hypothesis is that the innate and adaptive immune system and a host of numerous other 
processes are involved (Table 1-2). Firstly, it has been suggested that trastuzumab 
accelerates the endocytic degradation of the HER2 receptor [77]. In 2000, Klapper et al. 
showed that upon trastuzumab binding, a ubiquitin ligase, c-Cbl, is recruited to its 
docking site and HER2 is ubiquitinated which ultimately leads to its degradation [78]. 
35 
 
However, this degradation process is yet to be explored further. Upon over-expression, 
HER2 undergoes proteolytic cleavage which results in the extracellular domain (ECD) 
HER2 (110kDa) and a membrane bound truncated form, p95 in breast cancer cell lines 
and tissue extracts [79]. In 2001, Molina et al. proposed a new mechanism of action for 
trastuzumab, they detected p95 in over 50% of human breast cancer samples [80]. They 
demonstrated that trastuzumab treatment blocked shedding of the ECD of HER2 from 
breast cancer cell lines, and therefore inhibited production of p95. Further clinical 
studies have shown a correlation with the decrease in ECD HER2 in patient serum 
during trastuzumab treatment and tumour response and progression free survival [81, 
82]. Overall, these studies indicate that trastuzumab may act by inhibition of HER2 
cleavage. 
 
Another mechanism that has been proposed is that trastuzumab acts by disrupting the 
ligand independent interaction between HER2/HER3 and the PI3K/AKT pathway. 
HER2 over-expression in HER2 amplified cells leads to ligand-independent activation 
of HER2/HER3 complexes and HER3 phosphorylation (Figure 1-9) [83]. This in turn 
activates the downstream PI3K/AKT pathway. Junttila et al. found trastuzumab inhibits 
this ligand-independent HER2/HER3 dimerisation and in turn down-regulates the PI3K 
pathway [83].  
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Figure 1-9: Ligand independent HER2/HER3 dimerisation upon HER2 over-expression 
and subsequent HER3 phosphorylation. (A)  pHER3 activates the PI3K pathway which 
promotes cell survival and proliferation. (B) Trastuzumab disrupts the HER2/HER3 
dimerisation which leads to HER3 dephosphorylation and inhibition of the PI3K 
pathway and cell proliferation. Adapted from [83]. 
 
Trastuzumab also reduces signalling via the MAPK pathways [84, 85]. Delord et al. 
demonstrated trastuzumab had an inhibitory effect on cell proliferation through the 
MAPK and AKT pathway in ovarian cancer [84]. Another method of PI3K pathway 
blockade was proposed by Nagata et al. which involves Src and PTEN [85]. They 
demonstrated that trastuzumab disrupts HER2/Src interactions leading to Src 
inactivation which in turn reduces PTEN phosphorylation, increases PTEN phosphatase 
activity and AKT dephosphorylation resulting in inhibition of cell growth [85]. 
Interestingly, downstream components of the PI3K pathway, p27 and Cdk2 have been 
shown to be involved in the molecular mechanisms of trastuzumab. Increased 
association with p27 and Cdk2 complexes results in the inactivation of Cdk2 which 
ultimately inhibits cell proliferation [86, 87].  
 
Trastuzumab treatment is also associated with an immune response. ADCC mediated 
via natural killer (NK) cells has been shown to correlate with trastuzumab response 
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[88]. NK cells are activated upon binding of their Fc gamma receptors to the Fc domain 
of trastuzumab (Figure 1-10) [89]. Clynes et al. developed Fc receptor knockout mice 
and discovered that the cytotoxicity and anti-tumour ability was impaired indicating that 
the Fc/Fcγ receptor interaction is important for the trastuzumab mediated ADCC [89]. 
Correspondingly, patients who responded to trastuzumab treatment had significantly 
higher levels of NK cells and ADCC [90]. They also identified a correlation between 
progression free survival and NK cells [90].  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-10: Activation of ADCC upon trastuzumab binding. NK cells which express 
the Fc gamma receptors in turn bind to the Fc domain of trastuzumab which leads to 
tumour cell lysis or apoptosis.  
 
Trastuzumab has been shown to enhance apoptosis induction. Combination treatment of 
HER2 over-expressing cell line (BT474 and SKBR3) with trastuzumab and tumour 
necrosis factor-related apoptosis-inducing ligand (TRAIL) resulted in apoptosis [91]. 
Down-regulation of the HER2 receptor was shown to induce this TRAIL enhancement 
and inhibition of AKT activation [91]. In 2005, TRAIL and its association with 
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trastuzumab treatment were further investigated [92]. Similarly, they found an increased 
response to TRAIL in the SKBR3 cell line; however, they found trastuzumab decreased 
the BT474 cell line sensitivity to TRAIL. Down-regulation of the TRAIL receptor 1 and 
2 was associated with inhibition of the HER2/PI3K/AKT pathway in BT474 cells but 
not SKBR3 cells. Apoptotic events including; caspase-8 activation, BH3 interacting-
domain death agonist (BID) processing and Poly (ADP-ribose) polymerase (PARP) 
cleavage were inhibited in the HER2/PI3K/AKT-suppressed BT474 cells, and the 
authors surmised that HER2/PI3K/AKT pathway may play a cell-type specific pro-
apoptotic role enhancing cells sensitivity to TRAIL [92]. Trastuzumab also enhances 
response to chemotherapy, most likely via enhanced induction of apoptosis [93]. 
  
Finally, HER2 positive breast cancer has been shown to correlate with increased 
angiogenesis [94]. Inhibition of angiogenesis may be another mechanism of 
trastuzumab action in vivo. Izumi et al. showed that trastuzumab suppressed 
angiogenesis via reduction in pro-angiogenic factors e.g.: vascular endothelial growth 
factor (VEGF) and promotion of anti- angiogenic factors e.g.: thrombospondin-1 only in 
vivo [95].  HER2 over-expressing cell lines were found to have an increase in VEGF 
expression at the mRNA and protein levels [96]. Klos et al., discovered that inhibition 
of angiogenesis was greater in xenografts treated with a combination of trastuzumab and 
paclitaxel than the antibody alone [97]. Another important finding from their study was 
that AKT/PI3K and mTOR signalling pathways were involved in regulation of 
trastuzumab controlled VEGF activity [97]. Treatment with trastuzumab or silencing of 
HER2 resulted in a decrease in VEGF levels and interleukin-8 (IL-8) expression (pro-
angiogenic factors) and an increase in thrombospondin (TSP-1) expression (anti-
angiogenic factor) [98]. In BT474 xenografts in immunosuppressed mice, growth was 
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inhibited, microvascular density was decreased and the results corroborated with the in 
vitro study [98]. 
 
Table 1-2: Overall summary of proposed mechanisms of action of trastuzumab. 
Adapted from [99]. 
Proposed mechanism of action Details 
Effects on HER2 levels 
Induction of HER2 receptor 
internalisation and degradation via 
endocytosis [64, 91, 100] 
Blocks cleavage of HER2 ECD 
suppressing formation of p95HER2 [80] 
Effects on dimerisation 
Disruption of ligand-independent 
HER2/HER3 interactions [83] 
Effects on downstream signalling 
Inhibition of PI3K and MAPK pathways 
[83, 84] 
Effects on cell cycle regulators 
Induction of p27, p21 [86] 
Cdk2 inhibition [87] 
Immune effects Stimulation of ADCC [90] 
Effects on apoptotic regulators 
Enhancing TRAIL-induced apoptosis 
[91] 
Effects on angiogenesis 
Reduction in VEGF levels and 
angiogenesis [95] 
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1.6.1.4   Mechanisms of Resistance 
Despite the success of trastuzumab in the clinic, de novo or acquired resistance is a 
problem, particularly for patients with metastatic disease. In a recent study of metastatic 
breast cancer patients treated with trastuzumab-containing regimens, it was reported that 
9% of this cohort had a durable complete response [101]. Unfortunately many HER2 
positive metastatic breast cancer patients have primary resistance [25], and patients who 
initially  show a significant response frequently develop secondary resistance within a 
period of 1-2 years [60, 102]. Several resistance mechanisms have been proposed as 
outlined briefly in Table 1-3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
41 
 
Table 1-3: Brief details of several proposed mechanisms of trastuzumab resistance. 
Mechanisms of 
Resistance 
Details 
PTEN  loss & 
PI3K/AKT activity 
 Trastuzumab treatment resulted in PTEN membrane 
localisation and increased phosphatase activity, mediated 
by a reduction in PTEN tyrosine phosphorylation via Src 
inhibition [85].  
 Loss of PTEN and thus activation of the PI3K/AKT 
pathway correlated with trastuzumab resistance in a 
panel of HER2 positive breast cancer cell lines [103]. 
Alternative 
signalling 
pathways 
 IGF-1R levels were increased in trastuzumab resistant 
cell line models (SKBR3-T) [104]. 
 Inhibition of Met increases trastuzumab sensitivity [105]. 
 Over-expression of HER3 and HER2 leads to 
HER2/HER3 heterodimers which activate the PI3K/AKT 
pathway [83] 
Serum HER2 & 
ECD shedding 
 Retrospective studies have found an association with p95 
HER2 expression and poor patient outcome and an 
aggressive phenotype [106, 107]. 
Over-expression of 
MUC4 
 MUC4, a membrane bound glycoprotein binds and 
sterically hinders HER2 from binding to trastuzumab and 
knock-down of MUC4 leads to increased binding of 
trastuzumab [108].   
Molecular 
chaperones 
 Heat shock protein 90 (HSP90) is known to regulate the 
stability of HER2 which decreases receptor turnover and 
thereby strengthening HER2 signalling effects [109] 
.  
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1.6.1.5   Biomarkers of trastuzumab resistance 
There is a critical incentive to elucidate biomarkers of trastuzumab resistance and 
identify patients prior to treatment that are unlikely to respond. As mentioned 
previously there are several mechanisms of both innate and acquired resistance 
hypothesised however, none have been successfully validated clinically. Multivariate 
analysis of core biopsies from the GeparQuattro trial, identified aldehyde 
dehydrogenase 1 (ALDH1) and phosphorylated 4E binding protein (p4E-BP1) as 
significantly up-regulated in patients who relapsed, suggesting that the mTOR pathway 
(p4E-BP1) and stem cells features (ALDH1) may play a role in trastuzumab resistance 
[110]. Markers of sensitivity are also being explored; phosphorylated HER2 and co-
amplification of c-Myc and HER2 have been postulated as markers of 
trastuzumab/lapatinib sensitivity [111]. PTEN, c-Myc and p95 HER2 are predictive 
biomarkers that are currently being investigated in the ALTTO and NeoALTTO trials 
[112]. More recently, neuromedin (NmU) was identified as an extracellular biomarker 
of HER2 targeted therapy resistance. Over-expression of NmU was associated with both 
acquire and innate resistance to lapatinib, trastuzumab, neratinib and afatinib [113]. 
Ectopic over-expression of NmU in sensitive cell lines conferred resistance to all HER2 
targeted therapies. However, the only validated predictive marker of response to anti-
HER2 therapies is the over-expression and/or amplification of HER2. 
1.6.2 Lapatinib- Tyrosine Kinase Inhibitor 
1.6.2.1  Development and Discovery of Lapatinib 
Small molecules which target growth factors such as HER1 and HER2 were 
investigated as potential therapies in the late 1980’s. Novel chemistry, kinase 
biochemical screening platforms and cell line testing identified potential molecules that 
selectively and potently target HER1 and HER2 [114]. In vivo xenograft models 
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combined with the previous in vitro research led to the identification of GW2016 
(GW572016) which was later named lapatinib [114]. 
 
Lapatinib (Tykerb) is a reversible dual small molecule TKI which selectively inhibits 
both HER1  and HER2 [115]. Lapatinib can be administered orally, has a half life of 24-
48 hours and there is evidence that lapatinib can cross the blood brain barrier [116]. In 
2007, lapatinib was FDA approved for the treatment of metastatic HER2 positive breast 
cancer in combination with capecitabine in patients who have previously received prior 
treatment with anthracyclines, taxanes and trastuzumab [26, 115]. Patients with HER2 
positive metastatic breast cancer who have previously been treated with trastuzumab 
may develop brain metastases due to the aggressive nature of this cancer type [116]. 
TKIs are small in size and are therefore able to cross the blood brain barrier [117] and in 
a preclinical murine model, lapatinib was found to inhibit formation of large metastases 
however, did not completely prevent further metastasis [118]. 
1.6.2.2   Drug Structure 
Lapatinib is present as the monohydrate of the ditosylate salt (Figure 1-11) [119]. It has 
a molecular weight of 581.1 g/mol and formula C29H26ClFN4O4S. It is a member of the 
4-anilinoquinazoline class of kinase inhibitors.  
 
 
 
 
 
Figure 1-11: Chemical structure of lapatinib [120]. 
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1.6.2.3   Mechanism of Action 
The proposed mechanisms of action for lapatinib include inhibition of HER2 signalling, 
induction of cell cycle arrest and apoptosis, and induction of stress related responses 
(autophagy). The reversible binding to the ATP-binding site of both HER1 and HER2 
and blocking their activation [121] leads to growth arrest and induces apoptosis in 
HER1 and HER2-dependent tumour cell lines [122]. However, lapatinib sensitivity is 
independent of HER1 status in HER2 over-expressing cell lines suggesting [123]. In 
tumour samples, lapatinib response also correlates with HER2 expression not HER1 
expression [124, 125]. Inhibition of both MAPK-ERK1/2 and AKT by reducing the 
phosphorylation of HER1 and HER2 in HER2 positive breast cancer cell lines and 
human tumour xenografts [122]. Functional genomic studies carried out by Hegde et al. 
comparing lapatinib responsive cell lines (BT474 and SKBR3) to non-responsive cell 
lines (MDA-MB-468 and T47D) found differential expression of members of the AKT 
pathway. AKT1, MAK9, HSPCA, IRAK and CCND1 were down-regulated in lapatinib 
responsive and FOXO3A, which is negatively regulated by AKT, was up-regulated in 
lapatinib responsive cells. The ER and PR receptors were stimulated upon treatment 
with lapatinib and genes involved in cell cycle control, glycolysis and fatty acid 
metabolism were altered [126].  
 
Lapatinib induces apoptosis by inhibition of AKT in HER2 positive breast cancer cells 
and human tumour xenografts [122], and inhibition of survivin [127]. Survivin is an 
inhibitor of apoptosis (IAP) which can protect breast cancer cells from apoptosis and 
down-regulation has been observed in HER2 breast cancer patients treated with 
lapatinib [127, 128]. Induction of cell cycle arrest occurred in HER2 positive breast 
cancer cells (G1 accumulation) upon treatment of HER2 positive cells with lapatinib 
45 
 
[123]. Lapatinib has also been associated with an increase apoptosis protein Bcl-2 
interacting mediator of cell death (BIM) through inhibition of the MAPK signalling 
pathway [129]. The anti-apoptotic protein, myeloid cell leukemia 1 (MCL-1) has been 
show to be increased in response to lapatinib treatment [130].  
 
Autophagy has been reported as a potential mechanism of lapatinib action in chronic 
myelogenous leukemia (CML) K562 cells [131] and HER2 breast cancer cells [132]. In 
BT474 and AU565 HER2 over-expressing cells increased levels of cleaved caspase-3 
and PARP, and autophagy were detected in response to lapatinib treatment [132]. They 
also observed induction of apoptosis, upon pre-treatment with a specific autophagy 
inhibitor, 3-methyladenine (3-MA). This suggests that lapatinib treatment induces 
autophagy to initiate cell death.  
 
Another potential mechanism of action is the through inhibition of the 
HER2/AKT/mTOR pathway. Lapatinib sensitivity is associated with decreased AKT 
and p70S6K phosphorylation [133]. Inhibition of mTOR by rapamycin caused an 
increase in lapatinib sensitivity and reduced phospho-AKT levels in lapatinib 
insensitive cells. Combination treatment with rapamycin and lapatinib synergistically 
inhibited cell proliferation and reduced tumour growth in vivo, in innately trastuzumab 
resistant breast cancer cells. This suggests that trastuzumab resistance and poor response 
to lapatinib treatment may be overcome by simultaneous mTOR inhibition.  
 
Lapatinib treatment has been reported to increase the phosphorylation of 5' AMP-
activated protein kinase (AMPK), which is involved in the mammalian target of 
rapamycin complex 1 (mTORC1) complex. AMPK activation regulates tumour growth 
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through mTOR inhibition which led to decreased protein synthesis [134]. Lapatinib 
treatment has not been previously associated with cardiotoxicity and a lapatinib 
analogue, GW2974, protects cardiomyocytes from apoptosis through the activation of 
AMPK [135]. AMPK switches cells from an anabolic to catabolic state of metabolism 
suggesting lapatinib induced activation of AMPK is necessary to induce apoptosis in 
tumour cells while protecting cardiac cells.  
1.6.2.4   Lapatinib and trastuzumab 
Preclinical data determined that lapatinib and trastuzumab combination treatment was 
synergistic in HER2 over-expressing cell lines [136]. Interestingly, lapatinib also 
retained activity on acquired trastuzumab resistant cell lines which suggests that 
lapatinib alone or in combination with trastuzumab may overcome trastuzumab 
resistance. This was investigated by Blackwell et al. in a randomised phase III clinical 
trial where the combination significantly improved progression free survival and overall 
survival compared to lapatinib alone despite relapse on a previous trastuzumab based 
therapy [137, 138]. Further preclinical studies suggest that dual target of HER1/HER2 
with lapatinib and trastuzumab in combination with chemotherapy improves response 
compared to either agent alone [139]. However, more recently, results were presented at 
the American Society of Clinical Oncology (ASCO 2014) from the ALTTO trial 
showed that lapatinib in combination with trastuzumab was no more effective than 
trastuzumab treatment alone [140]. 
 
In the neoadjuvant setting, two pivotal trials have investigated the efficacy of lapatinib 
in combination trastuzumab. The NeoALTTO trial hypothesised that administering two 
anti-HER2 therapies would be greater than one [141]. This phase III study investigated 
lapatinib plus paclitaxel versus trastuzumab plus paclitaxel versus combined lapatinib 
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and trastuzumab plus paclitaxel when administered as neoadjuvant therapy in HER2 
positive breast cancer patients. Patients received the HER2 target therapies alone for 6 
weeks and then in combination with paclitaxel for a further 12 weeks. Following 
surgery, patients received adjuvant chemotherapy with fluorouracil (5FU), epirubicin 
and cyclophosphamide (FEC) followed by 1 year of the same targeted therapy in the 
neoadjuvant stage. pCR was significantly higher in the lapatinib and trastuzumab arm 
(51.3 %) compared to trastuzumab (29.5 %) or lapatinib alone (24.7 %). Another 
randomised phase III clinical trial, GeparQuinto investigated the efficacy and safety of 
lapatinib versus trastuzumab when added to an anthracycline-taxane-based neoadjuvant 
chemotherapy regimen [142]. Patients received four cycles of epirubicin plus 
cyclophosphamide (ECL) plus neoadjuvant treatment of trastuzumab (ECH-TH) or 
lapatinib (ECL-TL) before surgery. The pCR rated for the ECH-TH arm was 30.3 % 
and 22.7 % in the ECL-TL. Substantial toxicities were seen in the ECL-TL arm and 
33.1 % of patients withdrew from this arm due to adverse events. Trastuzumab showed 
a better clinical outcome in the neoadjuvant setting than lapatinib alone; however, long 
term follow up is ongoing.  
 
The CHER-LOB neoadjuvant trial reported an 80 % increase in pCR rate in the 
chemotherapy plus trastuzumab and lapatinib arm compared with chemotherapy or 
trastuzumab or lapatinib alone [143]. The NSABP-B41 trial found similar pCR rates 
between the lapatinib and chemotherapy arm (52.5 %) and the trastuzumab and 
chemotherapy arm (53.2 %) however, dual blockade seems more favourable (62.0 %) 
than either agent alone but the difference was not statistically significant [144]. 
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1.6.2.5   Mechanisms of Resistance 
Lapatinib has been shown to overcome trastuzumab resistance in HER2 over-expressing 
cell lines that are trastuzumab resistant [123]. However, resistance to lapatinib is also an 
emerging problem [145]. Several mechanisms of resistance have been proposed as 
outlined briefly in Table 1-4. 
Table 1-4: Brief details of several proposed mechanisms of lapatinib resistance. 
Mechanisms of 
Resistance 
Details 
Over-expression of 
AXL 
 Increased AXL expression was identified by western 
blotting, mass spectrometry and qRT-PCR in a lapatinib 
resistant cell line model [145] 
Induction of 
autophagy 
 In lapatinib resistant cell lines, there was increased levels 
of the autophagsome and that treatment of these cells 
with an autophagy inhibitor re-sensitised the cells to 
lapatinib [146] 
Over-expression of 
MCL-1 
 A BCL-2/BCL-X(L)/MCL-1 inhibitor (obatoclax-GX15-
070) restored lapatinib sensitivity in the HT116-parental 
and HT116-lapatinib resistant colon cancer cells [147]. 
Re-activation of the 
Estrogen Receptor 
 Gene expression analysis of lapatinib resistant cell lines 
compared to parental cells correlated ER signalling with 
the development of resistance to lapatinib [148]. 
Over-expression of 
XIAP 
 Overexpression of XIAP and resistance to apoptosis was 
found in lapatinib resistant inflammatory breast cancer 
cells: SUM-190 (HER2 over-expressing) and SUM-149 
(HER1 activated) [149]. 
Up-regulation of 
Src kinase activity 
 Increased phosphorylation of Src family kinases was 
found in six lapatinib resistant cell lines and inhibition of 
Src blocked PI3K-AKT signalling and lapatinib 
sensitivity was restored [150] 
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Any of these potential resistance mechanisms may also serve as potential predictive 
biomarkers to lapatinib resistance. 
 
1.7. microRNAs 
1.7.1   Introduction 
In 1993, during the study of the gene lin-14 in C.elegans development, the first 
microRNA (miRNA), Lin-4, was discovered by Victor Ambros. They found that lin-14 
abundance was under regulation of a short RNA product encoded by the lin-4 gene, 
which regulates timing in larval development in worms [151]. miRNAs are a family of 
21–25-nucleotides-long RNAs expressed in a wide variety of organisms ranging from 
plants to worms and humans [152]. miRNAs account for greater than 3% of all human 
genes [153]. They regulate gene expression sequence specific recognition of their target 
mRNAs. miRNAs play vital roles in apoptosis, control of growth in development, cell 
proliferation and stem cell properties [154-157]. In 2005, it was discovered that there 
are great changes in miRNA expression in cancers and in the development of tumours 
[158, 159]. By 2013, over 2000 miRNAs were found to be encoded by the human 
genome and the searchable miRNA database, miRBase version.21 has 5,441 mature 
miRNA sequences [3]. However, validation of miRNAs and their potential mRNA 
target interactions by experimental approaches has been limited [160]. miRNA genes 
are non-randomly distributed in the human genome and some are found within clusters 
sharing the same promoter [161]. Interestingly, miRNA genes are frequently located 
near tumour susceptibility loci in mouse cancer models [162] and deleted or amplified 
genomic regions [21]. 
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1.7.2 miRNA biogenesis 
There are two broad categories of miRNA promoters: intergenic and intragenic [22, 
163]. Intergenic miRNAs are located between genes and their transcription is 
independent of coding genes as they are transcribed by RNA polymerase II (RNApol II) 
[117]. This suggests the miRNAs form independent transcriptional units [118]. 
Intragenic miRNAs are located within exons or introns of protein coding genes [116] 
and are transcribed by RNApol II as part of their hosts transcription. miRNAs were 
found among repetitive elements that are transcribed by RNApol III and processed the 
same way [164]. The biogenesis of a mature miRNA occurs in a stepwise fashion 
(Figure 1-12) where, firstly, the miRNA gene undergoes transcription by RNApol II to 
produce a pri-miRNA [165]. These pri-miRNAs are 5′-7-methylguanosine capped, 
spliced and 3′-polyadenylated [124]. Pre-miRNAs have a coding capacity for one or 
more mature miRNAs and are then processed by Drosha family of enzymes (double 
stranded RNA specific ribonuclease), DGCR8 or Pasha (ds-RNA binding protein that 
dimerises with Drosha) in the nucleus and produce 70-100 nucleotide hairpin miRNAs 
called pre-miRNAs [152]. This pre-miRNA is transported to the cytoplasm in a Ran-
GTP dependent manner via Exportin-5 (nuclear export factor) [166, 167]. These pre-
miRNAs are cleaved by Dicer and TRBP (human immunodeficiency virus (HIV) 
transactivating response RNA (TAR) binding protein) into an approximately 20 
nucleotide miRNA duplex [168]. One of these strands functions as mature miRNA and 
is guided into an effector complex called the miRNA-containing ribonucleo-protein 
particle (miRNP), which is similar to the RNA induced silencing complex (RISC) [152, 
169], via the argonaute family protein (Ago) to form the mRISC complex [170]. This 
complex is guided to its target mRNA via complementary base pairing between the 
miRNA and its target mRNA 3’ untranslated region (UTR) and thus negatively 
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regulates mRNA [152]. The other strand in the duplex undergoes degradation [171]. 
Once sequence complementarity has been established between the miRNA and the 
target mRNA, the miRNA:RISC complex mediates gene repression by translational 
repression, mRNA target cleavage and mRNA deadenylation.   
 
 
 
 
 
 
 
 
 
 
 
Figure 1-12: Overview of miRNA biogenesis. Adapted from [126] . 
 
1.7.3 miRNA function 
Primarily, miRNA function in gene expression repression carried out by mRNA 
cleavage, mRNA degradation and translational repression [172]. However, it has been 
reported that miRNAs may exert their effects directly and/or indirectly on the gene in 
response to external conditions [127]. The outcome is also dependent on the strength of 
the miRNA:mRNA interaction and the repressive effect of the miRNA [127, 173]. The 
mode of post-transcriptional control is determined by the sequence complementarity 
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between miRNA and its target mRNA based on Watson-Crick pairing of miRNA 
5’proximal seed region (nucleotide 2-8) to the 3’UTR match site in the target mRNA 
[174]. It has also been reported that miRNAs can target the 5’UTR and/or coding region 
of their target mRNAs [175, 176]. Multiple miRNA-Recognition Elements (MREs) of a 
single miRNAs are present within the 3’ UTR of several mRNA transcripts and several 
MREs belonging to different miRNAs can be found within the same UTR resulting in 
synergistic miRNAs [177]. As previously mentioned, miRNAs exert their function as 
gene regulators. In 2010, gene regulation was reportedly carried out by mRNA 
cleavage, mRNA degradation and translational repression [172]. The RISC complex 
contains Ago protein members (1-4), however, Ago-2 has been implicated as the main 
driving force in miRNA:mRNA cleavage [178, 179]. The mode of post transcriptional 
control is determined by the sequence complementarity between miRNA and its target 
mRNA. mRNA target cleavage occurs when complete near-perfect base-pairing occurs 
between miRNA and its target mRNA and is carried out by the attached Ago2 protein 
only [171, 180]. Partial sequence complementarity between miRNA and its target 
mRNA results in mRNA degradation and translational inhibition by Ago2 and Ago4 
[172, 180]. miRNA target specificity may be changed due to alterations in the seed 
sequence depending on the Drosha/Dicer-dependent addition or deletion of 1-2 
nucleotides in the 5’ and 3’ ends of miRNAs [181]. Translation occurs through a 
number of steps including initiation, elongation and termination [180]. miRNAs are 
reported to repress translation during initiation or post initiation [182]. However, recent 
years, nine potential mechanisms have been reported for miRNA function. Morozova et 
al. detailed a model of the potential mechanisms of miRNA function based on literature 
analysis [183]. Nine potential mechanisms of action have been detailed (M 1-M 9) 
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(Table 1-6) including cap inhibition, elongation inhibition, ribosome drop-off and 
mRNA decay. The proposed model of these mechanisms is shown in Figure 1-13. 
.  
Table 1-5: Proposed mechanism of action of miRNA function as detailed by Morozova 
et al. [183]. 
Mechanism No Proposed Mechanism 
M 1 
Cap Inhibition 
(Inhibition of translation initiation via cap-40S association) 
M 2 
60S Joining Inhibition (Inhibition of translation initiation via40S-
AUG-60Sassociation) 
M 3 Inhibition of elongation 
M 4 Ribosome drop-off (premature termination) 
M 5 Cotranslational protein degradation 
M 6 Sequestration in P-bodies 
M 7 mRNA decay (degradation, destabilization) 
M 8 mRNA cleavage 
M 9 
Transcriptional Inhibition (miRNA-mediated chromatin 
reorganization following by gene 
silencing) 
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Figure 1-13: Overview of proposed mechanisms of miRNA action (Black). 
Mechanisms of gene expression from DNA to protein (Red). The mechanisms (M) are 
numbered as in Table 1-6. Adapted from [183]. 
 
1.7.4 Roles of miRNA 
miRNA have many physiological functions such as developmental timing, cell 
proliferation and differentiation, apoptosis, disease and anti-viral defence [171].  Due to 
the regulatory nature of miRNAs, it is extremely likely that they play a role in cancer.  
Studies carried out on the mir-17-92 cluster showed that miRNAs can modulate tumour 
formation and that this cluster is a potential oncogene [158].  It has been reported that 
miRNA expression is dysregulated in many human cancers and in breast cancer [184].  
In 2005, it was reported that certain miRNAs were differentially expressed in breast 
cancer tissue in comparison to normal breast tissue [184]. Some were found to be down-
regulated: miR-10b, miR-125b and miR-145 and others up-regulated: miR-21 and miR-
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155 [184]. Recently, miR-21 has been identified as an oncomiR along with other 
miRNAs in glioblastoma multiforme (GBM) [185]. miRNAs have been found to be 
predictive of the receptor status in breast cancer [186].  miRNAs have reported roles in 
metastasis and tumour invasion [187], [188, 189]. Some miRNAs function as metastasis 
suppressors [188]. In 2005 it was reported that miRNA expression profiles may classify 
cancer types [190]. More recently, Ganepola et al. discovered a panel of three miRNAs 
that could be used as diagnostic markers for early pancreatic cancer [191]. A miRNA 
panel was identified from patient plasma samples as a predictive biomarker panel for 
early diagnosis of gastric cancer [192]. These small molecules may also provide useful 
in the detection and profiling of cancers. In September 2010, the American Association 
for Cancer Research (AACR) released a press release for a miRNA-based screening tool 
that can be used to detect early stage colorectal cancer [193].  
 
1.7.5 miRNAs and HER2 positive breast cancer 
miRNA expression correlates with the receptor status of breast cancer [186]. ER, HER2 
and PR status were analysed and miRNAs were identified which are capable of 
distinguishing tumours with different hormone receptors status [186]. miR-183 has been 
implicated in HER2 positive breast cancer as it is significantly increased in HER2 
positive tumours in comparison to HER2 negative tumours [194]. Synthetic miRNAs 
targeting over-expressed protein have been shown to reduce HER2 levels  in ovarian 
cancer cells [195], suggesting a potential role for miRNA targeting therapies for breast 
cancer.   
 
Many miRNAs that potentially regulate the HER2 proto-oncogene have been identified. 
In 2006, a bioinformatical search revealed that miR-125a and miR-125b target 
56 
 
sequences are within the 3’UTR of HER2 and HER3 [196]. In experiments using the 
HER2 over-expressing cell line, SKBR3, transfection with miR-125a and miR-125b 
retroviral constructs resulted in the suppression of the HER2 and HER3 at the mRNA 
and protein level [196]. Suppression of AKT/PI3K and ERK1/2 activation occurred in 
these transfected cells. Another interesting finding was that in these transfected cells 
there was a reduction in migration and invasion [196]. Target elements for miR-584d-3p 
and miR-559 were also identified in the 3’UTR of HER2 [197]. Determination of the 
miRNA-mRNA interactions showed that both of these miRNA interact specifically with 
the 3’UTR of HER2 mRNA [197]. Transfection of both miRNAs together caused 
repression of HER2 mRNA whereas either mRNA alone did not [197].   
 
In the SKBR3 and BT474 HER2 positive breast cancer cell lines, microarray analysis 
showed that miR-194 was up-regulated in both cell lines after treatment with 
trastuzumab [198]. MiR-194 over-expression inhibited cell migration/invasion in vitro 
and inhibited cell growth in vivo and knockdown of miR-194 increased cell migration. 
A link between miR-194 and talin 2 (cytoskeleton protein) was determined and over-
expression of miR-194 down-regulated levels of talin2 indicating it is a direct target of 
miR-194. miR-337 and -305f were identified as over-expressed whereas miR-139 and -
129 were identified as under-expressed in HER2 positive breast and gastric cancer 
patients samples [199]. miR-4728 is encoded within the intron of the HER2 gene and 
found to regulate expression of ER alpha [200]. 
1.7.6 miRNAs  and trastuzumab resistance 
In 2010, a link between the PTEN tumour suppressor, miR-21 and trastuzumab 
resistance was reported [201]. Over-expression of miR-21 in HER2 over-expressing cell 
lines was shown to correlate with reduced levels of PTEN expression which led to 
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trastuzumab resistance [201, 202].  High levels of miR-21 expression is also associated 
with aggressive disease [201]. Another study found that miR-21 was up-regulated by 
HER2 signalling and this promoted cell invasion [203]. This miRNA is up-regulated via 
the Ras/MAPK pathway upon HER2/neu stimulation and the metastasis suppressor 
protein programmed cell death 4 (PCD4) is down-regulated by miR-21 in HER2 over-
expressing breast cancer cells [203]. More recently, miR-21 expression was evaluated in 
HER2 positive and negative tumours, however miR-21 up-regulation did not predict 
resistance to trastuzumab [204]. In 2011, Jung et al., investigated plasma levels of 
miRNA in breast cancer patients and revealed altered expression of miR-210. This was 
confirmed in trastuzumab resistant cells compared to trastuzumab sensitive cells. miR-
210 circulating levels were significantly higher in patients who had residual disease 
than those who achieved pCR, before surgery than after surgery and in patients whose 
cancer had metastasised to the lymph nodes [205]. These results suggest that plasma 
levels of miR-210 maybe used to predict response to trastuzumab therapies [205]. Over-
expression of miR-375 restored sensitivity to trastuzumab resistant SKBR3 cells in vitro 
and IGF1R was determined as a direct target [206]. miR-221 was identified as a 
promoter of trastuzumab resistance and was involved in inhibition of apoptosis and 
promotion of metastasis in HER2 positive breast cancers. PTEN was identified as a 
direct target of miR-221 and potential targeting of miR-221 along with trastuzumab 
may improve overall patient benefit [207]. In trastuzumab resistant SKBR3 cells, miR-
220c was identified as the most significantly down-regulated miRNA [208]. Zinc finger 
protein 217 (ZNF217) was identified as a target and through restoration of miR-220c 
expression and silencing of ZNF217 trastuzumab sensitivity was restored and invasion 
was suppressed in the SKBR3 trastuzumab resistant cell lines. 
 
58 
 
1.7.7 microRNAs and Lapatinib resistance 
To date only three studies have investigated miRNA expression in lapatinib resistance. 
Firstly, down-regulation of miR-205 was identified in breast cancer tumours compared 
to normal breast tissue by Iorio et al. [209]. Target validation for miR-205 identified 
HER3 as a direct target and it has inhibitory action on the activation of AKT in SKBR3 
and MCF-7 cells [209]. Transfection of miR-205 in the SKBR3 cells caused a decrease 
in levels of AKT and inhibited cell growth. Transfection of miR-205 increased the 
sensitivity of SKBR3 cells to gefitinib and lapatinib and decreased the HER3-mediated 
resistance suggesting it could be a potential onco-suppressor and biomarker of TKI 
response. In triple negative breast cancer cells, lapatinib treatment was examined due to 
the high percentage (80%) of TNBC cases expressing HER1 [210]. Unfortunately 
lapatinib treatment in combination with paclitaxel led to worse clinical outcome for 
patients with TNBC and HER2 negative disease [211]. A potential explanation 
suggested for this worsened outcome is miR-7 expression and its ability to enhance 
migration and invasion of MDA-MB-231 triple negative cell lines through the induction 
of HER1 and COX-2 expression [212]. More recently in 2014, a study investigating 
TKI resistance and miRNAs  identified miR-630 as an altered miRNA in innate and 
acquired lapatinib resistant cell lines compared to their parent cell lines [213]. 
Introduction of miR-630 in the resistant cells enhanced growth inhibition by TKIs 
(lapatinib, neratinib and afatinib). Alternatively, inhibition miR-630 expression reduced 
sensitivity to TKI treatment. miR-630 was also associated with a more aggressive 
phenotype suggesting that miR-630 may be a potential diagnostic and predictive marker 
for HER2-targeted drug response.  
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1.8. Circulating miRNAs  
Circulating miRNAs (CmiRNA) have become a recent topic of investigation due to 
their stability and ability to survive freeze-thaw cycles, extended storage and extreme 
variations in heat and pH [214, 215]. CmiRNAs have been identified as predictive 
markers of invasion and metastasis of cancers and could be extremely useful non-
invasive biomarkers [216]. Dysregulation of some of the key players in miRNA 
biogenesis pathway have been found in cancer progression. DiGeorge syndrome critical 
region gene 8 (DGCR8) and the RISC components argonaute-1 (Ago1), argonaute-2 
(Ago2), as well as double-stranded RNA-binding proteins PACT, TARBP1, and 
TARBP2 levels are elevated in skin cancer [217]. In ovarian cancer, silencing DGCR8 
resulted in inhibition of proliferation and migration of ovarian cancer cells [218]. 
Mature miRNAs have been identified in a range of biological fluids including saliva 
[219], urine [220], blood, amniotic fluid, breast milk, cerebrospinal fluid and pleural 
fluid [221]. The mechanism by which miRNAs are released or secreted is still unclear. 
One suggested mechanism is miRNAs are secreted through a ceramide-dependent 
secretory pathway which induces secretion of exosomes [222]. Other possible 
mechanisms of release include passive leakage from cells due to injury [223, 224], 
active secretion via exosomes [222] and apoptotic bodies [225] or active secretion and 
transport with high density lipoproteins [226], or Ago2 [227] and nucleophosmin 1 
[228] (Figure 1-14). 
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Figure 1-14: Overview of potential mechanisms of CmiRNA release and uptake. Three 
potential mechanisms are detailed. (1) Exosomal release indicated by red arrows, (2) 
High-density lipoproteins or RNA binding proteins indicted by blue arrows and (3) 
direct transfer through leaky cells indicated by green arrow. Abbreviations: MVBs, 
multi-vesicular bodies; NPM1, nucleophosmin 1; AGO2, Argonaute-2; HDL, high-
density lipoprotein. Adapted from [229]. 
 
Utilising CmiRNAs as biomarkers can distinguish cancer patients from healthy 
populations. CmiRNAs have been identified within serum samples of lung [230], 
prostate [231], colorectal [232], gastric [192], liver [233], hematologic [234] and breast 
[235] cancer patients. In early stage breast cancers, oncomiRs (miR-155, miR-19a, miR-
181b, miR-24, relative to let-7a) were determined to predict the onset of breast cancer 
[236]. As these miRNAs can be measured non-invasively, are stable within biological 
specimens and can indicate a cancerous phenotype, they represent ideal biomarkers for 
translational research. However, there are still issues with sample collection, RNA 
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isolation and quantification. For example, plasma processing and platelet contamination 
can lead to high variation in CmiRNA expression profiles [237]. These factors need to 
be optimised and standardised for successful circulating biomarker studies. 
 
1.8.1. Circulating HER2 positive breast cancer miRNAs 
CmiRNA expression profiles from HER2 positive patients plasma samples undergoing 
neoadjuvant trastuzumab based chemotherapy were investigated by Jung et al. [205]. 
They also investigated the trastuzumab sensitive (BT-474) and trastuzumab resistant 
variants (BTR65) HER2 positive breast cancer cell line and determined that circulating 
miR-210 levels correlated with trastuzumab sensitivity and tumour presence. Serum 
from patients enrolled in the Geparquinto trial was examined for CmiRNAs which 
could possible predict response to trastuzumab or lapatinib [238]. Elevated levels of 
miR-21, -210 and -373 were identified in patients before and after treatment compared 
to normal healthy volunteers. They also identified that miR-21 and -373 levels increased 
further after chemotherapy treatment and miR-21 is a prognostic biomarker of overall 
survival. 
 
miRNAs have proven to be valuable as indicators of prognosis, predictors of response 
and are involved in resistance to chemotherapy and targeted therapies. Thus they hold 
potential as targets for the treatment of HER2 positive breast cancer patients and merit 
further investigation. 
 
1.9. Cancer stem cells (CSCs) 
According to the National Institute of Health (NIH), a stem cell is an unspecialised cell 
that has the ability to form multiple cell types which contain special characteristics 
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[239]. These characteristics include; the ability to self renew through division, being 
unspecialised and the ability to specialise into tissue or organ specific cells. Cancer stem 
cells (also known as tumour initiating cells TICs) share properties of normal stem cells 
in that they have three defining features. The ability to form tumours in immune-
compromised mice, to self renew and to differentiate [240]. Cancer stem cells were 
initially identified by Al-Hajj et al. using specific cell surface marker expression, 
CD44
+
/ CD24
-/low
/Lin
- 
[241]. They identified that cells from breast cancer patients with 
this pattern of cell surface markers had enhanced tumour initiating abilities in 
NOD/SCID mice and could also self renew (be serially passaged) and differentiate 
(reproduce the tumour). Other markers have been used to isolate cancer stem cells 
including aldehyde dehydrogenase (ALDH) activity [242] and used in combination with 
CD44
+
/ CD24
-/low
 surface markers can isolate enriched cancer stem cell populations. 
CSCs have been linked to increased cancer aggression and metastatic potential of 
tumours especially in secondary sites [243]. Interestingly, resistance has also been 
proposed to play a part in CSCs and their involvement in recurrence. CSCs have been 
identified as more resistant to lapatinib based neoadjuvant chemotherapy than the 
primary bulk breast tumour [244]. Previously, it has been show that targeting the CSCS 
through the inhibition of cellular transformation by the diabetic drug Metaformin can 
overcome Herceptin resistance in xenografts models [245]. Therefore a therapy in 
which the bulk tumour and the CSCs (TICs) are both targeted could improve overall 
survival by combating resistance. 
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1.10. Study Aims 
The aims of this study were as follows: 
1. To identify novel miRNAs which are altered in acquired and innate trastuzumab 
and lapatinib resistant cell lines. 
a.  investigate the functional relevance of miRNAs altered in trastuzumab 
and lapatinib resistant cell lines 
b. identify miRNA gene targets that may serve as potential biomarkers 
and/or targets in trastuzumab and lapatinib resistant cells. 
2. To examine altered miRNA in tumour specimens from HER2 positive breast 
cancer patients who achieved a durable complete response following 
trastuzumab-based therapy.  
3. To examine circulating miRNA expression in serum samples from HER-2 
positive breast cancer patients who received neoadjuvant chemotherapy and 
trastuzumab with/without lapatinib. 
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Chapter Two  
Materials & Methods 
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2.1. Cell lines, cell culture and reagents 
The cell lines SKBR3, BT474, HCC1419, HCC-1569, HCC-1954, MDA-MB-361, 
MDA-MB-453, UACC-732 and EFM-192A were obtained from the American Type 
Culture Collection (ATCC).  JIMT-1 cells were purchased from the German Collection 
of Microorganisms and Cell Cultures (DSMZ).  All cell lines were cultured in RPMI 
1640 medium (Sigma Aldrich, R8758) supplemented with 10 % fetal calf serum (FCS) 
(PAA Laboratories). The acquired trastuzumab and lapatinib resistant cell lines (Table 
2-1) were created by continuous culture cells for a minimum of 6 months in RPMI 
supplemented trastuzumab or lapatinib as described in Figure 2-1 [123, 246, 247], with 
aged matched media controls (parental).  The trastuzumab and lapatinib response details 
of all cell lines used in this study are detailed in Table 2-2. Trastuzumab (Herceptin™) 
was obtained from St. Vincent’s University Hospital and lapatinib (Tykerb ®) was 
obtained from GlaxoSmithKline. All cell lines were routinely tested for the presence of 
mycoplasma using the indirect staining method [248]. In addition, mitochondrial DNA 
from all cell lines, including newly developed lapatinib-resistant cell lines, was 
sequenced in 2010 to confirm their identity (in collaboration with Dr. Neil O’Brien and 
Dr. Charles Ginther in UCLA). 
Table 2-1: Summary of cell line models of trastuzumab and lapatinib acquired 
resistance used in this study.  
 
 
 
 
 
 
Model of Resistance Cell Line 
Trastuzmab 
SKBR3-T 
BT-474-Tr 
Lapatinib 
SKBR3-L 
HCC1954-L 
66 
 
Media Only
2 x weekly 
treatment with 
drug – 6 months
Parental Resistant
 
 
 
 
 
 
 
 
Figure 2-1: Overview of creation of cell line models of resistance. Resistant cell lines 
were created by continuous culture of cells for a minimum of 6 months in RPMI 
supplemented trastuzumab or lapatinib Aged matched parental controls were also 
included. 
 
Table 2-2: Trastuzumab and lapatinib response details of all cell lines used in this 
study. R: resistant and S: sensitive to drug inhibition. Information is adapted from [103]. 
Cell Line Trastuzumab Response Lapatinib Response 
BT-474 S S 
BT-474-Tr R S 
EFM-192A S S 
SKBR3 S S 
SKBR3-T R S 
SKBR3-L R R 
MDA-MB-361 S S 
UACC-732 R R 
HCC-1419 R S 
JIMT-1 R R 
HCC-1954 R S 
HCC-1954-L R R 
HCC-1569 R R 
MDA-MB-453 R R 
67 
 
2.2. Proliferation assays 
Cells were seeded at density of 3x10
4
 (SKBR3, SKBR3-T, BT474, HCC1419, 
HCC1569, HCC-1954, MDA-MB-361, MDA-MB-453, UACC-732 and JIMT-1), and 
5x10
4
 (BT474, BT474-Tr and EFM-192A) in 96 well flat bottomed plates and incubated 
overnight at 37 °C with 5% CO2. Cells were treated with appropriate media controls, 
10/100 µg/mL trastuzumab (SKBR3/BT474), serial dilutions of lapatinib ranging from 
0.2 – 10 µM or all-trans-retinoic acid (ATRA) ranging from 0.05 - 0.2 µM (Sigma, 
R2625). Proliferation was measured after 5 days using the acid phosphatase method.  
Briefly, media was removed and each well rinsed with phosphate buffered saline (PBS); 
100 µL of acid phosphatase substrate (10 mM p-nitrophenol phosphate (Sigma, 34045) 
in 0.1 M sodium acetate pH 5.5, 0.1% triton-100 (Sigma, X100) was added to each well 
and incubated at 37°C for 1-2 hours after which 50 µL of 1 M NaOH (Sigma, S5881) 
was added to each well and the absorbance was read at 405 nm with 620 nm as a 
reference on a Biotek microplate reader. Proliferation was calculated relative to 
untreated controls. Each assay was carried out in triplicate. 
 
2.3. microRNA extraction 
microRNA (miRNA) was extracted using the mirVana™ miRNA Isolation Kit 
(Ambion, AM1560). Briefly, cells were grown to 70-80% confluency, trypsinised 
(trypsin-EDTA (Gibco)) and centrifuged at 160 x g for 3 mins. Cell pellets were washed 
with PBS, centrifuged as before and placed on ice. Cells were lysed in 300-600 µL of 
lysis buffer and 1/10 volume miRNA homogenate additive was added, vortexed and 
incubated on ice for 10 mins. A volume of acid:phenol chloroform equal to the amount 
of lysis buffer was then added, vortexed for 30-60 secs and centrifuged at top speed 
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(17,530 x g) for 5 mins at room temperature. The top aqueous layer was then removed 
(volume noted) and 1.25 volumes of room temperature ethanol (100%) was added. The 
mixture was added to a filter cartridge, centrifuged for 15 sec at 12,400 x g and the flow 
through was discarded. Wash solution 1 was added (700 µL) and centrifuged as before 
followed by wash solution 2/3 (500 µL) twice and centrifuged as before with flow 
through discarded each time. The filter cartridge was centrifuged for 1 min to remove 
residual ethanol and placed in a fresh collection tube. Pre-heated (95°C) nuclease free 
water (100 µL) was applied to the filter cartridge and incubated for 1 min at room 
temperature. The filter cartridge was centrifuged at 12,400 x g for 20-30 sec to elute 
miRNAs. miRNA extracts were stored at -80°C. Each extraction was carried out in 
triplicate. The RNA concentration (ng/μL) was determined using the Nanodrop ND 
1000 (Thermo Scientific).  
 
2.4. Agarose gels 
A 0.8% agarose (Sigma Aldrich, A9539) gel was prepared in 50 mL 1X TAE buffer 
(Tris-Acetate-EDTA) with 2 µL ethidium bromide (Sigma Aldrich, E1510) added. 
Molecular weight markers (P1473, Sigma) and RNA (1 µg) were loaded into the 
appropriate wells (10 µL of sample: 10 µL of 1X loading buffer (30% glycerol, 0.1 M 
EDTA, 0.25% bromophenol blue).  The gel was electrophoresed at 90 V for 20 min. 
RNA was visualised on the Epi Chemi II Darkroom (Ultra-Violet Products, UVP) using 
the software Labwork 1(Bioimaging Systems). 
2.5. TLDA data analysis 
Previously, Taqman Low Density Arrays (TLDAs) were carried out by Salima Soualhi. 
The overall workflow is outlined in Figure 2.2. The experimental design was to identify 
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potential microRNAs involved in trastuzumab and lapatinib resistance by screening the 
SKBR3-T and SKBR3-L cell lines and calibrating these results to their parental cell 
line, SKBR3-P.  
Figure 2-2: Array workflow for Taqman Low Density Arrays (TLDA). Isolated 
microRNA is reverse transcribed with megaplex RT-primers, diluted RT product is then 
mixed with universal PCR master mix and loaded onto pre-configured 384-well micro 
fluidic cards which include endogenous controls. The data is then analysed to identify 
microRNAs of interest. Image taken from www.lifetechnologies.com  
 
The sequence detection systems (SDS) files from the SDS 2.2.2 software (Applied 
Biosystems) were analysed as follows: the two resistant cell lines, SKBR3- H and 
SKBR3-L were compared to the SKBR3 cell line which was set as a calibrator using a 
manual threshold of 2.0. Expression values were calculated using the comparative 
threshold cycle (Ct) method. RNU48 was selected as the endogenous control. The 
threshold cycle Ct indicates the cycle number by which the amount of amplified target 
reaches a fixed threshold. The Ct data for each specific miRNA and RNU48 were used 
to create delta Ct (ΔCt) values. ΔΔCt values were calculated by subtracting the 
calibrator (SQ) from the ΔCt value of each target (e.g. resistant minus control). Relative 
quantification (RQ) values were calculated using the equation:  
RQ = 2
ΔΔCt
 = 2 
ΔCt control–ΔCt test = 2 (Ct.X-Ct.R)control – (Ct.X-Ct.R)test [249] 
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Where, CtX is the cycle threshold of the gene of interest and Ct.R is the cycle threshold 
of the endogenous reference gene.
 
2.6.   miRNA reverse transcriptase reaction (RT-PCR)  
Stock solutions of RNA (2 ng/µL) were prepared by diluting miRNA with RNase free 
water (Ambion, 9932). An RT master mix solution was prepared as per Table 2-3. 
Briefly, for each reaction 5 µL of miRNA sample (10 ng), 7 µL of master mix and 3 µL 
of miRNA assay (5X) (Table 2-4) were combined in PCR tubes, mixed gently, briefly 
centrifuged and incubated on ice for 5 min. Samples were then loaded into the thermo-
cycler (G-STORM), reaction volume was set to 15 µL and the RT reaction performed as 
per Table 2-5. The samples were then stored at -20°C until required. Controls were 
included in the RT reaction; non-target control (NTC) which was prepared without the 
RNA template, and a minus reverse transcriptase control (RT-) which was prepared 
without the reverse transcriptase enzyme. Each sample was tested in triplicate. 
 
Table 2-3. Components and make up of RT reaction master mix  
 
Component 
Master mix volume per  
one reaction* 
100 mM dNTPs (with dTTP) 0.15 
10X Reverse Transcription Buffer 1.50 
RNase Inhibitor (20 U/µL) 0.19 
Nuclease free water 4.16 
MultiScribe™ Reverse Transcriptase (50 
U/µL) 
1.00 
Master Mix Total Volume 7.00 
TaqMan®  miRNA assay (5X) 3.00 
RNA (10 ng) 5.00 
Total 15.00 
* Each 15 μL RT reaction consists of 7 μL master mix, 3 μL of 5X RT primer                                                                                                 
(miRNA assay) and 5 μL RNA sample. 
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Table 2-4: TaqMan® miRNA assays for RT (5X) and qRT-PCR (20X). Assay ID refers 
to the ordering code for each specific miRNA (Applied Biosystems). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2-5. G-Storm thermal cycler program for RT-PCR reaction 
 
 
 
 
 
 
 
 
2.7. Gene expression reverse transcriptase reactions 
Stock solutions of RNA (1 µg /10 µl) were prepared by diluting RNA extracts with 
RNase free water (Ambion, 9932). Using a high capacity cDNA Reverse Transcription 
Kit (Applied Biosystems, 4368814), a 2X master mix solution was prepared as per 
Table 2-6. For each reaction 10 µl of RNA sample and 10 µL of master mix were 
combined in PCR tubes, briefly centrifuged and loaded into the thermo-cycler (G-
Assay Name Assay ID Assay Name Assay ID 
miR-100 000437 miR-30a-5p 000417 
miR-135a 000470 miR-30e-3p 000422 
miR-148a 000471 miR-30d 000420 
miR-192 000491 miR-31 002279 
miR-194 000493 miR-375 000564 
miR-203 000507 miR-9 000583 
miR-205 000509 miR-92 000430 
miR-21 002438 miR-550 002410 
miR-221 000524 miR-let7a 000377 
miR-222 002276 miR-let7c 000379 
miR-224 002099 RNU48 001006 
miR-30a-3p 000416   
Temperature (°C) Time (min) 
16 30 
42 30 
85 5 
4 ∞ 
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STORM) and the reverse transcription run as per Table 2-7. The samples were then 
stored at 4 °C until required. Controls were included: non-target control (NTC) which 
was prepared without the RNA template, and a minus reverse transcriptase control (-
RTC) which was prepared without the reverse transcriptase enzyme. 
 
Table 2-6: Components of master mix for RT reactions. 
Component Volume / Reaction (µl) 
10X RT buffer 2.0 
25X dNTP Mix (100 mM) 0.8 
MultiScribe 
TM
 Reverse transcriptase 1.0 
RNase-free water 4.2 
10X  RT random primers 2.0 
Total per reaction 10.0 
 
 
 
 
Table 2-7: Thermo-cycler steps, indicating the temperature and duration, for RT 
reactions. 
Step Temperature (°C) Time (min) 
1 25 10 
2 37 120 
3 85 5 
4 4 Hold 
 
2.8. Real time quantitative reverse transcription polymerase chain 
reaction (qRT-PCR) 
qRT-PCR was performed using individual TaqMan® miRNA assays (20X) as per  or 
TaqMan® Gene Expression Assays (20X) as per Table 2-8. TaqMan® miRNA and 
gene expression experiments were carried out in 20 µL reactions as detailed in Table 2-
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9 and added to the appropriate wells in a 96-well PCR reaction plate (Applied 
Biosystems, 4346906). cDNA was then added to the appropriate wells (1 µL). The PCR 
plate was sealed using optical adhesive film, mixed gently and placed on ice for 5 min. 
The qRT-PCR reaction was performed on the ABI7900HT standard system using SDS 
automated controller software (version 2.2) (Applied Biosystems) with the thermal 
cycling conditions detailed in Table 2-10. 
 
Table 2-8: TaqMan® Gene Expression Assay (20X) details. Assay ID refers to the 
ordering code for each specific miRNA (Applied Biosystems). 
Assay Name Gene ID Assay ID 
p27
Kip1 
 CDKN1B Hs00153277_m1 
RARα RARA Hs00940446_m1 
GAPDH GAPDH HS02758991_g1 
 
  
Table 2-9: Components of qRT-PCR reaction. 
Component Volume (µL)/ 20 µL reaction 
TaqMan®  Universal PCR Master Mix* 10.0 
TaqMan®  MiRNA assay (20X) 1.0 
Nuclease Free Water 8.0 
cDNA from RT reaction 1.0 
Total Volume 20.0 
  * No AmpErase UNG (2X) 
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Table 2-10: ABI 7500 Fast real-time PCR system thermal cycler program for qRT-PCR  
 
 
2.9. MiRWalk- Target prediction & validation 
miRWalk is a comprehensive database that provides information on both predicted and 
validated miRNAs associated with particular genes, pathways and diseases. 
(http://www.umm.uni-heidelberg.de/apps/zmf/miRWalk/index.html). The database 
consists of two modules; predicted and validated target modules as shown in Figure 2- 
3. The predicted targets module holds information on miRNA-target interactions on the 
complete sequence of all known genes of humans, mouse and rat. miRWalk obtains 
results from eight established miRNA target prediction programs; miRanda, DIANA 
MT, miRDB, PICTAR 4 & 5, RNA22, Target Scan and miRWalk, where each of these 
programs contain different algorithms. miRWalk compiles a table of all predicted 
targets using all the above programs and also provides predicted binding sites on genes 
associated with biological pathways (449) and OMIM (online mendelian inheritance in 
man) disorders (2356). The validated targets module provides information on miRNA-
target interactions that have been experimentally validated with associations to genes, 
pathways, diseases, organs, cell lines and OMIM disorders. It also yields information on 
proteins involved in miRNA processing [250]. 
 
 
Step Step Type Time Temperature (°C) 
Initial Step HOLD 10 min 95 
PCR 
(40 cycles) 
 
Cycle 
15 sec 95 
1 min 60 
75 
 
 
 
 
 
 
 
 
 
 
 
Figure 2- 3: Overview of the miRwalk database for prediction and validation of targets 
[251]. 
 
2.10. Lentiviral stable transduction 
The lentiviral stable transduction for miR-221 and -222 was performed by Dr. Laoighse 
Mulrane in University College Dublin (UCD) [252]. The lentiviral vector system used 
in this study was obtained from the Trono laboratory, University of Geneva, 
Switzerland. It consists of the shRNA lentivector, pLVTHm system and the accessory 
viral packaging (psPAX2) and envelope (pMD2.G) constructs. Viral particles were 
produced in HEK 293T cells by transfection using Genejuice transfection reagent 
(Millipore, Billerica, MA, USA). Viral production and infection of target cells was 
carried out in a P2 containment facility and infected cells were passaged twice 
following selection before being returned to the main tissue culture facilities. Stable 
ectopic expression of miR-221/222 was carried out using the pEZX-MR03 vectors 
(Genecopoeia, Rockville, MD, USA) containing expression cassettes for each miRNA. 
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A control for ectopic expression of miR-221/222, was also included with a pEZX-
MR03 vector expressing a scrambled miRNA sequence. Selection was carried out in 
media containing 2 µg/mL puromycin (Sigma-Aldrich, St Louis, MO, USA) over a 
period of 2-5 days. Ectopic expression was validated by fluorescent microscopy using 
the Leica DFC 500 microscope (GFP-positivity) and quantitative real time polymerase 
chain reaction (qRT-PCR). Further information is available from the laboratory‘s 
website (http://tronolab.epfl.ch/).   
2.11. Wound scratch migration assay 
The wound scratch migration assay was conducted in triplicate under serum-reduced 
(2% FBS) conditions to reduce proliferation as described previously [253]. Cells were 
seeded at a density of 1.0 x 10
5
 in a 12 well tissue culture plate. Once the cells reached 
100% confluency, they were incubated in PBS for 15 min, after which, a scratch was 
made using a P200 tip. Cells were rinsed once with PBS and RPMI-1640 medium 
supplemented with 1% FCS was then added to the cells. Images were captured at T0, 
T24 and T48 using the Nikon Eclipse TS100 microscope with attached Olypus DP70 
digital microscope camera. The quantification was conducted using Tscratch software 
[254]. All open areas at T0 were set to 100% and all open areas at later time points were 
calculated relative to the T0 value.  
2.12. Doubling time assays 
Cells were seeded at density of 1 x 10
4
 in 96 well flat bottomed plates and media 
controls or media containing trastuzumab (1 µg/mL) was added on Day 0 to appropriate 
wells and incubated in a CO2 incubator at 37 °C overnight. We chose this trastuzumab 
concentration as previous dose analysis (not presented) on our stable transduced cell 
lines showed treatment with 1 µg/mL yielded similar results to treatment at 10 µg/mL. 
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Proliferation was measured at Day 1 (24 hrs after plating), Day 3, Day 5 and Day 7 
using the acid phosphatase method as per 2.2. Doubling time was calculated as: 
ln2(96)/ln2(Abs
Day7
/Abs
Day3
). Each assay was carried out in triplicate. 
2.13. Preparation of cell lysates 
Cells were grown in petri dishes (100 mm) until 70-80% confluent. Trastuzumab (10 
µg/µL), lapatinib (250 nM) or media controls were set up for 24 h and 48 h. Whole cell 
lysates were prepared as follows: cells were washed thrice with cold phosphate buffered 
saline solution (PBS) and 250-500 µL/dish RIPA buffer ((Sigma, R0278) 5 mM Tris-
HCl pH 7.4, 1% NP-40, 0.1% SDS, 150 mM NaCl, 1% Triton x-100) containing 1x 
Protease Inhibitor cocktail (Calbiochem, 539131), 2 mM PMSF (Sigma, P7626), and 1 
mM sodium orthovanadate (Sigma, 6508), was added and cells were incubated on ice 
for 20 minutes. Cells were scraped into lysis buffer. The lysis buffer was collected, 
passed through a 21G needle and centrifuged at 16,100 x g for 10 minutes at 4 
o
C. The 
pellets were discarded and the supernatants collected and stored at -80
o
C. Protein 
quantification was performed using the bicinchoninic acid (BCA) quantitation kit 
(Pierce, 23227). 
 
2.14. Western blotting 
Protein (20-50 µg) was electrophoretically resolved on NuPAGE® Novex® 4-12% Bis-
Tris gels (BioSciences, NP0329) under denaturing conditions. The resolved proteins 
were then transferred to nitrocellulose membranes (Invitrogen, IB3010-01) using the 
iBlot transfer system (Invitrogen, IB1001). Protein transfer was visually confirmed 
using Ponceau S staining (Sigma, P7170). Membranes were blocked for 1hr using 1x 
NET buffer (0.5 M NaCl, 0.05 M EDTA, 0.1 M Tris pH 7.8)  at room temperature and 
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incubated overnight at 4 
o
C with primary antibodies in 1x NET. Stock 10X NET buffer 
is prepared using the components listed in Table 2-11. The 1X NET buffer is prepared 
by the addition of water (17.5 L) to a 20 mL container with the addition of 10X NET (2 
L). Dissolved gelatine (50g in 0.5 L of H20) is added to the 10X NET/H20 solution. The 
blotting conditions for each primary antibody are detailed in Table 2-12. Membranes 
were washed with 1x NET 3 times for 10 mins each, both prior to and following 
incubation with secondary antibodies. Proteins were visualised using horseradish 
peroxidase-conjugated anti-mouse, anti-goat or anti-rabbit antibodies (Sigma) and 
Luminol reagent (Santa Cruz Biotechnology, SC2048) or Clarity Western ECL 
substrate (BioRad, 170-5060). Protein bands were semiquantified by densitometry, and 
protein levels were calculated relative to α-tubulin levels by Image J. 
 
Table 2-11. Protocol for the preparation of 10X NET Buffer.   
Stock Conc Compound Volume (mls.) Final Conc 
5M NaCl 600 1.5M 
0.5M EDTA 200 0.05M 
1M Tris pH 7.8 1000 0.5M 
100% Triton X-100 10 0.5% 
100% H20 190  
Total Volume  2000  
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Table 2-12: Details of Primary and Secondary antibodies used in this study, including blotting conditions and source. 
Antibody dilution Blotting conditions Secondary + ve control Company Cat no. 
α-tubulin 1:1000 1X NET Mouse  Sigma T6199 
anti-RARα   1:200 1X NET Mouse MCF7 Abcam #9272 
anti-RARβ 1:500 1X NET Rabbit MCF7 Abcam ab53161 
anti-RARγ 1:500 1X NET Mouse MCF7 Abcam ab41938 
anti-RXRα   1:200 1x NET Rabbit MCF7 Santa Cruz sc-553 
anti-p27Kip1 1:400 1X NET Mouse HEK-293 Santa Cruz sc-53871 
anti-rabbit secondary 1:2000 1X NET Rabbit  Sigma A6154 
anti-mouse secondary 1:1000 1X NET Mouse  Sigma A6782 
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2.15. miRNA extraction from conditioned media 
miRNA was isolated from conditioned media as previously described [255]. Briefly, 
cells at 70-80% confluency were incubated in appropriate media (RPMI + 10% FCS) in 
a T75cm
2
 for 24 hr at 37°C and 5% CO2. The supernatant was then harvested for 4 min 
at 160 x g at 4°C. The samples were stored at -20°C. miRNA extraction was carried out 
on 1 mL of the collected conditioned media, TRIzol (15596-026, Life Technologies) 
was added (700 µL), the sample was vortexed and incubated at room temperature for 5 
min. Acid: phenol chloroform (140 µL) was added and vortexed vigorously for 15 sec. 
Sample was then centrifuged at 17,530 x g for 15 min at 4°C. The upper aqueous phase 
was transferred to a new tube and the miRvana extraction protocol was followed from 
the ethanol separation step as detailed in 2.3. RNA concentration (ng/µL) was assessed 
using the NanoDrop ND1000.  
2.16. miRCURY RNA isolation kit- Biofluids 
miRNA was extracted from patient serum samples using the miRCURY biofluids kit 
(Exiqon, 300112). Briefly, 250 µL of serum samples were centrifuged at 3000 x g for 5 
min to pellet any debris or insoluble components. Supernatant (200 µL) was transferred 
to a new tube and lysis solution BF (60 µL) was added, vortexed for 5 sec and incubated 
at room temperature for 3 min. Protein precipitation solution BF (20 µL) was added, 
vortexed for 5 sec and incubated at room temperature for 1 min. Sample was then 
centrifuged at 11,000 x g for 3 min. The clear supernatant was transferred to a new 
collection tube (2 mL) and isopropanol (270 µL) was added. Solution was vortexed for 
5 sec, transferred to a miRNA mini spin column BF in a collection tube and incubated at 
room temperature for 5 sec. Sample was then centrifuged at 11,000 x g for 30 sec, flow 
through discarded and column placed back in collection tube. Wash solution 1 BF (100 
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µL) was added, centrifuged at 11,000 x g for 30 sec and flow through discarded. Wash 
solution 2 BF (700 µL) was added, centrifuged at 11,000 x g for 30 sec and flow 
through discarded. A final wash with wash solution 2 BF (250 µL) was added and 
centrifuged at 11,000 x g for 2 min to dry the membrane completely. The miRNA mini 
spin column BF was added to a new collection tube (1.5 mL), RNase free H20 was 
added directly to centre of membrane and incubated at room temperature for 1 min. 
Sample was then centrifuged 11,000 x g for 1 min. Purified RNA was stored at -80 °C 
for downstream experiments. 
 
2.17. ALDEFLOUR assay 
The ALDEFLUOR assay was carried out in collaboration with Dr. Michael Gallaghers 
‘Cancer Stemness Group’ in Trinity College Dublin. Briefly, cell pellets were prepared 
from 70-80% confluent cells in a T75cm
2
 flask, trypsinised and washed in PBS and 
centrifuged briefly to pellet the cells. These cells were then analysed by ALDEFLUOR 
(ALDH) assay in TCD. This assay, which is detailed in Figure 2-4, identifies putative 
cancer stem cells (pCSCs) based on their ability to metabolise a synthetic 
aldehydrogenase 1 substrate, BODIPY-aminoacetaldehyde (BAAA), to produce a 
brightly fluorescing substance (BODIPY-aminoacetate). This reaction can be inhibited 
by an aldehydrogenase inhibitor called Diethylaminobenzaldehyde (DEAB). By adding 
BAAA to a sample of cells one can discriminate pCSCs and non-pCSCs based on 
fluorescent intensity. When DEAB is added to the reaction it prevents the production of 
the fluorescent by-product thus acting as a negative control. By subtracting the negative 
control data from the uninhibited sample data, pCSCs and non-pCSCs sub-populations 
can be discriminated and quantified. 
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Figure 2-4: ALDEFLUOR assay which is depicted in (A) ALDH-negative cells and (B) 
ALDH-positive cells. Bodipy-aminoacetaldehyde diethyl acetal (BAAA-DA) is 
converted to the ALDH substrate Bodipy-aminoacetaldehyde (BAAA) in the presence 
of dimethylsulfoxide (DMSO) and hydrochloric acid, which diffuses freely across the 
plasma membrane of intact viable cells. Intracellular ALDH converts BAAA into the 
fluorescent product BAA (BODIPY-aminoacetate). In the presence of ALDH, cellular 
fluorescence can be detected with the green fluorescence channel of a standard flow 
cytometer and compared with treatment using the ALDH inhibitor diethylamino-
benzaldehyde (DEAB) as a negative control. Adapted from [256]. 
 
2.18. Establishment of primary mammosphere assays from cell lines 
The primary mammosphere protocol was previously described [257] and is shown in 
the illustration in Figure 2-5. Cells were grown to 70-80% confluency. Cells were 
trypsinised and resuspended in RPMI media supplemented with 10% FCS, centrifuged 
at 100 x g for 3 min and the media supernatant was removed. Cells were resuspended in 
10 mL PBS, syringed using a 25 gauge needle to form a single cell suspension and a 
cell count was performed. Mammosphere media (2 mL) (detailed in Table 2-13) was 
added to corresponding wells on a 6-well polyhema coated plate with/without 
83 
 
trastuzumab (10 µg/mL) or lapatinib (50 nM). Cells were seeded at an optimised 
seeding density as per Table 2-14. Plates were incubated in a CO2 incubator at 37°C for 
5 days without moving/disturbing the plates and without replenishing the media. After 5 
days, the numbers of mammospheres greater than 50 µm were counted using the Nikon 
TS100 microscope (40X magnification) fitted with a graticule as shown in Figure 2-6. 
Primary mammosphere formation is expressed as percentage mammosphere formation 
efficiency (MFE), that is: (number of mammospheres formed/original number of cells 
seeded)*100. 
 
 
 
 
Figure 2-5: Overview of the primary mammosphere protocol. Single cells suspension is 
plated out into polyhema coated 6-well plates in mammosphere media (MS media). The 
resulting mammospheres are counted after 5 day incubation in 5% CO2 at 37°C. 
 
   Table 2-13. Constituents of Mammosphere Media. 
Constituents Company & Catalogue Number 
DMEM/F12 Gibco, 21041 
B27 supplement (no vitamin A) Invitrogen, 12587 
Recombinant epidermal growth factor 
(20ng/µL) 
Sigma Aldrich, E-9644 
 
 
 
 
 
Polyhema
MS media
Single cells Mammospheres
5 days
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Table 2-14: Optimised seeding densities for mammospheres for each cell line. 
Cell Line Density 
SKBR3-Parental 300 cells/well 
SKBR3-T 500 cells/well 
SKBR3-L 500 cells/well 
SKBR3-P-Scramble 500 cells/well 
SKBR3-P-221 500 cells/well 
SKBR3-P-222 500 cells/well 
SKBR3-P-221-222 
500 cells/well 
 
 
 
 
 
 
 
 
Figure 2-6: Image of graticule which is used to count mammospheres of greater than 50 
µM diameter. 
 
2.19. Assessment of self-renewal – secondary mammosphere generation 
Media containing the known amount of mammospheres from the primary generation 
were collected into a 30 mL steralin. The wells were washed with PBS to ensure 
collection of all mammospheres and centrifuged at 100 x g for 2 min. The supernatant 
was carefully removed, resuspended in trypsin (200 µL) and placed in incubator at 37°C 
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for 2 min. The mammospheres were disaggregated using a 25 gauge needle to form a 
single cell suspension. RPMI media supplemented with 10% FCS was added (1 mL) to 
neutralise the trypsin and centrifuged at 1000 x g for 2 min. Supernatant was removed 
and the appropriate amount of mammosphere media was added corresponding to the 
number of wells calculated from the primary generation, as follows:  
 
No of 1° mammospheres x 100 cells per mammosphere/No of cells seeded per well = 
No of wells set up for secondary generation. 
 
Plates were incubated undisturbed for 5 days and the resulting secondary 
mammospheres were counted as per 2.18 and mammosphere self-renewal was 
calculated as follows: Total number of 2° mammospheres formed/ total number of 1° 
mammospheres formed. Any value under 1, was deemed a decrease in self renewal 
properties and a value above 1 was deemed an increase in self renewal properties. 
2.20. Preparation of cell culture blocks as block donors 
SKBR3 parental cells were grown to 75-80% confluency, trypsinised and resuspended 
in 10 mL of media. Cells were pelleted by centrifugation at 75 x g for 3 min and the 
supernatant was removed. Cells were washed once in PBS, re-pelleted and the 
supernatant was removed. The cell pellet was fixed in 5 mL of a 10 % (v/v) neutral-
buffered formalin solution, containing formaldehyde solution (Sigma, 252549), sodium 
dihydrogen phosphate (Fisher Scientific, 7558-79-4) and disodium hydrogen phosphate 
(Fisher Scientific, 7558-80-7), and incubated overnight at room temperature. Cells were 
pelleted by centrifugation at 75 x g for 3 min, washed with PBS and re-pelleted. Cells 
were re-suspended in 200 µL of a 0.8 % agarose (Sigma, A9539) solution and 
transferred to a 1.5 ml microcentrifuge tube, from which the tapered end had been 
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removed. The agarose plug was left to solidify within the tube, removed via the cap end 
and transferred to an embedding cassette (Fisher Scientific, 15-200-402E). The cassettes 
were placed in a slide bath and were washed for 1 hour each in the following solutions: 
ultra-high purity (UHP) water, 50 % ethanol (Merck, 100983), 70 % ethanol, 90 % 
ethanol, 100 % ethanol. This was followed by 2 x 1 hour washes in 100 % xylene 
(Applichem, A0663), before being placed into melted paraffin (McCormick Scientific, 
561006) for 2 hours. Using the Leica EG1150H machine the cassettes were placed in 
plastic moulds (SKS Science, M475), embedded with paraffin and left to cool. Once the 
paraffin was set the cell culture blocks were stored at 4 °C with desiccant prior to 
sectioning.  
2.21. Sectioning and coring of cell culture donor blocks 
Sectioning of cell culture blocks was carried out on a Reichert-Jung 2030 microtome. 
Briefly, 10 µM sections were cut from the cell blocks, sections were floated out in a 
water bath at 40 
o
C, mounted on super frost slides (Thermo Scientific, 
10143560WCUT) and allowed to dry at room temperature. Once dry, the sections were 
trimmed of any excess paraffin and scraped into a microcentrifuge tube (1.5 mL). Cores 
of 1.0 mm and 1.5 mm were taken using biopsy punches (Brymill Cyrogenic Systems, 
BPP-10F, BPP-15F) and immediately placed into a microcentrifuge tube (1.5 mL). Both 
sections and cores were stored at 4°C.  
2.22. De-paraffinisation and H & E staining of sections 
Sections were placed into an oven at 60⁰C for 20 min. Once paraffin had melted 
thoroughly, sections were transferred to a slide bath and washed for 5 min each in the 
following solutions; xylene (Applichem, A0663), 100 % ethanol (Merck, 100983), 90 % 
ethanol, 70 % ethanol and running tap water. Sections were then transferred to bath of 
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Haematoxylin (Reactifs Ral, 361070) for 4 min and rinsed in running tap water until a 
purple colour developed, differentiated in 0.3% acid alcohol until a blue colour 
developed and rinsed in running tap water for 4 min. Sections were then stained with 
Eosin (Acros Organics, 409430250) for 2 min and underwent dehydration, clearing and 
mounting. Briefly, sections were washed for 5 min each in the following solutions; 70% 
ethanol, 90% ethanol, 100% ethanol and xylene. Sections were mounted using Di-n-
butyl phthalate (Dpx) mounting liquid (Sigma Aldrich, 44581), coverslips and allowed 
to dry at room temperature. Images were captured using the Nikon Eclipse TS100 
microscope with attached Olypus DP70 digital microscope camera. 
2.23. HER2 Immunohistochemistry  
Automated immunohistochemistry was performed using the DAKO Autostainer system. 
Antibodies against HER2 (c-eRBB2) (Dako, A0485) were used in this study. Previously 
HER2 positive breast samples were scored by a pathologist and only sections with a 2+-
3+ score were used as positive controls for IHC experiments (Table 2-15). A 
representative image showing the scoring system for HER2 is detailed in Figure 2-7. 
Antigen retrieval and dewaxing was performed using automated Dako PT Link in 
Target Retrieval Solution pH6 (Dako S1699). Slides were placed in Dako PT link at 65 
˚C and heated to 97 ˚C and maintained at 97 ˚C for 20 minutes. The slides are cooled to 
65 ˚C and removed. After de-paraffinisation, the slides were placed in the DAKO 
Autostainer, which performed the programmed application of reagents in order as listed 
in Table 2-16. The dilution of HER2 antibody was 1 in 250. Washes were performed, 
with DAKO wash buffer, before and after the application of the each reagent, except in 
the case of the Real HP Block, where a blow step was performed. Slides were 
subsequently dehydrated in grading alcohols 70 %, 90 %, and 100 %, cleared in xylenes 
(2 x 3 minutes each) and mounted in Di(nbutyl) Phthalate in Xylene (DPX). 
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Table 2-15: Overview of the scoring system guidelines for Herceptin in tumour tissues. 
Adapted from [258]. 
Score 
HER2 Over-expression 
assessment 
Staining Pattern 
0 Negative 
No staining observed or membrane staining is 
observed in <10% of tumour cells 
1+ Negative 
Faint membrane staining is detected in more than 
10% of tumour cells 
2+ Weakly Positive* 
A weak to moderate complete membrane staining is 
observed in more than 10% of tumour cells  
3+ Strongly Positive ** 
A strong complete membrane staining is observed 
in more than 10% of cells 
*May be analysed further using fluorescence in situ hybridisation (FISH). 
**FISH analysis may be used as a complementary test in these cases. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-7: Illustration of the scoring system 0-3+ in breast tumour tissues. Images are 
adapted from [258] 
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Table 2-16: Dako autostainer programmed steps for HER2 immunohistochemistry 
 
2.24. Formalin Fixed Paraffin Embedded (FFPE) - miRNA extraction 
Total RNA/miRNA was extracted from the above sections/cores using three 
commercially available kits, Recoverall Total Nucleic Acid Isolation Kit (Ambion), 
High Pure miRNA Isolation Kit (Roche) and miRNeasy FFPE Kit (Qiagen) according 
to manufacturer’s instructions as per Table 2-17. Experiments were carried out in 
triplicate. 
 
 
Reagent Time (mins) 
Real HP Block (DAKO) 10 
Antibody 30 
Real EnVision (Dako) 30 
Real DAB (DAKO) 5 
Real HP Block (DAKO) 5 
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Table 2-17: Summary of protocols for RNA extraction using the 3 commercially 
available kits. 
 
2.25. RNA evaluation 
The Nanodrop ND 1000 (Thermo Scientific) was used to determine concentration 
(ng/μL) and quality (A260/280). To determine RNA integrity, the Agilent RNA 6000 
Nano Assay protocol was used for the Agilent 2100 Bioanalyser (Agilent Technologies) 
according to manufacturers’ instructions.  
 
Roche- 
High Pure miRNA 
Isolation Kit 
Ambion- 
RecoverAll Total 
Nucleic Acid 
Isolation Kit 
Qiagen-miRNeasy 
FFPE kit 
Sample input One 10 μM FFPE section or 1.0 mm/1.5 mm Core 
Deparaffinisation 
Xylene & 2 Ethanol 
Steps with a drying 
step of 55°C for 10 
mins 
Xylene & 2 
Ethanol steps with 
a melting step of 
50°C for 3 mins 
and an air-dry step 
of 45 mins 
Xylene & Ethanol 
step with a drying 
incubation at RT 
 
 
Lysis conditions 55 °C overnight 
50°C for 15 mins 
and 80 ⁰C for 15 
mins 
56 °C for 15 mins 
and 80°C for 15 
mins 
Proteinase K step Included in Lysis step - 
Included in Lysis 
Step 
DNase digest step Optional 
Included in 
protocol 
Included in 
protocol 
Elution volume 50 μL 60 μL 14-30 μL 
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2.26. qRT-PCR analysis 
Estimation of miRNA and mRNA recovery was determined by quantification of 
expression levels of the endogenous controls RNU48 and GAPDH respectively.  
Reverse transcriptase was carried out as per 2.6 for the miRNA endogenous control 
RNU48. qRT-PCR experiments were performed as per 2.8. Experiments were carried 
out in biological and technical triplicate. 
2.27. Patient population 
Sixteen FFPE tumour samples from the ICORG-12-09 pilot retrospective laboratory-
based cohort study investigating durable complete response following trastuzumab 
treatment were included for miRNA expression analysis. All patients were diagnosed at 
St Vincent’s University Hospital (SVUH), Dublin between 1995 and 2011 and ethical 
approval to conduct the study was granted by SVUH Ethics and Medical Research 
Committee in June 2012. Patient sera from the neoadjuvant phase II TCHL clinical trial 
(ICORG-10-05) investigating TCH (Docetaxel, Carboplatin and Trastuzumab) and 
TCHL (Docetaxel, Carboplatin, Trastuzumab and Lapatinib treatment in HER2 positive 
breast cancer patients were assessed for circulating miRNAs. Ethical approval for the 
TCHL trial was granted by the UCC Clinical Research Ethics Committee. Ethical 
approval has also been obtained from the DCU Research Ethics Committee for each of 
the studies. 
2.28. Statistical analysis 
Drug IC50 values were calculated using CalcuSyn (version 1.1.0.0) software. Analysis 
of the differences between the control and treated cell lines and changes in expression of 
miRNAs was performed using the Student t-test (two tailed with unequal variance). The 
cut-off for statistical significance was set at p ≤ 0.05. 
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Chapter Three 
Characterisation of acquired trastuzumab and 
lapatinib resistant cell lines 
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3.1. Introduction 
The monoclonal antibody, trastuzumab, and lapatinib, the dual EGFR and HER2 
tyrosine kinase inhibitor are both approved treatments for HER2 positive breast cancer.  
Trastuzumab has clinical efficacy, however, between 66-88 % of metastatic HER2 
positive breast cancer patients are innately resistant to treatment [25, 259]. Those who 
do initially respond, the majority will develop resistance to trastuzumab usually 
develops within 1-2 years [260]. In the adjuvant setting approximately 15 % of patients 
with early stage breast cancer relapse and develop metastatic disease despite 
trastuzumab based treatment [261]. Lapatinib treatment in combination with 
capecitabine was approved for the treatment of patients who relapsed on trastuzumab 
treatment due to achieving significant response in a phase III clinical trial [262, 263]. 
However, acquired resistance to lapatinib is also an emerging clinical problem. The 
problem of acquired resistance is still poorly understood. Cell line models of acquired 
trastuzumab and lapatinib resistance were previously developed in our laboratory by Dr. 
Browne and Dr. Mc Dermott using the HER2 positive SKBR3 [246] and HCC-1954 
[247] cell lines. We characterised these acquired resistant cell lines in relation to drug 
sensitivity, doubling time, migration and stem cell populations.  
 
3.2. Sensitivities of SKBR3-P and SKBR3-T cells to trastuzumab and 
lapatinib 
The SKBR3-T cell line was established by continuous exposure to trastuzumab (10 
µg/mL) for 6 months and represents a model of acquired trastuzumab resistance. The 
SKBR3-L cell line was established by continuous exposure to lapatinib (250 nM) for 6 
months and represents a model of acquired trastuzumab and lapatinib resistance. An 
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aged matched parental cell line, SKBR3-P was also created alongside these cell lines for 
comparison. Trastuzumab treatment (10 µg/mL) significantly inhibited proliferation by 
40.4 ± 7.2 % in the SKBR3-P cells compared to 5.1 ± 2.8 % in the SKBR3-T cells 
(p=0.0007) and 9.7 ± 3.9 % in the SKBR3-L cells (p=0.0000002) (Figure 3-1). 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-1: Determination of trastuzumab sensitivity in the SKBR3 cell line and the 
acquired resistant variants; SKBR3-T and SKBR3-L after trastuzumab treatment (10 
µg/mL). Proliferation was measured by acid phosphatase method after 5 days, and is 
expressed relative to untreated control. Error bars denote the standard deviation of 
triplicate experiments. Student’s t-test was performed to compare response in the 
resistant and parental cell lines: *** denotes p<0.0005, **** denotes p < 0.00005. 
 
We encountered a loss of resistance in the SKBR3-T cells in a new batch of FBS Gold 
(PAA) (Serum B). Previously, most experiments for this study were carried out in 
Serum A. We examined the resistant phenotype with three different batches of serum 
(serum A, B and C) (Figure 3-2). We found there was a significant difference in growth 
inhibition 19.6 % (p=0.02) when treated with trastuzumab (10 µg/mL), when cultured in 
serum A and B (2 different batches from the same company). Serum from two different 
companies (serum B vs C) also showed a significant effect on response to trastuzumab 
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(14.8 %, p=0.02). These results suggest that serum is an extremely important factor in 
acquired resistant cell lines. It is also a point to note that serum screens do not account 
for long term culture and the loss of resistance over time. 
 
 
 
 
 
 
 
 
Figure 3-2: Determination of trastuzumab sensitivity in the SKBR3-T cell line after 
culture in different batches of serum (A, B, C). Proliferation was measured by acid 
phosphatase method after 5 days, and is expressed relative to untreated control. Error 
bars denote the standard deviation of triplicate experiments. Student’s t-test was 
performed to compare response: * denotes p<0.05. 
 
The lapatinib IC50 for the SKBR3-P was 0.05 ± 0.008 µM compared to that of the 
SKBR3-T 0.13 ± 0.05 µM and the SKBR3-L 4.04 ± 0.46 µM cell lines (Figure 3-3). 
Cells are classified as resistant to lapatinib if the IC50 is greater than 1µM [123]. The 
SKBR3-L cells are significantly resistant to lapatinib treatment compared to the 
SKBR3-P (p=0.01) whereas the SKBR3-T cells are not lapatinib resistant. 
 
 
 
 
 
96 
 
*
0
20
40
60
80
100
0 0.5 1 1.5 2 2.5
%
 G
ro
w
th
Lap Conc (µM)
SKBR3-P
SKBR3-T
SKBR3-L
 
 
 
 
 
 
 
 
Figure 3-3: Determination of lapatinib sensitivity in the SKBR3-P cell line and the 
acquired resistant variants; SKBR3-T and SKBR3-L. Proliferation was measured by 
acid phosphatase method after 5 days, and is expressed relative to untreated control. 
Line represents 50% growth. Error bars denote the standard deviation of triplicate 
experiments. Student’s t-test was performed to determine statistical significance: * 
denotes p<0.05.  
3.3. Doubling times 
We determined the doubling times of the SKBR3-P, SKBR3-T and SKBR3-L cell lines. 
The SKBR3-L cells have a significantly longer doubling time 67.0 ± 9.8 h than the 
SKBR3-P; 32.2 ± 2.2 h (p= 0.02) and the SKBR3-T; 32.6 ± 2.5 h (p = 0.02) (Table 3-1) 
(Figure 3-4). 
Table 3-1: Average doubling time (h) for the SKBR3-P, SKBR3-T and SKBR3-L cell 
lines. Proliferation was measured by acid phosphatase at Day 0, 3, 5 and 7. 
 
 
 
 
 
Doubling time (h)
SKBR3-P 32.2 ± 2.2
SKBR3-T 32.6 ± 2.5
SKBR3-L 67.0 ± 9.8
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Figure 3-4: Average doubling times (h) of the SKBR3-P, SKBR3-T and SKBR3-L cell 
lines. Proliferation was measured by acid phosphatase at Day 0, 3, 5 and 7. Error bars 
denote the standard deviation of triplicate experiments. * denotes p<0.05 determined by 
Students t-test. 
 
3.4. Migratory properties of the acquired resistant cell lines 
We examined migration of the cell lines using a wound scratch assay after 24 h and 48 h 
(Figure 3-5). No significant differences were seen in migration after 24 h (Figure 3-5 
A). The SKBR3-T cell line is more migratory than the SKBR3-P cell line (p=0.0001) 
after 48 h (Figure 3-5 A). The SKBR3-L (93.3 ± 4.0 %) cell line is significantly more 
migratory than the SKBR3-P (12.3 ± 1.0 %) (p=0.02) cell line after 48 h (Figure 3-5 
A). Representative images of the triplicate assays at each time point is shown in Figure 
3-5 B. 
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Figure 3-5: Average migration in the SKBR3-P, SKBR3-T and SKBR3-L cell lines 
after 24 h and 48 h time points graphical representation (A) and wound scratch images 
(B). Open space (%) was calculated using the TScratch program and migration was then 
calculated (100% - open space %). Error bars denote the standard deviation of triplicate 
experiments. Student’s t-test was performed to determine significant difference between 
the SKBR3-P, SKBR3-T and SKBR3-L cell lines: * denotes p<0.05 and *** denotes 
p<0.005. 
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3.5. Sensitivity of BT474-Tr acquired trastuzumab resistance cell line 
model 
Previously, an acquired trastuzumab variant of the BT474 cells, BT474-Tr was created 
in UCLA [123]. Treatment of the BT474-P cells with 10 µg/mL trastuzumab inhibited 
growth by 59.5 ± 8.6 %; however treatment of the BT474-Tr cells with 10 µg/mL 
trastuzumab has no significant effect on growth (1.1 ± 3.3 %) (Figure 3-6). We also 
investigated the sensitivity of these cell lines to lapatinib treatment. These cell lines are 
extremely sensitive to lapatinib treatment with IC50 values of 0.02 ± 0.006 µM for the 
BT-474-P and 0.03 ± 0 .002 µM for the BT-474-Tr (Figure 3-7).  
 
 
 
 
 
 
 
 
 
Figure 3-6: Determination of trastuzumab sensitivity in the BT474-P and acquired 
trastuzumab resistant BT474-Tr cell line after trastuzumab treatment (10 µg/mL). 
Proliferation was measured by acid phosphatase method after 5 days, and is expressed 
relative to untreated control. Error bars denote the standard deviation of triplicate 
experiments. Student’s t-test was performed to determine significant difference: **** 
denotes p < 0.00005. 
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Figure 3-7: Determination of lapatinib sensitivity in the BT-474-P cell line and the 
acquired resistant variant; BT-474-Tr. Proliferation was measured by acid phosphatase 
method after 5 days, and is expressed relative to untreated control. Line represents 50% 
growth. Error bars denote the standard deviation of triplicate experiments. 
 
3.6. HCC-1954-L acquired lapatinib resistance cell line model 
Previously, an acquired lapatinib resistant variant of the HCC-1954 cell line, HCC-
1954-L was created by continuous conditioning with increasing doses of lapatinib by 
Dr. Martina McDermott [247]. Resistance to lapatinib is classified when the IC50 is 
above 1 µM, as defined by O’Brien et al. [103]. Both the HCC-1954-P (3.16 ± 2.9 %) 
and the HCC-1954-L (2.64 ± 4.3%) are resistant to trastuzumab (Figure 3-8). The 
HCC-1954-L (2.7 ± 0.1 µM) (p = 0.01) were previously determined resistant to 
lapatinib when compared to the HCC-1954-P (0.42 ± 0.02 µM) cells by Dr. Martina 
McDermott. We confirmed lapatinib resistance of the HCC-1954-L cells (24.5 ± 6.2 %) 
compared to its parent (55.0 ± 4.4 %) at a concentration of 1 µM (Figure 3-9). 
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Figure 3-8: Determination of trastuzumab sensitivity in the HCC-1954-P and acquired 
lapatinib resistant HCC-1954-L cell line after trastuzumab treatment (10 µg/mL). 
Proliferation was measured by acid phosphatase method after 5 days, and is expressed 
relative to untreated control. Error bars denote the standard deviation of triplicate 
experiments. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-9: Confirmation of lapatinib resistance at 1 µM in the HCC-1954-L cell line 
compared to its parental, HCC-1954-P. Proliferation was measured by acid phosphatase 
method after 5 days, and is expressed relative to untreated control. Error bars denote the 
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Gene Name Sequence Description Fold Change P-value Accession # Sequence Code
SFRP1 secreted frizzled-related protein 1 1.6 0.0009 BC036503 A_23_P10121
JAG2 jagged 2 1.6 0.0011 NM_002226 A_23_P106024
MYC v-myc myelocytomatosis viral oncogene homolog (avian) 1.6 0.0000 NM_002467 A_23_P215956
KLF4 Kruppel-like factor 4 (gut) 1.5 0.0107 NM_004235 A_23_P32233
GLI3 GLI family zinc finger 3 -1.5 0.0071 NM_000168 A_23_P111531
YY1 YY1 transcription factor -1.5 0.0034 AK026497 A_24_P916288
FOXO1 forkhead box O1 -1.6 0.0018 NM_002015 A_23_P151426
LTBP1 latent transforming growth factor beta binding protein 1 -1.6 0.0013 NM_000627 A_23_P43810
WNT4 wingless-type MMTV integration site family, member 4 -1.9 0.0001 NM_030761 A_23_P11787
BMP7 bone morphogenetic protein 7 -2.2 1.08E-06 NM_001719 A_23_P68487
BMP7 bone morphogenetic protein 7 -2.3 2.11E-07 AK094784 A_23_P154643
WNT6 wingless-type MMTV integration site family, member 6 -3.3 2.87E-11 NM_006522 A_23_P119916
standard deviation of triplicate experiments. Student’s t-test was performed to determine 
significant difference: *** denotes p < 0.0005. 
3.7. Microarray data analysis of the SKBR3-T and SKBR3-L cell lines 
Previously, gene expression analysis (microarrays) were preformed for the SKBR3-P, 
SKBR3-T and SKBR3-L cell lines in UCLA (n=1). We analysed the data and identified 
significantly altered genes in the SKBR3-T cell line compared to its parent when 
applying a p<0.05 and a ± 1.5 fold change cut-off. As breast cancer stem cells have been 
implicated in resistance to chemotherapy and trastuzumab [264, 265] we investigated a 
list of putative stem cell markers in our microarray in collaboration with Dr. Michael 
O’Gallagher, Trinity College Dublin (TCD). This list was cross compared with our 
microarray data for the SKBR3-T (Table 3-2) and SKBR3-L (Table 3-3) cell lines.  
 
Table 3-2: Significantly altered putative stem cell markers in the SKBR3-T cell line 
microarray data (UCLA, n=1) compared with the SKBR3-P cell line. Targets were 
selected using a 1.5 fold cut-off and p<0.05. 
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Table 3-3: Significantly altered stem cell markers in the SKBR3-L cell line microarray 
data (UCLA, n=1) compared with the SKBR3-P cell line. Targets were selected using a  
1.5 fold cut-off and p<0.05. 
Gene Name Sequence Description Fold Change P-value Accession # Sequence Code
ALDH1A1 aldehyde dehydrogenase 1 family, member A1 5.0 4.55E-15 NM_000689 A_23_P83098
BMP7 bone morphogenetic protein 7 4.0 3.99E-13 NM_001719 A_24_P91566
BMP7 bone morphogenetic protein 7 3.4 1.40E-11 AK094784 A_23_P154643
KLF4 Kruppel-like factor 4 (gut) 3.3 2.51E-11 NM_004235 A_23_P32233
BMP7 bone morphogenetic protein 7 3.1 1.64E-10 NM_001719 A_23_P68487
CTNNB1 catenin (cadherin-associated protein), beta 1, 88kDa 2.9 4.14E-21 NM_001904 A_23_P29495
CTNNB1 catenin (cadherin-associated protein), beta 1, 88kDa 2.2 8.21E-07 NM_001904 A_23_P29499
WNT7B wingless-type MMTV integration site family, member 7B 2.1 1.43E-06 NM_058238 A_23_P320054
BMP1 bone morphogenetic protein 1 2.0 8.65E-06 NM_006128 A_23_P33277
LTBP1 latent transforming growth factor beta binding protein 1 1.9 0.00003 NM_000627 A_23_P43810
BMP1 bone morphogenetic protein 1 1.8 0.00005 NM_001199 A_24_P129417
ADAM17 ADAM metallopeptidase domain 17 1.7 0.0003 NM_003183 A_23_P143120
JAG1 jagged 1 (Alagille syndrome) 1.7 0.0003 NM_000214 A_23_P210763
JAK1 Janus kinase 1 1.5 0.00 NM_002227 A_23_P97005
MYC v-myc myelocytomatosis viral oncogene homolog (avian) 1.5 0.0003 NM_002467 A_23_P215956
JAG2 jagged 2 1.5 0.0078 NM_002226 A_23_P106024
WNT7B wingless-type MMTV integration site family, member 7B 1.5 0.01 NM_058238 A_24_P911607
FOXO1A CDNA FLJ12289 fis, clone MAMMA1001788 -1.7 0.00026 AK022351 A_24_P930391
PTCH1 patched homolog 1 (Drosophila) -1.8 0.00017 AK124593 A_24_P106910
BMP8A bone morphogenetic protein 8a -2.2 4.98E-07 NM_181809 A_23_P115118
WNT4 wingless-type MMTV integration site family, member 4 -2.3 1.45E-07 NM_030761 A_23_P382607
FOXO1 forkhead box O1 -2.6 1.48E-08 NM_002015 A_23_P151426
POU5F1 POU class 5 homeobox 1 -2.8 1.71E-09 NM_002701 A_23_P59138
JAK3 Janus kinase 3 -2.9 5.39E-10 BC028068 A_24_P59667
WNT4 wingless-type MMTV integration site family, member 4 -3.4 1.38E-11 NM_030761 A_23_P11787
 
Interestingly, ALDH1A1 was significantly up-regulated in the SKBR3-L (5.0 fold, 
p=4.55E-15) compared to the SKBR3-P cell line. ALDH1A1 was slightly down-
regulated in the SKBR3-T (-1.3 fold, p=0.04). We investigated the expression and 
activity of ALDH1A1 in our SKBR3 cell lines by immunoblotting. ALDH1A1 is 
decreased in the SKBR3-T compared to the SKBR3-P, however it is not significantly 
altered (Figure 3-10). We detected a significant up-regulation of ALDH1A1 in the 
SKBR3-L cell lines compared to the parental (p=0.003) which is consistent with the 
microarray data (Figure 3-10).  
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Figure 3-10: ALDH1A1 expression in the SKBR3-P, SKBR3-T and SKBR3-L cell 
lines. α-tubulin was used as a loading control on each gel. Images are representative of 
triplicate experiments. Densitometry analysis of triplicate immunoblots was performed 
using ImageJ software. 
 
3.8. ALDEFLUOR analysis of SKBR3-P & SKBR3-L cell lines 
The ALDEFLUOR assay is a non-immunological assay which identifies putative stem 
and progenitor cells based on ALDH (aldehyde dehyrdogenase) enzyme activity. The 
assay is based on expression of ALDH in cells which converts its substrate BAAA 
(Bodipy aminoacetaldehyde) into a negatively charged product, BAA-. This product is 
retained within the cells causing cells with ALDH+ expression to fluoresce. The 
putative cancer stem cells (pCSCs) can be discriminated from non-pCSCs based on the 
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fluorescent intensity. In Dr. Gallagher’s group, they find the diethylamino-
benzaldehyde (DEAB) negative control insufficient when a cell contains >80 % 
ALDH+ cells. They use a mixed population control which contains known ALDH- cells 
and the query cell line which can then be used to discriminate between the ALDH+ and 
ALDH- cells in the query cell line. They utilise three technical flow cytometry controls; 
discrimination of debris, discrimination of single cells from doublets and/or clusters and 
discrimination of live cells from dead cells. 
 
Initially, Dr. Gallagher’s group (TCD) carried out the ALDEFLUOR assay on pellets of 
the SKBR3-P and SKBR3-L cell lines to determine the amount of putative cancer stem 
cells (pCSCs) in these cell lines. The samples were analysed and the technical controls 
were applied to determine the mixed population, the ALDH+ stained population and the 
optimal ALDH+ stained population for the SKBR3-P (Figure 3-11 A) and the SKBR3-
L (Figure 3-11 B) cell lines. The results from the ALDEFLUOR assay show a high 
level of ALDH+ stained population within the SKBR3-P cell line (95.4 ± 0.9%) (Figure 
3-11) (Table 3-4). The SKBR3-L cell line had a significantly reduced level of ALDH+ 
stained cells (78.2 ± 6.0 %) compared to the SKBR3-P (p=0.04).  
 
These results conflict with our microarray data and our western data which show the 
SKBR3-L cells have significantly higher expression of ALDH1A1 than the SKBR3-P 
(Figure 3-10). The western blotting data may not be a true representative of ALDH1A1 
expression as it may be present within a subpopulation of the cells.  
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Mix Population ALDH Stained ALDH St. Opt. Gate
SKBR3-P 34.2  3.5 90.5  0.4 95.4  0.9
SKBR3-L 39.3  8.2 63.2  13.6 78.2  6.0
A
i) Mixed population                             ii) ALDH stained                    iii) ALDH stained optimal gate
i) Mixed population                             ii) ALDH stained                    iii) ALDH stained optimal gateB
 
Figure 3-11: ALDEFLUOR FACS profiles for the (A) SKBR3-Par and (B) SKBR3-L 
cell lines. The mixed population consists of known ALDH- A2780 cells and SKBR3-
Par cells. This allowed for a gate (black line) to be set between the ALDH- and ALDH+ 
populations. B) The ALDH Stained sample uses the Mixed Population gate to identify 
ALDH+ cells. This has a certain degree of false negatives. C) Due to the clear 
distinction between the ALDH- and ALDH+ fractions in the SKBR3-Par cell line a 
more optimal gate can be drawn. 
 
Table 3-4: Overall mean ALDH+ cell population within the SKBR3-P and SKBR3-L 
cell lines. Standard deviation is representative of triplicate experiments. 
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3.9.  Summary 
The SKBR3-T and SKBR3-L were confirmed as acquired trastuzumab and lapatinib 
resistant cell lines. Interestingly, the SKBR3-L also shows cross resistance to 
trastuzumab treatment. We also confirmed the SKBR3-P and SKBR3-T are lapatinib 
sensitive cell lines. Over time, we identified that changes in serum batches can have 
drastic effects on resistance. Serum screens can indicate if a cell line will lose 
resistance; however, this is a short-term assay (7 days). There is a large variation in 
resistance to trastuzumab upon culturing in serum from different batches and different 
suppliers. 
 
The doubling time of the SKBR3-L cell line is significantly longer than the SKBR3-P 
and SKBR3-T cell lines. This suggests that acquired lapatinib resistance has a 
significant effect on the growth rate of these cells. The SKBR3-T cell line is more 
migratory than the SKBR3-P cell line after 48 h. The SKBR3-L cell line after 48 h was 
significantly more migratory than both the SKBR3-P and SKBR3-T cell lines.  
 
We confirmed the BT-474-Tr cells are resistant to trastuzumab. Determination of 
lapatinib sensitivity of these cell lines showed they are extremely sensitive to lapatinib. 
The HCC-1954-L cell line, another model of acquired lapatinib resistance was also 
confirmed as lapatinib resistant and innately resistant to trastuzumab. These resistant 
cell line models will be the focus of our microRNA profiling in Chapter Four. 
 
Previously, gene expression analysis was carried out on the SKBR3-P, SKBR3-T and 
SKBR3-L cell lines in UCLA. We identified that ALDH1A1 is up-regulated in the 
SKBR3-L cell line. Protein expression analysis by western blotting confirmed the 
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microarray results. Further analysis of our cell lines by the ALDEFLUOR assay 
indicated the SKBR3-P cell line had a high population of pCSCs. The SKBR3-L cell 
line had a significantly lower pCSC population compared to the SKBR3-P. The 
ALDEFLUOR results contradict the results seen in our microarray and protein 
expression analysis and suggest that there is not an increase in the pCSC population 
within the lapatinib resistant cell line. Further analysis of ALDH1A1 using 
immunocytochemistry may indicate the subpopulations that are expressing this putative 
stem cell marker.  
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Chapter Four 
miRNA expression in trastuzumab and lapatinib 
resistant cell lines 
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4.1. Introduction 
As previously mentioned, miRNAs have been shown to play a role in regulating genes 
involved in drug resistance [266, 267]; therefore we chose to investigate miRNAs and 
their differential expression in acquired and innate trastuzumab and lapatinib resistant 
HER2 positive breast cancer cells.  
4.2. miRNA expression analysis (Taqman Low Density arrays) 
To identify differentially expressed miRNAs in the acquired trastuzumab and lapatinib 
resistant cells compared to the parental cell line, TaqMan Low Density Arrays (TLDA-
Applied Biosystems) were performed previously by Salima Souahli at the NICB, DCU. 
Expression values were calculated using the comparative threshold cycle (Ct) method 
where the SKBR3-T (Table 4-1) and SKBR3-L (Table 4-2) cell lines were normalised 
to the endogenous control RNU48 and compared to the SKBR3-P cell line. A fold 
change cut-off of ± 1.5 fold change and p<0.05 cut-off was applied to the data. 
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Table 4-1: Significantly altered miRNAs from TLDA analysis in the SKBR3-T cell line 
compared to the SKBR3-P cell line that met the cut off criteria of a ± 1.5 fold change 
cut-off and a p-value of < 0.05. Fold changes were calculated using the comparative Ct 
method. Student’s t-test was performed to determine significant differences.  
 Fold Change ± std dev p-value 
miR-149 1.9 ± 0.5 0.03 
miR-192 -2.8 ± 0.5 0.03 
miR-205 3.4 ± 0.5 0.02 
miR-221 3.2 ± 0.2 0.02 
miR-222 2.4 ± 0.7 0.04 
miR-301 -1.5 ± 0.2 0.03 
miR-342 1.6 ± 0.2 0.02 
miR-362 1.6 ± 0.4 0.02 
miR-550 -2.2 ± 0.8 0.03 
miR-9 2.4 ± 0.0 0.00001 
 
 
 
 
 
 
 
 
 
 
 
A B 
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Fold Change ± std dev p-value
miR-135a 7.7 ± 1.3 0.03
miR-181b -1.6 ± 0.1 0.04
miR-192 3.7 ± 0.2 0.0003
miR-194 4.7 ± 1.4 0.05
miR-221 -1.5 ± 0.4 0.03
miR-224 -4.3 ± 1.2 0.04
miR-26b -1.6 ± 0.3 0.03
miR-30a-3p -3.0 ± 0.8 0.05
miR-30e-3p -2.3 ± 0.1 0.02
miR-375 -4.1 ± 0.1 0.0006
miR-550 -2.2 ± 0.7 0.03
miR-92a -2.2 ± 0.4 0.01
miR-9 1.6 ± 0.1 0.001
Table 4-2: Significantly altered miRNAs from TLDA analysis in the SKBR3-L cell line 
compared to the SKBR3-P cell line that met the cut off criteria of a ± 1.5 fold change 
cut-off and a p-value of <0.05. Fold changes were calculated using the comparative Ct 
method. Student’s t-test was performed to determine significant differences. 
  
 
 
 
 
 
 
 
4.3. RNA extraction 
RNA extracted from the SKBR3-P, SKBR3-T and SKBR3-L cell lines was separated on 
an agarose gel to determine RNA integrity. Bands representing total RNA (28S and 
18S) and miRNA (small RNA) were assessed in all samples (Figure 4-1).  
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28s rRNA
18s rRNA
Small RNA
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Concentration (µg/µl) and purity (A260/280) of RNA was determined by analysis on a 
Nanodrop (Thermo Scientific).  
 
Figure 4-1: RNA extractions for SKBR3-P (1-3), SKBR3-T (4-6) and SKBR3-L (7-9).  
 
4.4. qRT-PCR validation of miRNA targets in trastuzumab and lapatinib 
resistant cells 
Validation of the differentially expressed miRNAs from the TLDA analysis was carried 
out by individual qRT-PCR. Six miRNAs plus miR-224 out of the ten altered miRNAs 
in the SKBR3-T cell line were selected for further validation. We confirmed that miR-
221 (p=0.04), miR-222 (p=0.01) and miR-9 (p=0.04) were significantly up-regulated 
and miR-224 (p=0.01) was significantly down-regulated in the SKBR3-T cell line 
compared to the SKBR3-P cell line (Table 4-3).  
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Table 4-3: Validation of miRNAs identified in TLDA analysis was carried out using 
individual qRT-PCR analysis in the SKBR3-T cell line compared to the parental cell 
line. Fold changes were calculated using the comparative Ct method. Student’s t-test 
was performed to determine significant differences (highlighted in bold). 
 
 
In the SKBR3-L cell line, ten miRNAs plus miR-222 were selected for further 
validation. We confirmed that miR-221 (p=0.02), miR-222 (p=0.04), miR-224 (p=0.01), 
were significantly down-regulated and miR-9 (p=0.01) was the only significantly up-
regulated miRNA in the SKBR3-L cell line compared to the SKBR3-P cell line. miR-
30a-3p was significantly altered, however, it was the opposite trend as seen in the 
TLDA analysis (Table 4-4).  
 
 
 
 
 
 Fold Change ± std dev p-value 
miR-192 -1.5 ± 0.6 0.33 
miR-205 1.1 ± 0.3 0.60 
miR-221 5.8 ± 0.8 0.04 
miR-222 3.8 ± 0.4 0.01 
miR-224 -1.6 ± 0.2 0.01 
miR-550 1.1 ± 0.2 0.45 
miR-9 2.2 ± 0.8 0.04 
115 
 
Fold Change ± std dev p-value
miR-135a -1.3 ± 0.2 0.21
miR-192 2.1 ± 0.8 0.08
miR-221 -2.7 ± 1.1 0.02
miR-222 -2.0 ± 1.0 0.04
miR-224 -5.2 ± 0.3 0.01
miR-30a-3p 2.3 ± 0.3 0.01
miR-30e-3p -1.7 ± 0.1 0.14
miR-375 -1.5 ± 0.3 0.02
miR-550 -1.6 ± 0.6 0.04
miR-92a -1.9 ± 0.5 0.02
miR-9 2.7 ± 0.7 0.01
Table 4-4: Validation of miRNA targets identified in TLDA analysis was carried out 
using individual qRT-PCR analysis in the SKBR3-L cell line compared to the parental 
cell line. Fold changes were calculated using the comparative Ct method. Student’s t-
test was performed to determine significant differences (highlighted in bold). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
We selected miR-221 and -222 for validation in both SKBR3-T and SKBR3-L despite 
miR-222 not being altered in the TLDA data. They are clustered genes located in an 
intergenic region which contain identical seed sequences and suggest that these 
miRNAs are expressed together and function on the same target mRNAs [268]. miR-
224 was validated in the SKBR3-T cell line despite only being significantly altered in 
the SKBR3-L TLDA data due to the large decrease in expression seen in SKBR3-L cell 
lines. 
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Fold Change ± std dev p-value
miR-221 5.7 ± 0.9 0.02
miR-222 5.3 ± 0.8 0.004
miR-224 On-Off* ± 1.5 0.0004
miR-9 -1.1 ± 0.6 0.65
4.5. Validation of miRNA targets in the BT474-Tr acquired trastuzumab 
resistance cell line model 
The miRNA targets identified in the acquired trastuzumab resistant cell line, SKBR3-T 
were validated in the BT474-Tr cell line to determine if any of the alterations were cell 
line specific. miR-221 (p=0.02) and miR-222 (p=0.004) were significantly up-regulated 
and miR-224 expression was switched off in the BT474-Tr cell line compared to that of 
its parent (Table 4-5). However, miR-9 expression was not significantly altered in this 
model of acquired resistance (Table 4-5). 
 
Table 4-5: Validation of miRNA expression in BT-474-Tr cells compared to BT474 
cells. Fold changes were calculated using the comparative Ct method. Student’s t-test 
was performed to determine significant differences (highlighted in bold). *On - Off fold 
change denotes Ct values < 36 to Ct values of > 36 in the BT474-TR resistant cell lines 
respectively. 
 
  
4.6. Validation of miRNA targets in the HCC-1954-L acquired lapatinib 
resistance cell line model 
miRNA expression analysis of the HCC-1954 and HCC-1954-L cells identified that; 
miR-222 (p=0.05) was significantly down-regulated and miR-9 (p=0.04) were 
significantly up-regulated in the HCC1954-L cell line compared to the HCC-1954 cell 
line (Table 4-6).  
117 
 
Fold Change ± std dev p-value
miR-221 1.0 ± 0.7 0.98
miR-222 -1.9 ± 0.4 0.05
miR-224 1.7 ± 0.7 0.17
miR-9 1.9 ± 0.3 0.04
 
Table 4-6: Validation of miRNA expression in HCC-1954-L cells compared to HCC-
1954 cells. Fold changes were calculated using the comparative Ct method. Student’s t-
test was performed to determine significant differences (highlighted in bold). 
 
 
4.7. Analysis of miRNA targets in a cell line panel of innate trastuzumab 
and lapatinib resistance 
miRNA was extracted from cell lines that were previously characterised as innately 
sensitive or resistant to trastuzumab and lapatinib by Dr Neil O’Brien (refer to Table 2-
2) [103]. Expression values for the innate trastuzumab resistant cell lines were 
compared to a pooled trastuzumab sensitive control sample (BT474-P and SKBR3-P). 
In the innate trastuzumab setting (Table 4-7); miR-221 expression was significantly 
higher in 5/6 innately resistant cell lines compared to the sensitive cell lines. miR-222 
expression was significantly higher in 3/6, however, was significantly lower in 3/6 
innately resistant cell lines compare to the sensitive cell lines. miR-224 expression was 
significantly lower in 5/6 innately resistant cell lines compared to the sensitive cell 
lines. miR-9 was significantly higher in 1/6 innately resistant cell lines compared to the 
sensitive. However, opposing the trend seen in the acquired resistance setting, miR-9 is 
significantly lower in 5/6 innately resistant cell lines compared to the sensitive cell 
lines. 
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Table 4-7: miRNA expression analysis of miR-221, -222, -224 and -9 in the innate 
trastuzumab resistant cell lines compared to innate trastuzumab sensitive cell lines; 
SKBR3-P and BT-474-P. Arrow indicates increasing levels of resistance. Fold changes 
were calculated using the comparative Ct method and represented with ± std dev. 
Student’s t-test was performed to determine significant differences (highlighted in 
bold). 
 
 miR-221 miR-222 miR-224 miR-9 
UACC-732 
3.4 ± 0.6 -5.6 ± 0.2 -7.1 ± 0.6 -2.9 ± 0.4 
HCC-1419 7.9 ± 0.4 -28.2 ±0.5 -5.3 ± 0.5 -7.7 ± 0.3 
JIMT-1 45.4 ± 0.9 283.8 ± 0.3 -5.8 ± 0.2 -3.4 ± 0.3 
HCC-1954 964.5 ± 0.3 687.2 ± 0.5 15.7 ± 0.4 -1.2 ± 0.2 
HCC-1569 -1.6 ± 0.8 2.1 ± 0.5 -5.5 ± 0.3 45.0 ± 0.2 
MDA-MB-
453 
5.7 ± 0.6 -11.1 ± 1.1 -7.1 ± 0.4 -2.4 ± 0.4 
 
 
Expression values for the innate lapatinib resistant cell lines were compared to a pooled 
trastuzumab sensitive control sample (SKBR3-P, BT-474-P, HCC-1419 and HCC-
1954). In the innate lapatinib resistance setting; miR-221 expression is significantly 
lower in 2/4 and significantly higher in 1/4 innately lapatinib resistant cell lines 
compared to the sensitive cell lines (Table 4-8). miR-221 expression is unaltered in the 
MDA-MB-453 cell line. miR-222 expression is significantly lower in 2/4 and 
significantly higher in 1/4 innately resistant cell lines compared to the sensitive pool. 
miR-222 expression is unaltered in the HCC-1569 cell line. miR-224 expression is 
significantly lower in 4/4 innately lapatinib resistant cell lines compared to the sensitive 
pool. miR-9 expression levels are significantly higher in 1/4 and significantly lower in 
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1/4 innately lapatinib resistant cell lines compared to the sensitive pool. However, miR-
9 expression is unaltered in the UACC-732 and MDA-MB-453 cell lines. 
 
Table 4-8: miRNA expression analysis of miR-221, -224 and -9 in the innate lapatinib 
resistant cell lines compared to innate lapatinib sensitive cell lines; SKBR3-P,  BT-474-
P, HCC-1419 and HCC-1954. Arrow indicates increasing levels of resistance Fold 
changes were calculated using the comparative Ct method and represented with ± std 
dev. Student’s t-test was performed to determine significant differences (highlighted in 
bold). 
 
 
 
 
 
 
 
4.8. Short-term trastuzumab treatment of SKBR3-P cell line 
SKBR3-P cells were treated for 24 h and 48 h with media, trastuzumab (10 µg/mL) or 
lapatinib (250 nM) after which time cells were harvested for miRNA extraction. Fold 
changes were calculated as treated compared to untreated controls. However, no 
significant changes were observed after 24 h or 48 h short-term trastuzumab treatment 
in the miRNA expression (Table 4-9). However, lapatinib induced significant down-
regulation of miR-221,-222 and -224 after 24 h (Table 4-10). No alterations in miRNA 
expression were seen after 48 h treatment with lapatinib. 
 miR-221 miR-224 miR-9 
UACC-732 -2.3 ± 0.7 -7.5 ± 0.3 -1.2 ± 0.3 
JIMT-1 5.2 ± 0.8 -7.1 ± 0.2 -1.6 ± 0.4 
HCC-1569 -10.1 ± 0.5 -4.9 ± 0.0 122.1 ± 0.1 
MDA-MB-453 -1.9 ± 0.6 -10.5 ± 0.5 -1.3 ± 0.3 
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Table 4-9: miRNA expression analysis after short-term treatment (24 h & 48 h) with 10 
µg/mL trastuzumab. 
 
24 h ± std dev 48 h ± std dev 
miR-9 1.3 ± 0.3 1.7 ± 0.6 
miR-221 1.0 ± 0.5 1.7 ± 1.0 
miR-222 1.1 ± 0.7 1.5 ± 1.3 
miR-224 1.2 ± 0.9 1.2 ± 0.1 
 
Table 4-10: miRNA expression analysis after short-term treatment (24 h & 48 h) with 
lapatinib (250 nM). Significant fold changes are highlighted in bold.* denotes p<0.05 
and ** denotes p<0.005. 
 
24 h ± std dev 48 h ± std dev 
miR-9 -3.0 ± 0.8  1.1  ± 0.5 
miR-221 -14.2 ± 0.5 ** -2.5 ± 0.9 
miR-222 -20.1 ± 0.7 * 1.4 ± 0.4 
miR-224 -7.6 ± 1.2 ** -1.2 ± 0.5 
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Gene Name Sequence Description Fold Change p-value Accession # Sequence Code
ANG
Homo sapiens angiogenin, ribonuclease, RNase A family, 5 
(ANG), transcript variant 1, mRNA.
-2.2 1.23E-06 NM_001145 A_23_P428738
CDKN1C cyclin-dependent kinase inhibitor 1C (p57, Kip2) -2.0 0.00001 NM_000076 A_23_P428129
Gene Name Sequence Description Fold Change P-value Accession # Sequence Code
CCL2 chemokine (C-C motif) ligand 2 3.3 3.09E-26 NM_002982 A_23_P89431
PPARG peroxisome proliferator-activated receptor gamma 2.6 1.15E-17 NM_015869 A_23_P252062
CSK c-src tyrosine kinase 2.3 0.000000211 NM_004383 A_23_P152024
CXCR4 chemokine (C-X-C motif) receptor 4 2.1 1.12E-10 NM_003467 A_23_P102000
ITGAV
integrin, alpha V (vitronectin receptor, alpha polypeptide, 
antigen CD51)
2.0 0.00001 NM_002210 A_23_P381992
TPM1 tropomyosin 1 (alpha) 2.0 0.00001 L02922 A_24_P924721
MET met proto-oncogene (hepatocyte growth factor receptor) 2.0 0.00001 NM_000245 A_23_P145844
4.9. Target prediction for microRNAs 
We utilised miRWalk to identify potential targets and cross compared this with the 
UCLA dataset for miR-221 (Table 4-11) (Table 4-12), miR-222 (Table 4-13) (Table 
4-14), miR-224 (Table 4-15) (Table 4-16) and miR-9 (Table 4-17) (Table 4-18) in 
both SKBR3-T and SKBR3-L cell lines respectively. We applied a fold change cut-off 
of ± 2.0 and p<0.05. 
 
Table 4-11: Potential targets for miR-221 in the SKBR3-T cell lines. miRWalk 
identified targets related to miR-221 and these were cross compared with our UCLA 
dataset (n=1). Fold change cut-off of ± 2.0 and p<0.05 were applied. 
 
 
Table 4-12: Potential targets for miR-221 in the SKBR3-L cell lines. miRWalk 
identified targets related to miR-221 and these were cross compared with our UCLA 
dataset (n=1). Fold change cut-off of ± 2.0 and p<0.05 were applied. 
 
 
 
122 
 
Gene Name Sequence Description Fold Change p-value Accession # Sequence Code
ANG
Homo sapiens angiogenin, ribonuclease, RNase A family, 5 
(ANG), transcript variant 1, mRNA.
-2.2 1.23E-06 NM_001145 A_23_P428738
CDKN1C cyclin-dependent kinase inhibitor 1C (p57, Kip2) -2.0 0.00001 NM_000076 A_23_P428129
Gene Name Sequence Description Fold Change p-value Accession # Sequence Code
FGFR3 fibroblast growth factor receptor 3 3.9 6.59E-13 NM_000142 A_23_P500501
CCL2 chemokine (C-C motif) ligand 2 3.3 3.09E-26 NM_002982 A_23_P89431
PPARG peroxisome proliferator-activated receptor gamma 2.6 1.15E-17 NM_015869 A_23_P252062
MMP1 matrix metallopeptidase 1 (interstitial collagenase) 2.5 1.24E-15 NM_002421 A_23_P1691
CSK c-src tyrosine kinase 2.3 0.000000211 NM_004383 A_23_P152024
FGFR3 fibroblast growth factor receptor 3 2.2 0.00000114 NM_000142 A_23_P212830
PPP2R2A
protein phosphatase 2 (formerly 2A), regulatory subunit B, 
alpha isoform
2.0 0.00000727 NM_002717 A_23_P123539
SOD2 superoxide dismutase 2, mitochondrial 2.0 0.00000759 NM_000636 A_23_P134176
TPM1 tropomyosin 1 (alpha) 2.0 0.00001 L02922 A_24_P924721
MET met proto-oncogene (hepatocyte growth factor receptor) 2.0 0.00001 NM_000245 A_23_P145844
Table 4-13: Potential targets for miR-222 in the SKBR3-T cell lines. miRWalk 
identified targets related to miR-222 and these were cross compared with our UCLA 
dataset (n=1). Fold change cut-off of ± 2.0 and p<0.05 were applied. 
 
Table 4-14: Potential targets for miR-222 in the SKBR3-L cell lines. miRWalk 
identified targets related to miR-222 and these were cross compared with our UCLA 
dataset (n=1). Fold change cut-off of ± 2.0 and p<0.05 were applied. 
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Gene Name Sequence Description Fold Change p-value Accession # Sequence Code
FOSB FBJ murine osteosarcoma viral oncogene homolog B 2.8 1.57E-09 NM_006732 A_23_P429998
JUNB jun B proto-oncogene 2.2 0.00000112 NM_002229 A_24_P241815
RARA retinoic acid receptor, alpha 2.0 0.00000709 NM_000964 A_23_P207842
Gene Name Sequence Description Fold Change p-value Accession # Sequence Code
JUNB jun B proto-oncogene 3.3 2.33E-11 NM_002229 A_24_P241815
CTNNB1 catenin (cadherin-associated protein), beta 1, 88kDa 2.9 4.14E-21 NM_001904 A_23_P29495
PAK2 p21 protein (Cdc42/Rac)-activated kinase 2 2.6 1.50E-08 NM_002577 A_23_P327307
AP2M1 adaptor-related protein complex 2, mu 1 subunit 2.3 0.000000241 NM_004068 A_23_P155624
CTNNB1 catenin (cadherin-associated protein), beta 1, 88kDa 2.2 0.000000821 NM_001904 A_23_P29499
CXCR4 chemokine (C-X-C motif) receptor 4 2.1 1.12E-10 NM_003467 A_23_P102000
JUNB jun B proto-oncogene 2.0 0.00000908 NM_002229 A_23_P4821
Table 4-15: Potential targets for miR-224 in the SKBR3-T cell lines. miRWalk 
identified targets related to miR-224 and these were cross compared with our UCLA 
dataset (n=1). Fold change cut-off of ± 2.0 and p<0.05 were applied. 
 
Table 4-16: Potential targets for miR-224 in the SKBR3-L cell lines. miRWalk 
identified targets related to miR-224 and these were cross compared with our UCLA 
dataset (n=1). Fold change cut-off of ± 2.0 and p<0.05 were applied. 
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Gene Name Sequence Description Fold Change p-value Accession # Sequence Code
RARA CDNA clone IMAGE:5162874 -2.8 2.13E-09 BC038432 A_24_P551302
DDIT3 DNA-damage-inducible transcript 3 -2.0 0.00000599 NM_004083 A_23_P21134
Gene Name Sequence Description Fold Change p-value Accession # Sequence Code
BACE1 beta-site APP-cleaving enzyme 1 -4.8 1.07E-14 NM_012104 A_23_P52806
CDK6 cyclin-dependent kinase 6 -3.2 6.15E-11 NM_001259 A_24_P166663
PROM1 prominin 1 -2.8 1.77E-09 NM_006017 A_23_P258463
PTBP2 polypyrimidine tract binding protein 2 -2.8 1.88E-09 NM_021190 A_23_P46396
JUN jun oncogene -2.7 7.41E-19 NM_002228 A_23_P201538
ELAVL1
ELAV (embryonic lethal, abnormal vision, Drosophila)-like 1 
(Hu antigen R)
-2.7 5.40E-09 NM_001419 A_32_P200165
PTBP2 CDNA clone IMAGE:4797534 -2.6 1.49E-08 BC030757 A_24_P136711
FOXO1 forkhead box O1 -2.6 1.48E-08 NM_002015 A_23_P151426
CEBPA CCAAT/enhancer binding protein (C/EBP), alpha -2.5 1.55E-08 NM_004364 A_24_P216165
BCL6 B-cell CLL/lymphoma 6 (zinc finger protein 51) -2.4 9.26E-08 NM_138931 A_23_P57856
MYCN
v-myc myelocytomatosis viral related oncogene, 
neuroblastoma derived (avian)
-2.3 1.50E-07 AF320053 A_23_P303390
FOXP1 CDNA FLJ12381 fis, clone MAMMA1002566 -2.3 3.16E-07 AK022443 A_24_P460763
NEUROG3 neurogenin 3 -2.1 2.28E-06 NM_020999 A_23_P35534
CDKN2A
cyclin-dependent kinase inhibitor 2A (melanoma, p16, 
inhibits CDK4)
-2.0 8.49E-10 NM_058197 A_23_P43484
CEBPB CCAAT/enhancer binding protein (C/EBP), beta -2.0 9.62E-10 NM_005194 A_23_P411296
Table 4-17: Potential targets for miR-9 in the SKBR3-T cell lines. miRWalk identified 
targets related to miR-9 and these were cross compared with our UCLA dataset (n=1). 
Fold change cut-off of -1.5 and p<0.05 were applied. 
 
Table 4-18: Potential targets for miR-9 in the SKBR3-L cell lines. miRWalk identified 
targets related to miR-9 and these were cross compared with our UCLA dataset (n=1). 
Fold change cut-off of -1.5 and p<0.05 were applied. 
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4.10. Summary 
TLDA analysis yielded ten potential miRNAs that were differentially expressed in the 
acquired trastuzumab SKBR3-T cell line and thirteen potential miRNAs in the acquired 
lapatinib resistant SKBR3-L cell line when compared to their aged parental controls. 
We also included miR-224 in the analysis for the SKBR3-T cell line and miR-222 in the 
SKBR3-L cell line due to the close linkages between these miRNAs as explained 
previously.  
 
Validation of these findings by individual qRT-PCR in biological and technical 
triplicates in the SKBR3-T cells confirmed miR-221, -222 and -9 were significantly up-
regulated and miR-224 was down- regulated. Further validation in the SKBR3-L cell 
line confirmed that; miR--9 was significantly up-regulated and miR-221,-222 and -
224were all significantly down-regulated.  
 
To determine if these alterations were cell line specific, we examined the selected 
miRNAs in other cell line models of acquired resistance; BT474-Tr (an acquired 
trastuzumab resistant cell line model from UCLA) and the HCC-1954-L (an acquired 
lapatinib resistant cell line model). We determined that miR-221 and -222 are 
significantly up-regulated in the BT474-Tr cell line compared to the BT-474-P which 
follows the same trend as seen in the SKBR3-T cell line. Interestingly, miR-224 
expression is switched off in the BT-474-Tr cells as it is undetectable by qRT-PCR (Ct 
values >39) in the BT-474-Tr cells compared to its parental cell line. In the HCC-1954-
L cell lines; miR-222 is significantly down-regulated and miR-9 is significantly up-
regulated in these cells.  
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miR-221, -222 and -224 are involved in trastuzumab resistant cell lines whereas miR-
222 and -9 are involved in acquired lapatinib resistant cell lines. There is one common 
miRNA in the acquired trastuzumab and lapatinib setting; miR-222.  
 
From these results we focused on the miR-221, -222, -224 and -9 in the innate 
trastuzumab resistant setting and found: miR-221 expression was significantly higher in 
5/6; miR-222 expression was significantly higher in 3/6; miR-224 was significantly 
lower in 5/6; and miR-9 was significantly higher in only 1/6 innately resistant cell line 
models tested compared to a innately sensitive cell lines. There are alterations in 
miRNAs in the innate setting and while miR-221 and miR-224 seem to follow the trend 
observed in the acquired resistance setting, miR-222 and miR-9 follow opposing trends. 
We focused on miR-221, -224 and miR-9 in the innate lapatinib resistance setting and 
found: miR-221 expression is significantly lower in 2/4; miR-224 is significantly down 
regulated in 4/4; and miR-9 is significantly higher in 1/4 innately resistant cell lines 
compared to innately sensitive cell lines.  
 
We also investigated the short term treatment effects of trastuzumab and lapatinib in the 
SKBR3-P cell line to determine if there were any changes in miRNA expression. After 
24 h treatment with trastuzumab (10 µg/mL) no significant changes were seen in the 
miRNA expression levels. However, after 24 h treatment with lapatinib (250 nM), there 
were significant alterations in miR-221, -222 and -224 expression levels. This suggests 
that the miRNAs we identified in the trastuzumab acquired resistant are specific to long 
term resistance and not short-term resistance. In the lapatinib setting, we identified that 
after 24 h treatment, miR-221, -222 and -224 are significantly down-regulated in the 
SKBR3-P cell line.  
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Target prediction is a useful tool to identify potential mRNA targets for specific 
miRNAs. We utilised the miRWalk database and the UCLA microarray analysis that 
was carried out on our SKBR3-P, SKBR3-T and SKBR3-L cell lines to identify 
potential druggable targets. Cross comparison yielded a small list of potential targets 
including; retinoic acid receptor alpha (RARΑ), met proto-oncogene (MET), angiogenin 
(ANG), cyclin dependent kinase 6 (CDK6) and beta-site APP cleaving enzyme 1 
(BACE1). 
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Chapter Five 
miR-9 and retinoic acid receptors in trastuzumab and 
lapatinib resistant cells 
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5.1 Introduction 
miR-9 was identified as up-regulated in the SKBR3-T, SKBR3-L and HCC-1954-L 
trastuzumab and lapatinib resistant cell lines. Target prediction utilising miRWalk to 
identify potential down-regulated targets for miR-9 was carried out. 
5.2 Identification of potential miR-9 targets 
Microarray analysis performed on the SKBR3, SKBR3-T and SKBR3-L cell lines was 
previously carried out in UCLA (n=1). This UCLA dataset was compared with a 
miRWalk validated target list for miR-9 (159 targets) thus yielding targets that are 
altered in the resistant cell lines compared to their parental cell line. Briefly, as miR-9 
was up-regulated, only messenger RNA (mRNA) targets that were significantly down-
regulated were selected (> 2 fold change, p < 0.05) as potential targets. Only two 
statistically significant mRNA targets for miR-9 were identified in the SKBR3-T; 
retinoic acid receptor alpha (RARα) and DNA-damage-inducible-transcript-3 (DDIT3) 
as shown in Table 4-17. We focused on RARα expression as it has been previously 
associated with tamoxifen resistance [269] and HER2 positive breast cancer [270, 271]. 
Three different RARα probes were included on the array. Two showed significant up-
regulation while one showed down-regulation in the microarray analysis in both the 
SKBR3-T and SKBR3-L cell lines (Table 5-1). We examined sensitivity to all-trans 
retinoic acid in the resistant cells and measured the expression of RARα. All-trans 
retinoic acid (ATRA), commonly known as vesanoid (tretinoin) is most commonly used 
for the treatment of promyelocytic leukemia [272].  
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Table 5-1: RARα microarray expression data for SKBR3-T and SKBR3-L versus 
SKBR3-P cell lines including all probes on the microarray (UCLA, n=1). 
 
 
5.3 All-trans retinoic acid (ATRA) treatment  
5.3.1 SKBR3-P, SKBR3-T and SKBR3-L cell lines 
We investigated the effect of ATRA treatment on the SKBR3-P, SKBR3-T and 
SKBR3-L cell lines with a range of ATRA concentrations (0.2-0.5 µM). The SKBR3-T 
cells displayed significant resistance to ATRA at 2 µM compared with the SKBR3-P 
(p=0.01), whereas, the SKBR3-L cells show similar sensitivity to the SKBR3-P cells 
(Figure 5-1) (Table 5-2).  
 
 
Array 
Sequence 
Name 
Fold 
Change 
p-value Accession # 
Sequence 
Code 
SKBR3-T 
RARA 
1.5 
 
0.01 
 
NM_000964 
 
A_32_P5251 
 
RARA 
2.0 
 
7.09E-06 
 
NM_000964 
 
A_23_P207842 
 
RARA 
-2.8 
 
2.13E-09 
 
BC038432 
 
A_24_P551302 
 
SKBR3-L 
RARA 
1.2 
 
0.26932 
 
NM_000964 
 
A_32_P5251 
 
RARA 
1.8 
 
0.0001 
 
NM_000964 
 
A_23_P207842 
 
RARA -1.5 0.01 BC038432 A_24_P551302 
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Figure 5-1: Determination of ATRA sensitivity in the SKBR3-P cell line and the 
acquired resistant variants; SKBR3-T and SKBR3-L. Proliferation was measured by 
acid phosphatase method after 5 days, and is expressed relative to untreated control. 
Student’s t-test was performed to determine significance of the difference in response to 
treatment: * denotes p < 0.05 when comparing ATRA treatment (2 µM) in the SKBR3-
T to the SKBR3-P cell line. Error bars denote the standard deviation of triplicate 
experiments. 
 
 
Table 5-2: Growth inhibition (%) of the SKBR3-P, SKBR3-T and SKBR3-L cell lines 
upon ATRA treatment (2 µM). Proliferation was measured by acid phosphatase method 
after 5 days, and is expressed relative to untreated control. 
 
 
 
Cell Line % Growth Inhibition ± std dev 
SKBR3-P 57.9 ± 3.3 
SKBR3-T 19.4 ± 8.6 
SKBR3-L 52.0 ± 4.9 
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5.3.2 Other cell line models –BT-474, HCC-1954 and EFM-192A 
To determine if ATRA resistance is linked to trastuzumab resistance we examined 
ATRA sensitivity in three other cell lines. The BT-474-P and its acquired trastuzumab 
resistant variant BT-474-Tr were both insensitive to ATRA treatment (Figure 5-2 A). 
The HCC-1954 and its acquired lapatinib resistant variant, HCC-1954-L were also both 
insensitive to ATRA treatment (Figure 5-2 B). The EFM-192A cell line has been 
previously classed as sensitive to trastuzumab [103], however, we found it was 
moderately sensitive showing 28.6 ± 4.8 % growth inhibition upon trastuzumab 
treatment (10 µg/mL). This cell line showed slight sensitivity to ATRA treatment with 
maximum growth inhibition of 12.8 ± 3.2 % at 0.2 µM (Figure 5-2 C). 
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Figure 5-2: Determination of ATRA sensitivity in the (A) BT-474-P and BT-474-Tr 
and (B) HCC-1954-P and HCC-1954-L and (C) EFM-192A cell lines. Proliferation was 
measured by acid phosphatase method after 5 days, and is expressed relative to 
untreated control. Error bars denote the standard deviation of triplicate experiments. 
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5.4 All-trans retinoic acid (ATRA) and trastuzumab combination treatment 
5.4.1 SKBR3-P, SKBR3-T and SKBR3-L 
We also examined the effect of ATRA in combination with trastuzumab on proliferation 
using a fixed concentration of trastuzumab (10 µg/mL). In the SKBR3-P cells, 
combined treatment with ATRA and trastuzumab significantly enhanced growth 
inhibition compared to ATRA (p=0.0002) or trastuzumab (p=0.0002) treatment alone 
(Figure 5-3 A). The SKBR3-T cells are insensitive to ATRA alone, however, combined 
treatment with ATRA and trastuzumab significantly inhibited cell growth (p=0.003) 
when compared to ATRA (p=0.002) or trastuzumab (p=0.003) alone (Figure 5-3 B). 
The SKBR3-L cells are sensitive to ATRA inhibition alone similar to the SKBR3-P 
cells. Combined treatment with ATRA and trastuzumab significantly enhanced growth 
inhibition compared to ATRA (p=0.01) or trastuzumab (p=0.001) alone (Figure 5-3 C). 
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Figure 5-3: Proliferation of (A) SKBR3-P, (B) SKBR3-T and (C) SKBR3-L cells 
treated with trastuzumab (Trast) (10 µg/mL) or ATRA (0.025 µM - 2 µM) as single 
agents and the combination. Proliferation was measured after five days by the acid 
phosphatase method. Percent proliferation is expressed relative to untreated control. 
Student’s t-test was performed to compare the combination to the single agents.* 
denotes p < 0.05, ** denotes p < 0.005 and *** denotes p < 0.0005. Error bars represent 
standard deviation of triplicate experiments. 
 
136 
 
0
20
40
60
80
100
Trast (10 µg/mL) 0.025 µM ATRA 0.05 µM ATRA 0.1 µM ATRA 0.2 µM ATRA 
%
 G
ro
w
th
 r
el
a
ti
v
e 
to
 c
o
n
tr
o
l
Trastuzumab ATRA ATRA + Trast 
A
B
0
20
40
60
80
100
Trast (10 µg/mL) 0.025 µM ATRA 0.05 µM ATRA 0.1 µM ATRA 0.2 µM ATRA 
%
 G
ro
w
th
 r
el
a
ti
v
e 
to
 c
o
n
tr
o
l
Trastuzumab ATRA ATRA + Trast 
*
**
5.4.2 Other cell line models –BT-474, HCC-1954 and EFM-192A 
We also examined the effect of ATRA in combination with trastuzumab in other cell 
lines. Combined treatment of ATRA and trastuzumab did not enhance growth inhibition 
compared to trastuzumab alone in the BT-474-P (p=0.14) and the BT-474-Tr (p=0.11) 
cells (Figure 5-4). Similarly, combined treatment did not enhance response compared to 
trastuzumab alone in either the HCC-1954-P (p=0.37) or HCC-1954-L (p=0.22) cells 
(Figure 5-5). 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-4: Proliferation of (A) BT-474 and (B) BT-474-Tr treated with trastuzumab 
(Trast) (10 µg/mL) or ATRA (0.025 µM - 2 µM) and the combination. Proliferation was 
measured after five days by the acid phosphatase method. Percent proliferation is 
expressed relative to untreated control. Student’s t-test was performed to compare the 
combination to the single agents.* denotes p < 0.05 and ** denotes p < 0.005. Error bars 
represent standard deviation of triplicate experiments. 
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Figure 5-5: Proliferation of (A) HCC-1954 and (B) HCC-1954-L treated with 
trastuzumab (Trast) (10 µg/mL) or ATRA (0.025 µM - 2 µM) and the combination. 
Proliferation was measured after five days by the acid phosphatase method. Percent 
proliferation is expressed relative to untreated control. Student’s t-test was performed to 
compare the combination to the single agents.* denotes p < 0.05. Error bars represent 
standard deviation of triplicate experiments. 
  
 
In the slightly sensitive cell line, EFM-192A, combined treatment enhanced response to 
trastuzumab treatment when compared to trastuzumab (p=0.003) or ATRA (p=0.0001) 
alone (Figure 5-6). 
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Figure 5-6: Proliferation of EFM-192A cells treated with trastuzumab (Trast) (10 
µg/mL), ATRA (0.025 µM - 2 µM) and the combination. Proliferation was measured 
after five days by the acid phosphatase method. Percent proliferation is expressed 
relative to untreated control. Student’s t-test was performed to compare the combination 
to the single agents. ** denotes p < 0.005 and *** denotes p<0.0005. Error bars 
represent standard deviation of triplicate experiments. 
 
5.5 All-trans retinoic acid (ATRA) treatment - Lapatinib combinations 
5.5.1 SKBR3, SKBR3-T and SKBR3-L cell lines 
We examined the effect of ATRA in combination with lapatinib in the SKBR3 cell line 
panel, using a fixed concentration of 50 nM lapatinib in the SKBR3-P and SKBR3-T 
cell lines and 1 µM in the SKBR3-L cell line. In the SKBR3 cells, combined treatment 
with ATRA and lapatinib significantly enhanced growth inhibition compared to ATRA 
(p=0.003) or lapatinib (50 nM) (p=0.0009) alone (Figure 5-7 A). The combined 
treatment in the SKBR3-T cell line was also more effective compared to ATRA 
(p=0.002) or lapatinib (50 nM) (0.001) alone (Figure 5-7 B). The SKBR3-L cells are 
resistant to lapatinib (1 µM) treatment, however, the combined treatment enhanced 
response compared to ATRA (p=0.0004) or lapatinib (p=0.01) alone (Figure 5-7 C). 
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Figure 5-7: Proliferation of (A) SKBR3, (B) SKBR3-T and (C) SKBR3-L cells treated 
with and without lapatinib (50 nM or 1 µM) and ATRA (0.025 µM- 2 µM) as single 
agents or in combination. Proliferation was measured after five days by the acid 
phosphatase method. Percent proliferation is expressed relative to untreated control. 
Student’s t-test was performed to determine significance of the difference in response to 
treatment: * denotes p< 0.05, ** denotes p < 0.005 and *** denotes p < 0.0005 when 
comparing ATRA treatment or combined treatment with lapatinib alone. Error bars 
represent standard deviation of triplicate experiments. 
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5.5.2 Other cell line models –BT-474, HCC-1954 and EFM-192A 
We examined the effect of ATRA in combination with lapatinib using a fixed 
concentration of 50 nM in the BT-474-P and BT-474-Tr and EFM-192A and 1 µM in 
the HCC1954 and HCC-1954-L cell lines. In the BT-474-P cells, the combined 
treatment did not enhance growth inhibition compared to lapatinib alone (p=0.86) 
(Figure 5-8 A). Similarly, the combined treatment did not enhance growth inhibition in 
the BT-474-Tr compared to lapatinib alone (p=0.14) (Figure 5-8 B). In the HCC-1954-
P and HCC-1954-L cells, combined treatment did not enhance growth inhibition 
compared to lapatinib alone (p=0.89 and p=0.27 respectively) (Figure 5-9). Similarly 
combined treatment did not enhance growth inhibition in the EFM-192A cell line 
compared to lapatinib treatment alone (p=0.12) (Figure 5-10) 
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Figure 5-8: Proliferation of (A) BT-474 and (B) BT-474-Tr treated with lapatinib (Lap) 
(50 nM), ATRA (0.025 µM - 2 µM) and the combination. Proliferation was measured 
after five days by the acid phosphatase method. Percent proliferation is expressed 
relative to untreated control. Student’s t-test was performed to compare the combination 
to the single agents.* denotes p < 0.05 and ** denotes p < 0.005. Error bars represent 
standard deviation of triplicate experiments. 
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Figure 5-9: 
Proliferation of (A) HCC-1954 and (B) HCC-1954-L treated with lapatinib (Lap) (1 
µM), ATRA (0.025 µM - 2 µM) and the combination. Proliferation was measured after 
five days by the acid phosphatase method. Percent proliferation is expressed relative to 
untreated control. Student’s t-test was performed to compare the combination to the 
single agents.* denotes p < 0.05 and ** denotes p < 0.005. Error bars represent standard 
deviation of triplicate experiments. 
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Figure 5-10: Proliferation of the EFM-192A cell line treated with lapatinib (Lap) (50 
nM), ATRA (0.025 µM - 2 µM) and the combination. Proliferation was measured after 
five days by the acid phosphatase method. Percent proliferation is expressed relative to 
untreated control. Student’s t-test was performed to compare the combination to the 
single agents. ** denotes p < 0.005. Error bars represent standard deviation of triplicate 
experiments. 
 
5.6 RARα expression analysis  
5.6.1 RARα mRNA expression 
We investigated the expression of RARα mRNA in our SKBR3-T and SKBR3-L cell 
lines compared to the SKBR3-P. Gene expression analysis was carried out by qRT-PCR 
using RARα specific primers. GAPDH was used as the endogenous control. RARα 
mRNA expression levels were not significantly altered in the SKBR3-T and SKBR3-L 
cell lines compared to the SKBR3-P cell line (Table 5-3).  
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Table 5-3: mRNA expression analysis of RARα in the SKBR3-T and SKBR3-L 
acquired resistant cell lines. Fold changes were calculated using the comparative Ct 
method and is expressed relative to expression in the SKBR3-P cells. Student’s t-test 
was performed to determine significant difference.  
Cell line Fold change ± stdev p-value 
SKBR3-T -1.2 ± 0.5 0.5 
SKBR3-L -1.4 ± 0.2 0.2 
 
5.6.2 RARα protein expression  
We examined RARα protein expression in our acquired resistant cell lines by Western 
blotting. We found no significant changes in the RARα protein expression between the 
SKBR3 and the SKBR3-T (p=0.3) cell line and the BT-474-P and BT-474-Tr (p=0.4) 
cell lines (Figure 5-11).  
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Figure 5-11: RARα protein expression in the SKBR3-P, SKBR3-T, BT-474-P and BT-
474-Tr cell lines. α-tubulin was used as a loading control for each gel. Images are 
representative of triplicate experiments. Densitometry analysis of triplicate 
immunoblots was performed using ImageJ software. 
 
 
5.7 RARβ, RARγ and RxRα protein expression 
As we saw no significant change in the levels of RARα protein between the parental and 
the acquired resistant variants, altered RARα protein expression does not contribute to 
the decreased ATRA sensitivity in the SKBR3-T cells. Further investigation on 
miRWalk using the predictive miRNA targets algorithms identified RARβ, RARγ, 
RxRα and RXRβ as potential targets of miR-9 (Table 5-4).  
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MicroRNA Gene miRanda miRDB miRWalk RNA22 Targetscan SUM
hsa-miR-9-1 RARB 1 0 1 0 1 3
hsa-miR-9-2 RARB 1 0 1 0 1 3
hsa-miR-9-3 RARB 1 0 1 0 1 3
hsa-miR-9-1 RARG 1 0 0 0 0 1
hsa-miR-9-2 RARG 1 0 0 0 0 1
hsa-miR-9-3 RARG 1 0 0 0 0 1
hsa-miR-9-1 RXRA 1 0 1 0 1 3
hsa-miR-9-2 RXRA 1 0 1 0 1 3
hsa-miR-9-3 RXRA 1 0 1 0 1 3
hsa-miR-9-1 RXRB 1 0 0 0 0 1
hsa-miR-9-2 RXRB 1 0 0 0 0 1
hsa-miR-9-3 RXRB 1 0 0 0 0 1
Table 5-4: miRNA Predicted Targets on mRNA 3' UTR Region produced by miRWalk 
and other programs. Hsa-miR-9-1, -2 and -3 refer to the 3 miR-9 seed sequences. 
 
As both RARβ and RARγ are targeted by ATRA, we examined their mRNA expression 
in the UCLA microarray data (Table 5-5) and measured protein expression by western 
blotting. RARβ mRNA was unaltered in the SKBR3-T cell line microarray (Table 5-5) 
and protein expression was not significant altered (p=0.57) (Figure 5-12). RARβ 
expression was not significantly altered in the BT-474-Tr cells compared to the BT-
474-P (p=0.93) (Figure 5-12). RARγ expression was up-regulated in the microarray 
data (Table 5-5), however; its protein expression was not significantly altered in either 
the SKBR3-T or BT-474-Tr cell lines (Figure 5-13). 
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Primary Sequence Name Fold Change P-value Sequence Description Accession #
RARB -1.1 0.49 retinoic acid receptor, beta NM_000965
RARB -1.1 0.47 retinoic acid receptor, beta NM_000965
RARG 1.4 0.02
retinoic acid receptor, 
gamma
NM_000966
RARG 1.2 0.14 retinoic acid receptor, gamma NM_000966
RARG 1.6 0.001
retinoic acid receptor, 
gamma
NM_000966
RARG 1.4 0.02
retinoic acid receptor, 
gamma
NM_000966
RXRA -1.3 0.04 retinoid X receptor, alpha NM_002957
RXRA 1.1 0.45 retinoid X receptor, alpha NM_002957
RXRA 1.0 0.75 retinoid X receptor, alpha AK090416
RXRA 1.1 0.61 retinoid X receptor, alpha NM_002957
RXRA -1.1 0.37 retinoid X receptor, alpha AK090416
RXRA -2.2 7.18E-07 retinoid X receptor, alpha NM_002957
RXRB 1.3 0.04 retinoid X receptor, beta NM_021976
RXRB 1.5 0.00 retinoid X receptor, beta NM_021976
Table 5-5: RARβ, RARγ, RXRα and RXRβ expression in the SKBR3-T cell lines 
compared to SKBR3-P from UCLA microarray (n=1). Significant altered proteins are 
highlighted in bold. 
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Figure 5-12: RARβ protein expression in the SKBR3-P, SKBR3-T, BT-474-P and BT-
474-Tr cell lines. α-tubulin was used as a loading control for each gel. Images are 
representative of triplicate experiments. Densitometry analysis of triplicate 
immunoblots was performed using ImageJ software. 
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Figure 5-13: RARγ protein expression in the SKBR3-P, SKBR3-T, BT-474-P and BT-
474-Tr cell lines. α-tubulin was used as a loading control for each gel. Images are 
representative of triplicate experiments. Densitometry analysis of triplicate 
immunoblots was performed using ImageJ software. 
 
RxRα was significantly down-regulated in the microarray data (Table 5-5) however; no 
changes in RxRα protein levels were observed in the SKBR3-T cells compared to the 
SKBR3-P (Figure 5-14). The BT-474-P cells have a higher level of RxRα expression 
than the SKBR3-P or SKBR3-T cell line, however, no significant changes were 
observed in the levels of RxRα between the BT-474-Tr and BT-474-P cell line (p=0.22) 
(Figure 5-14).   
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Figure 5-14: RxRα protein expression in the SKBR3-P, SKBR3-T, BT-474-P and BT-
474-Tr cell lines. α-tubulin was used as a loading control for each gel. Images are 
representative of triplicate experiments. Densitometry analysis of triplicate 
immunoblots was performed using ImageJ software. 
 
5.8 24 hour ATRA treatment and the effect on the retinoic acid receptors 
We investigated the expression levels of RARα, RARβ, RARγ and RxRα after a 24 
hour treatment with trastuzumab (10 µg/mL). We used the SKBR3 (ATRA sensitive) 
and the SKBR3-T, BT-474 and BT-474-Tr (ATRA insensitive) cell lines for these 
experiments. No significant differences were seen in the expression levels of receptors 
in the SKBR3-P or SKBR3-T cell line upon trastuzumab treatment (Figure 5-15). 
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Figure 5-15: Expression analysis of retinoic acid receptors after 24 h treatment with 
trastuzumab (10 µg/mL) in the SKBR3-P and SKBR3-T cell lines. Densitometry was 
carried out to determine relative expression of (A) RARα, (B) RARβ and (C) RARγ to 
the loading control, α-tubulin. Experiments were carried out in triplicate. 
 
No significant differences were observed in the BT-474-P cell line for the RARs 
(Figure 5-16). A small but statistically significant increase in RARγ expression 
(p=0.05) was observed in the BT-474-Tr cell line upon trastuzumab treatment compared 
to its untreated control.  
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Figure 5-16: Expression analysis of retinoic acid receptors after 24 h treatment with 
trastuzumab (10 µg/mL) in the BT-474-P and BT-474-Tr cell lines. Densitometry was 
carried out to determine relative expression of (A) RARα, (B) RARβ and (C) RARγ to 
the loading control, α-tubulin. Experiments were carried out in triplicate. * denotes 
p<0.05. 
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5.9 Summary 
Utilising the miRWalk database we identified RARα as a potential target for miR-9. 
RARα was differently altered in the SKBR3-T and SKBR3-L cell line compared to the 
SKBR3-P cell lines in the microarray dataset.  
 
Interestingly, the SKBR3-P and SKBR3-L cell lines were sensitive to ATRA inhibition 
however, the SKBR3-T were less sensitive. Combination treatment with trastuzumab 
and/or lapatinib was significantly more effective than either trastuzumab or lapatinib 
treatment alone.  
 
The BT-474-P, BT-474-Tr, HCC1954-P, and HCC-1954-L cell lines are insensitive to 
ATRA inhibition, while the EFM-192A cells show slight sensitivity. Combined 
trastuzumab and ATRA treatment in the BT-474-P, BT-474-Tr, HCC-1954-P and HCC-
1954-L cell lines does not enhance growth inhibition compared to trastuzumab 
treatment alone. Combined trastuzumab and ATRA treatment in the EFM-192A cell 
line enhances growth inhibition compared to trastuzumab alone. 
 
Combined treatment with lapatinib in the BT-474-P, BT-474-Tr, HCC-1954-P, HCC-
1954-L and EFM-192A cells does not enhance the growth inhibition compared to 
lapatinib treatment alone.  
 
In the cell lines that show response to ATRA alone, the combinations with trastuzumab 
and lapatinib enhance response. However, in the cell lines that are innately ATRA 
resistant i.e.: no growth inhibition, no enhancement on growth inhibition was observed. 
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We found no alterations in RARα mRNA or protein expression in the resistant cell lines 
compared to the parental cell lines. As RARα expression is unchanged in the SKBR3-T 
cells it does not account for the resistance to ATRA observed in the SKBR3-T. We 
identified that RARγ and RxRα showed altered expression in the microarray data; 
however we also investigated RARβ expression. RARβ and RARγ expression were 
unchanged in both the acquired resistant cell lines compared to their parental. This 
suggests that RARβ and RARγ expression do not contribute to the decreased sensitivity 
seen in the SKBR3-T cell line. RxRα expression was also unchanged in the SKBR3-T 
cell line.  
 
We also investigated the expression of the RARs upon trastuzumab treatment in our cell 
lines. No significant alterations were seen in the SKBR3-P, SKBR3-T and BT-474-P 
cell lines. However, RARγ expression was significantly up-regulated in the BT-474-Tr 
cell line after 24 h treatment. 
 
The results observed suggest that RARα, RARβ, RARγ or RxRα do not contribute to 
the decreased sensitivity in the SKBR3-T cell line and do not predict response or 
resistance to ATRA treatment. 
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Chapter Six 
The role of miR-221 & -222 in resistance, migration 
and ‘stemness’ 
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6.1 Introduction 
We previously identified that expression of miR-221 and -222 is increased in acquired 
trastuzumab resistant cell lines. miR-221 and -222 have been implicated in epithelial-to-
mesenchymal transition (EMT) in basal-like breast cancers through a reduction in E-
cadherin abundance [273]. They also have reported roles in tamoxifen, [274] and 
fulvestrant [275] resistance and in cancer stem cells [276, 277]. To investigate the role 
of mi-221 and -222 in trastuzumab response in HER2 positive breast cancer we 
generated SKBR3-P cells stably transfected with miR-221, miR-222 and both miRNAs. 
6.2 Characterisation of the stable transfected SKBR3-P cell line 
6.2.1 Confirmation of transfection in the SKBR3-P cell line 
Lentiviral transfected SKBR3-P cell lines expressing pre-miR-221, -222 or both -221 
and -222 were created by Dr. Laoighse Mulrane UCD (Chapter 2.11). A pre-scrambled 
control (SKBR3-P-Scramble) was also established. Over-expression of miR-221 and 
miR-222 was determined by qRT-PCR using the SKBR3-P-Scramble as the calibrator 
sample (which was comparable in Ct values to the SKBR3 cell line). We confirmed that 
levels of miR-221 were significantly increased in the SKBR3-P-221 and SKBR3-P-221-
222 cell lines and not in the SKBR3-P-222 (Table 6-1). We also confirmed that miR-
222 levels were highly over-expressed in only the SKBR3-P-222 and SKBR3-P-221-
222 cell lines (Table 6-1). As the lentiviral vector contained a GFP-gene we also used 
fluorescent microscopy to confirm successful transfection. The stably transfected cell 
lines were green fluorescent protein (GFP) positive as shown in (Figure 6-1). 
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Fold change in expression  std dev
SKBR3-P-221 SKBR3-P-222 SKBR3-P-221_222
miR-221 139.0  0.7 * -2.8  0.6 72.2  0.3 *
miR-222 1.7  0.3 1175.5  0.2 * 746.7  .04 *
A
B
C
D
Table 6-1: miR-221 and miR-222 expression levels by qRT-PCR in the stably 
transfected SKBR3 cell lines. SKBR3-P-Scramble was used as a calibrator and RNU48 
was used as the endogenous control. * indicates p < 0.05 by Student’s t-test. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6-1: Phase contrast and fluorescent images of the stably transfected cell lines; 
SKBR3-P-Scramble (A), SKBR3-P-221 (B), SKBR3-P-222 (C) and SKBR3-P-221-222 
(D). Images were captured using the Leica DFC 500 microscope Nikon TS100 
microscope at 10X magnification. Scale bar represents 200 µm. 
158 
 
A B C
D E F
6.2.2 Effect of miR-221 and -222 over-expression on morphology and 
doubling time 
No morphological changes were observed between the SKBR3, SKBR3-T and the 
stably transfected cell lines (Figure 6-2).  
 
 
 
 
 
 
Figure 6-2: Phase contrast images observing the morphology of the SKBR3-P (A), 
SKBR3-T (B), SKBR3-Scrm (C), SKBR3-221 (D), SKBR3-222 (E) and SKBR3-221-
222 (F). Images were captured at 20X magnification using the (Nikon TS100) at 20X 
magnification. Scale bar = 200 µM. 
 
We investigated the effect of over-expression of miR-221 and miR-222 on the doubling 
time of the cells (Figure 6-3) (Table 6-2). The lentiviral transduction showed no 
significant effect on the doubling time of the SKBR3-Scrm compared to the SKBR3-P 
cell lines (p =0.3).   
 
Trastuzumab treatment increased the doubling times i.e: slowed down cell growth in 
most of the cell lines investigated. The SKBR3-P-221 (31.8 ± 0.2) and SKBR3-P-221-
222 (29.1 ± 1.8) cell lines showed slightly reduced doubling times compared to the 
SKBR3-P-Scrm (34.9 ± 3.0), however, the reductions were not statistically significant 
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(p=0.3, p=0.1 respectively) (Figure 6-3). Trastuzumab treatment significantly increased 
the doubling time of the SKBR3-P (p=0.01), SKBR3-P-Scrm (p=0.04), SKBR3-P-221 
(p=0.01), SKBR3-221-222 (p=0.001), but not the SKBR3-T (p=0.1) and SKBR3-P-222 
(p=0.08) cell lines (Table 6-2).  
 
 
 
 
 
 
 
Figure 6-3: Average doubling times (h) ± stdev for the SKBR3-P, SKBR3-T and stably 
transfected cells with or without trastuzumab treatment. Doubling time was assessed by 
the acid phosphatase method on Day 0, 3, 5 and 7. Error bars represent the standard 
deviation of triplicate experiments. Student’s t-test was performed to determine 
significant effects of trastuzumab on doubling time. * denotes p<0.05 and ** denotes 
p<0.005. 
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Doubling Time (h)  std dev
Ctl Trast
SKBR3-P 32.2  2.2 41.2  3.6 *
SKBR3-T 32.6  2.5 36.6  2.0
SKBR3-P-Scrm 34.9  3.0 46.7  5.9 * 
SKBR3-P-221 31.8  0.2 38.8  2.6 *
SKBR3-P-222 34.5  3.2 43.2  5.7
SKBR3-P-221-222 29.1  1.8 38.9  2.6 **
 
Table 6-2: Average doubling times (h) ± stdev for the SKBR3-P, SKBR3-T and stably 
transfected cells with or without trastuzumab treatment. Student’s t-tests were carried 
out to determine significant effects of trastuzumab on doubling times. * denotes p<0.05 
and ** denotes p<0.005. 
 
 
 
 
 
 
 
 
 
 
6.2.3 Effect of miR-221 and -222 on trastuzumab sensitivity  
As miR-221 and -222 were up-regulated in the acquired trastuzumab resistant cell lines, 
we investigated the trastuzumab sensitivity of the stably cell lines. The SKBR3-P-Scrm 
cell line is growth inhibited by 34.7 ± 6.3 % upon treatment with 4 µg/mL trastuzumab 
compared with a 43.0 ± 1.2 % growth inhibition in the SKBR3-P cell line (Figure 6-4). 
However, this is not a significant difference (p=0.15) which suggests the lentiviral 
transduction has a small but non-significant effect on the resistance profile of the cells. 
The SKBR3-P-221, SKBR3-P-222 and the SKBR3-P-221-222 cell lines show growth 
inhibition of 33.8 ± 4.1 %, 37.4 ± 4.6 % and 35.8 ± 2.9 %, not statistically different 
compared to the SKBR3-P-Scrm (p=0.85, 0.37 and 0.80 respectively) (Figure 6-4) 
(Table 6-3) .  
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Figure 6-4: Determination of trastuzumab sensitivity in the SKBR3-P and SKBR3-P-
stably transfected cell lines. Proliferation was measured by acid phosphatase assay after 
5 days, and is expressed relative to untreated control. Error bars denote the standard 
deviation of triplicate experiments.  
 
Table 6-3: Growth inhibition of the SKBR3-P and the SKBR3-P-stably transfected cell 
lines after trastuzumab treatment (4 µg/mL) ± std dev. 
 
 
 
 
 
 
 
 
6.2.4 Effect of miR-221 and -222 on migration 
We examined the effect of over-expression of these miRNAs on migration at 24 h and 
48 h time-points by wound scratch assay as they have both been previously reported to 
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increased migration in basal-like breast cancer (Figure 6-5) [278]. When we compared 
the SKBR3-P to the SKBR3-P-Scrm, we noticed the lentiviral transduction had a 
significant effect on migration at 24 h (p=0.02) and 48 h (p=0.01) (Table 6-4) (Figure 
6-6). The SKBR3-P-221 (45.2 ± 5.6 %, 61.5 ± 9.4 %) cell line is significantly more 
migratory than the SKBR3-P-Scrm (28.7 ± 6.4 %, 36.5 ± 4.3 %) after both 24 and 48 h 
(p=0.03, 0.03) respectively (Table 6-4) (Figure 6-6). The SKBR3-P-221-222 (59.1 ± 
6.7 %) cell line is also significantly more migratory than the SKBR3-P-Scrm (36.5 ± 4.3 
%) cell line after 48 h (p=0.01) (Table 6-4) (Figure 6-6). No significant change in 
migration was observed for the SKBR3-P-222 compared to the SKBR3-P-Scrm after 24 
h (p=0.47) and 48 h (p= 0.67) (Table 6-4) (Figure 6-6). 
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Figure 6-5: Representative images of the TScratch analysed wound scratch images of 
the SKBR3-P, SKBR3-P-Scrm, SKBR3-P-221, SKBR3-P-222 and SKBR3-P-221-222 
at 0 h, 24 h and 48 h timepoints using the Nikon TS100 microscope. 
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Table 6-4: Average migration in the SKBR3-P, SKBR3-P -221, SKBR3-P -222 and 
SKBR3-P -221-222 cell lines after 24 h and 48 h timepoints. Open space (%) was 
calculated using the TScratch program and migration was then calculated (100% - open 
space %). 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
Figure 6-6: Average migration in the SKBR3-P, SKBR3-P-Scrm, SKBR3-P-221, 
SKBR3-P-222 and SKBR3-P-221-222 cell lines after 24 h and 48 h time points. Open 
space (%) was calculated using the TScratch program and migration was then calculated 
(100 % - open space %). Error bars denote the standard deviation of triplicate 
experiments. Student’s t-test was performed to determine significant difference: * 
denotes p<0.05. 
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6.3  Target Prediction for miR-221 and miR-222 
We identified a study which involved transfection of MCF-7 cells with miR-221 and 
miR-222 [279] and a freely accessible microarray dataset (E-TABM-601) was available. 
Using R software hierarchical cluster analysis showed that the samples types separated 
out into control and transfected groups (Figure 6-7). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6-7: Hierarchical cluster analysis was carried out on the freely accessible GEO 
dataset E-TABM-601. The high level quality control shows the control groups and the 
transfected miR-221 and -222 groups clustering together. 
 
Differential expression of the data was calculated using a ± 1.2 fold change and a BH 
(Benjamini Hochberg) adjusted p-value of < 0.05. A list of differentially expressed 
targets was identified (886) and compared against predicted targets for miR-221 and -
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Gene Name Sequence Description Fold Change p-value Accession # Sequence Code
HNRNPA3 heterogeneous nuclear ribonucleoprotein A3 -1.9 0.00005 NM_194247 A_24_P488588
HIPK2 homeodomain interacting protein kinase 2 -1.7 0.0003 AK074291 A_24_P500621
MED1 mediator complex subunit 1 -1.5 0.003 NM_004774 A_23_P425704
RALGAPA1
Ral GTPase activating protein, alpha subunit 1 
(catalytic)
-1.5 0.007 AL834362 A_23_P151565
TMCC1 transmembrane and coiled-coil domain family 1 -1.4 0.02 NM_015008 A_23_P170986
CDKN1B cyclin-dependent kinase inhibitor 1B (p27, Kip1) -1.3 0.01 NM_004064 A_24_P81841
ARL6IP1 ADP-ribosylation factor-like 6 interacting protein 1 -1.3 0.05 NM_015161 A_23_P118150
222 using Target Scan. This identified 73 potential down-regulated targets that are 
predicted to be targeted by miR-221 and/or -222 in MCF-7 cells. This was cross-
compared to our microarray UCLA dataset and targets that were significantly down-
regulated were identified. We identified seven potential down-regulated targets from 
this array dataset (Table 6-5). As p27 
kip1 
has previously been linked with trastuzumab 
resistance we tested the stably transfected cell lines for p27 
kip1 
expression (Figure 6-8). 
p27 
kip1 
expression was significantly down-regulated in the SKBR3-222 (p=0.03) and -
221-222 (p=0.03) cell lines suggesting that p27 
kip1
 is a target for miR-222. p27 
kip1
 
levels were also reduced in the SKBR3-P-221 cell line although this did not achieve 
statistical significance (p=0.09). 
 
Table 6-5: Potential targets for miR-221 and -222 identified from microarray analysis 
of a freely accessible microarray, E-TABM-601 and cross comparison with a 
microarray dataset from UCLA (n=1) of the SKBR3-T cell line compared with the 
SKBR3-P. 
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Figure 6-8:  p27 
kip1
 expression in the stable transfected cell line. α-tubulin was used as 
a loading control on each gel. Images are representative of triplicate experiments. 
Densitometry analysis of triplicate immunoblots was performed using ImageJ software. 
* denotes p<0.05. 
 
p27 
kip1
 [280] along with SOCS1 [278] have previously been identified as a potential 
targets for miR-221 and -222. Miller et al., discovered that miR-221 and -222 play a 
role in tamoxifen resistance through their targeting of p27 
kip1
 and Li et al. discovered 
miR-221 and -222 were involved in migration through SOCS1 and p27 
kip1
. We have 
confirmed p27 
kip1
 expression is altered in our miR-222 over-expressing cell line 
(Figure 6-8). We investigated SOCS1 expression in our stably transfected cell lines. 
We determined a slight decrease in the expression levels in the SKBR3-P-221 cell line 
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compared to the scramble control; however, it was not significantly altered (p=0.34) 
(Figure 6-9). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6-9: SOCS1 expression in the stable transfected cell line. α-tubulin was used as 
a loading control on each gel. Images are representative of triplicate experiments. 
Densitometry analysis of triplicate immunoblots was performed using ImageJ software. 
 
6.4 miR-221 and -222 and their involvement in stemness 
Based on previously published associations between miR-221 and miR-222 and stem 
cells [281], we used an established mammosphere assay to examine alterations in 
stemness. Mammosphere assays are sphere-forming assays which are utilised for the 
quantification of stem cell activity and self renewal. An assay protocol was previously 
published and optimised by Shaw et al. [282]. We investigated the mammosphere 
forming efficiency (MFE) of the SKBR3-P, the trastuzumab resistant variant, SKBR3-T 
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and the stably transfected cell line panel (Figure 6-10). We determined no significant 
difference in the MFE of the SKBR3-T (1.3 ± 0.4 %) cells compared to the SKBR3-P 
(1.5 ± 0.2 %) cell line (p=0.7). MFE comparison between the SKBR3-P and SKBR3-P-
Scrm cell line shows that the lentiviral transduction had no significant effect on the 
MFE of the cell lines (SKBR3-P-Scrm (2.1 ± 0.4%) and SKBR3-Par (1.5 ± 0.2 %) cell 
line, p=0.03). Mammosphere assays of the stably transfected cell line show that over-
expression of miR-221 in the SKBR3-P-221 cell line has no effect on MFE when 
compared to the scrambled control, SKBR3-P-Scrm (p=0.4). Over-expression of miR-
222 has no significant effect on the MFE of the SKBR3-P cells when compared to the 
SKBR3-P-Scrm (p=0.9). Over-expression of both miRNAs together also does not have 
a significant effect on the MFE of the SKBR3-P-221-222 cell line compared to the 
SKBR3-P (p=0.3) and the SKBR3-P-Scrm (p=0.4) cell lines. 
 
 
 
 
 
 
 
Figure 6-10: Mammosphere forming efficiency (MFE %) of the SKBR3-P, SKBR3-T 
and the stably transfected cell lines. MFE was determined as the number of 
mammospheres >50 µm after 5 days culture in mammosphere media relative to the 
number of cells seeded initially. Error bars denote the standard deviation of triplicate 
experiments. Student’s t-test was performed to determine significant difference between 
the SKBR3-P and the stable transfected cell lines. * denotes p<0.05. 
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We also investigated the effect of trastuzumab (10 µg/mL) and lapatinib (50 nM) on the 
MFE of the cell lines (Figure 6-11). Lapatinib treatment significantly decreased MFE in 
the SKBR3-T cell lines (p=0.02), however trastuzumab or lapatinib treatment had no 
significant effect on the MFE of the other cell lines tested. The SKBR3-P cell line is 
sensitive to both trastuzumab and lapatinib inhibition but the MFE of the SKBR3-P cell 
line is unchangeed to treatment with either agent. 
 
 
 
 
 
 
 
 
Figure 6-11: Mammosphere forming efficiency (MFE %) of the SKBR3-P, SKBR3-T 
and the stably transfected cell lines following trastuzumab (10 µg/mL) and lapatinib (50 
nM) treatment. MFE was determined as the number of mammospheres >50 µm after 5 
days culture in mammosphere media relative to the number of cells seeded initially. 
Error bars denote the standard deviation of duplicate experiments.  
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6.5 Summary 
We successfully created stably transduced over-expressing SKBR3-P cell lines for miR-
221 and -222 (in collaboration with Dr. Mulrane). We observed no morphological 
differences between the SKBR3-P, SKBR3-T and the stably transfected cell lines. We 
investigated the effect of over-expressing miR-221 and -222 on doubling times and 
found no significant changes. However, trastuzumab treatment significantly increased 
the doubling time of the SKBR3-P, SKBR3-P-Scrm, SKBR3-P-221 and SKBR3-P-221-
222 cell lines when compared to the untreated controls. However, there was no 
significant effect on doubling time of the stably transfected cell lines compared to the 
scrambled control. The stably transfected cell lines do not show a significant change in 
trastuzumab sensitivity using a 2D proliferation assay. We investigated the effect of 
these miRNAs on migration and found the lentiviral transduction increased migration. 
When we compared the migratory potential of the stably transfected cell line to the 
scrambled control, SKBR3-P-Scrm, we observed that the SKBR3-P-221 is significantly 
more migratory than the scrambled control after 24 and 48 h. The SKBR3-221-222 cell 
line also was more migratory after 48 h than the SKBR3-P-Scrm.  
 
p27 
kip1 
(CDKN1B) was altered in the SKBR3-T cell line and is a previously validated 
target for miR-221 and -222. We determined that p27 
kip1
 expression is down-regulated 
in the SKBR3-P-222 and SKBR3-P-221-222 cell lines. 
  
miR-221 and -222 have been previously reported in stem cell activity and promotion. 
We examined the stemness potential of our stably transfected cells by the 
mammosphere assays. We observed no significant changes in the MFE of the stable 
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transduced cell lines compared to the SKBR3-P. Trastuzumab and lapatinib treatment 
had no significant effect on mammosphere formation in the stable transfected cell lines.  
 
In summary, miR-221 and/or miR-222 do not appear to play a significant role in the 
acquired trastuzumab phenotype. However, they appear to increase the migratory 
capacity of the cells which may contribute to a more aggressive phenotype. 
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Chapter Seven 
miRNA expression in HER2 positive breast tumours 
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7.1 Introduction 
Formalin fixation is the standard method of preserving patient tissue samples. However 
upon formalin fixation, cross-linking of DNA and degradation occur which can cause 
difficulties in extracting intact DNA. miRNAs are more stable than DNA and mRNA 
and therefore are ideal candidates for investigating biomarkers in archival patient 
samples [283]. For this study, we obtained tumour samples from a cohort of patients 
(n=16) with metastatic HER2 positive breast cancer, who either progressed on 
trastuzumab treatment (PFS <12 months) (n=10) or had a durable response to 
trastuzumab treatment (PFS >36 months) (n=6)  [101]. Initially, we investigated a 
number of commercially available kits for the extraction of miRNA from formalin fixed 
paraffin embedded (FFPE) samples, using cell culture donor blocks. Based on the 
results obtained, miRNA was extracted from the FFPE tumour samples for miRNA 
analysis of the four miRNAs; miR-221, -222,-224 and -9 previously identified in 
Chapter Four. 
 
7.2 Assessment of FFPE miRNA extraction kits 
7.2.1 Cell culture donor block preparation  
Cell culture donor blocks (CCDB) were prepared from SKBR3-P cells. Sections (5 µM) 
were cut from the CCDB and were Hematoxylin & Eosin (H&E) stained to ensure 
sufficient cell numbers and quality as shown in Figure 7-1. 
.  
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Figure 7-1: H&E stained sections from SKBR3-P cell culture donor blocks. Images 
were captured at 10X (A), 20X (B) and 40X (C) magnification using the Nikon TS100 
microscope. Scale bars represent 500 µm (A), 200 µm (B) and 100 µm (C). 
 
7.2.2 Comparison of miRNA extraction methods  
We tested miRNA extraction using three commercially available kits; RecoverAll™ 
Total Nucleic Acid Isolation Kit (Ambion) which extracts total RNA, High Pure 
miRNA Isolation kit (Roche) which extracts miRNAs and total RNA and miRNeasy 
FFPE Kit (Qiagen) which extracts miRNA and total RNA. We also investigated 
different sources of starting material; full-face sections (10 µM) and cores (1.0 mm and 
1.5 mm). miRNA was analysed by Nanodrop (Thermo Scientific) and the RNA quantity 
(µg) and A260/280 (~ 1.8-2.2) were determined (Table 7-1). 
 
 
 
 
 
 
A B C 
176 
 
Table 7-1: Total amount (µg) of RNA, A260/280 ratios using the Nanodrop (Thermo 
Scientific) extracted from sections (10 µM), cores; 1.0 mm and 1.5 mm using three 
commercially available kits. 
 
RecoverAll™ Total 
Nucleic Acid 
Isolation Kit 
High Pure miRNA 
Isolation Kit 
miRNeasy FFPE 
Kit 
 µg A260/280 µg A260/280 µg A260/280 
Section 
(10 µM) 
2.3 2.0 3.7 2.1 4.4 2.0 
Core 
(1 mm) 
2.4 2.0 2.4 2.1 1.2 2.0 
Core 
(1.5 mm) 
3.7 2.1 6.0 2.0 2.6 2.0 
 
The miRNA extracts were also analysed using the Agilent 2100 Bioanalyzer. The 
Bioanalyzer yields electropherograms (peaks) which can identify intact small (5S-
fragments) and total RNA (18S and 28S – fragments) (Figure 7-2 A). It also determines 
the integrity of RNA by RNA Integrity Number (RIN). RNA extracted using the 
RecoverAll™ Total Nucleic Acid Isolation Kit yielded small RNA peaks at 5S in all of 
the starting material, however, no total RNA was detected at 18S and 28S (Figure 7-2 
B). miRNA extracted using the High Pure miRNA Isolation kit from Riche yielded no 
small RNA peaks in any of the sample (Figure 7-2 B). miRNA extracted from the 
miRNeasy FFPE Kit from Qiagen yielded small RNA peaks from all of starting material 
(Figure 7-2 B). RNA integrity is assessed using the RIN, the intactness of the sample is 
graded from 1 to 10, 10 being the most intact. RIN values for FFPE samples are 
generally lower than cell line RNA, ranging from values of 1.0 upwards [284]. The RIN 
values for the RecoverAll™ Total Nucleic Acid Isolation Kit ranged from 1.2 – 2.1 
(Table 7-2). The RIN values for the Roche kit are comparable between sections and 1.5 
mm cores. The 1.0 mm cores had a slighter lower value of 1.2 (Table 7-2). Sections 
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extracted using the RecoverAll kit had a higher RIN value than the cores of either size. 
The RIN values for the miRNeasy kit were lower than the other two kits however; the 
1.5 mm cores had a higher RIN value than sections or 1.0 mm cores (Table 7-2). 
 
High Pure miRNA 
Isolation kit-Roche 
RecoverAll™ Total Nucleic 
Acid Isolation Kit 
miRNeasy FFPE Kit
- Qiagen
i
ii
iii
A
B
 
Figure 7-2: (A) An electropherogram from the Agilent 2100 Bioanalyzer with small 
RNA peaks indicated by the 5S fragment and total RNA peaks indicated by the 18S and 
28S fragments. (B) miRNA extracts from (i) sections (10 µM), (ii) 1.0 mm core and (iii) 
1.5 mm core using the RecoverAll, High Pure and Qiagen kit were analysed using the 
Agilent Bioanalyzer. Electropherograms shown are representative of triplicate RNA 
extractions.   
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Table 7-2: RIN values determined by the Agilent Bioanalyzer for miRNA extracts from 
sections (10 µM), 1.0 mm core and 1.5 mm core using the three commercially available 
kits. 
  RIN 
RecoverAll™ Total 
Nucleic Acid Isolation Kit  
 
Section (10 µM) 1.8 ± 0.6 
Core (1.0 mm) 1.2 ± 0.1 
Core (1.5 mm) 2.1 ± 0.7 
High Pure miRNA 
Isolation Kit  
 
Section (10 µM) 1.4 ± 0.2 
Core (1.0 mm) 1.2 ± 0.1 
Core (1.5 mm) 1.4 ± 0.3 
miRNeasy FFPE Kit 
 
Section (10 µM) 1.0 ± 0.0 
Core (1.0 mm) 1.1 ± 0.6 
Core (1.5 mm) 1.8 ± 0.4 
 
CCDB RNA extracts were tested by qRT-PCR to determine if miRNA extracted from 
FFPE samples are detectable by qRT-PCR. Taqman qRT-PCR assays using an 
endogenous control assay for RNU48 was carried out. The resulting threshold cycle (Ct) 
values were comparable to those seen in cell line miRNA extracts (Ct values ~ 25) 
(Table 7-3).  
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Table 7-3: Cycle threshold (Ct) values determined from qRT-PCR analysis for the 
endogenous control RNU48 using miRNA extracted from CCDB. Standard deviations 
are representative of triplicate experiments. 
  Ct 
RecoverAll™ Total 
Nucleic Acid Isolation Kit  
 
Section (10 µM) 25.1 ± 0.1 
Core (1.0 mm) 25.1 ± 0.2 
Core (1.5 mm) 24.6 ±0.1 
High Pure miRNA 
Isolation Kit 
 
Section (10 µM) 26.4 ± 0.1 
Core (1.0 mm) 24.6 ± 0.1 
Core (1.5 mm) 24.8 ± 0.1 
miRNeasy FFPE Kit 
 
 
Section (10 µM) 25.0 ± 0.2 
Core (1.0 mm) 25.0 ± 0.2 
Core (1.5 mm) 24.7 ± 0.6 
miRVana Kit  Cell line – SKBR3 25.4 ± 0.3 
 
The High Pure kit yielded no visible small RNA peaks (5S-fragments) in the 
Bioanalyzer analysis; we decided to focus on the RecoverAll and miRNeasy kits. 
miRNA extraction was carried out on two tumour samples (the SKBR3-T cell line  was 
used as a positive control) using the RecoverAll™ Total Nucleic Acid Isolation Kit and 
miRNeasy FFPE Kit. We successfully extracted RNA from FFPE tumours using both 
kits as seen in Table 7-4. The A260/280 and A260/230 results were comparable to that seen 
in the cell line positive control (Table 7-4)  
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Table 7-4: Quantification of concentration (ng/ µL), total RNA (µg) and assessment of 
RNA purity by A260/280 and A260/230 ratios of RNA extracts from FFPE patient samples 
and SKBR3-T cell line. 
 
 
Sample 
Conc 
(ng/µL) 
Total 
RNA (µg) 
A260/280 A260/230 
RecoverAll™ 
Total Nucleic Acid 
Isolation Kit 
Tumour 
No.1 
376.8 11.3 2.0 1.8 
SKBR3-T 244.0 2.5 2.1 1.8 
miRNeasy FFPE 
Kit 
 
Tumour 
No.2 
84.2 2.5 1.9 1.8 
SKBR3-T 1233.4 37.0 2.1 2.0 
 
RNA was further analysed using the Agilent Bioanalyzer. The cell line positive controls 
using either the RecoverAll (Figure 7-3 A) or miRNeasy extraction (Figure 7-3 B) kits 
resulted in intact small RNA peaks at the 5S fragment and total RNA peaks at the 18S 
and 28S- fragments. In comparison, the tumour samples yielded no intact total RNA 
peaks, however, a large peak at the small RNA 5S fragment. Therefore both kits were 
successful in the extraction of miRNA from FFPE tumour samples. 
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Figure 7-3: miRNA extracted from SKBR3-T cell line as a positive control and FFPE 
patient samples using the (A) RecoverAll™ Total Nucleic Acid Isolation Kit and (B) 
miRNeasy FFPE Kit extraction kits and extracts were analysed on the Agilent 
Bioanalyzer. 
 
Based on the results and combined with the cost and ease of handling, we chose the 
miRNeasy FFPE kit for this study.  
 
7.3 Primary tumour miRNA analysis in a FFPE HER2 positive breast cancer 
cohort 
A cohort of patient samples from St. Vincent’s University Hospital (n=16) that are 
classified as DCR (> 36 months in remission) and non-DCR (progressed < 12 months) 
were used for miRNA expression analysis in HER2 positive breast cancer (outlined in 
Section 2.27). Normal breast FFPE sections (Insight Biotechnology Ltd, Cat No: 
CS802489) were used for calculations and comparison. 
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7.3.1. Patient characteristics 
The HER2 status of all the patients included in this study were previously scored by a 
pathologist as HER-2 positive with membrane staining and a  3+ score and whenever 
necessary (Scoring 2+/1+) HER2 amplification was confirmed by fluorescent in situ 
hybridisation (FISH). 
 
Table 7-5: Patient characteristics from ICORG-12-09 study. * indicates HER2 
amplification was confirmed by further FISH analysis. 
  DCR (n = 6) Non-DCR (n = 10) 
Median Age  69.5 yrs 58.5 yrs 
ER status 
Positive 1/6 7/10 
Negative 5/6 1/10 
Unknown - 2/10 
PR status 
Positive 1/6 3/10 
Negative 3/6 2/10 
Unknown 2/6 5/10 
Histology 
IDC 6/6 7/10 
DCIS - - 
Unknown - 3/10 
Grade 
1+ - 1/10 * 
2+ - 2/10 * 
3+ 6/6 6/10 
Unknown - 1/10 
ER: Estrogen Receptor, PR: Progesterone Receptor, IDC: Invasive ductal carcinoma, 
DCIS: Ductal carcinoma in situ, * patients were confirmed HER2 amplified by FISH. 
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7.3.2. HER2 immunohistochemistry and miRNA extraction  
As these patients had previously been identified as HER2 positive by a pathologist, 
sections (4 µM) were HER2 stained using the DAKO autostainer to identify HER2 
positive tumour tissue for coring from DCR as illustrated in Figure 7-4 and non-DCR 
as illustrated in Figure 7-5. Two 1.0 mm cores were punched and subsequently 
extracted using the miRNeasy FFPE kit. The miRNA extracts were analysed using the 
Nanodrop (Thermo Scientific) (Table 7-6) and subsequently used for further 
downstream reactions.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7-4: Immunohistochemical analysis of HER2 protein expression in the cohort of 
durable complete responders (DCR). Scale bar = 500 µm. Images were captured at 10X 
magnification using the Nikon TS100 Microscope.                   
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Figure 7-5: Immunohistochemical analysis of HER2 protein expression in the cohort of 
non-durable complete responders (non-DCR). Scale bar=500 µm. Images were captured 
at 10X magnification using the Nikon TS100 Microscope. 
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Response Patient No Conc (ng/µl)
Total Conc 
(µg)
A260/280 A260/230
DCR 1 25.7 0.8 1.8 1.5
Non-DCR 2 54.6 1.6 1.9 1.7
Non-DCR 3 31.7 1.0 1.8 1.5
Non-DCR 4 16.8 0.5 1.4 1.1
Non-DCR 5 17.3 0.5 1.5 1.1
Non-DCR 6 18.9 0.6 1.5 1.0
DCR 7 60.9 1.8 2.0 2.7
DCR 8 68.3 2.0 1.9 1.9
Non-DCR 9 24.0 0.7 1.8 2.3
Non-DCR 10 25.8 0.8 1.7 1.7
DCR 11 18.4 0.6 1.8 1.5
DCR 12 42.5 1.3 1.9 1.8
DCR 13 66.3 2.0 1.8 0.9
Non-DCR 14 100.5 3.0 2.2 2.3
Non-DCR 15 85.0 2.6 2.1 3.2
Non-DCR 16 70.5 2.1 2.3 3.6
Normal Breast Section 20.3 0.6 1.7 1.2
 Table 7-6: miRNA extracted form FFPE patient samples using the miRneasy kit was 
analysed by Nanodrop to determine concentration (ng/µl) and A260/280.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
7.3.3. qRT-PCR analysis 
The miRNAs identified from the cell line analysis (miR-221, -222, -224 and -9) were 
tested in this patient cohort. RNU48 was used as the endogenous control and normal 
breast tissue was a calibrator sample. The fold changes were calculated using the 
comparative method. The average fold change of each group (DCR or non-DCR) was 
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DCR  Non-DCR
miR-221 2.0 (-1.9 - 4.7 ) 2.4 ( -2.8 - 13.8)
miR-222 1.8 (-1.3 - 4.2) 3.2 (-2.7 - 13.8)
miR-224 2.0 (-9.7 – 14.2) -6.3 (-64.3 – 26.3)
miR-9 4.3 (-1.6 – 14.8) 11.2 (-1.7 – 48.6)
calculated (Table 7-7). miR-221 expression was higher in the non-DCR (2.4 fold 
change) group in comparison to the DCR group (1.8 fold change) (Figure 7-6). miR-
222 expression was also higher in the non-DCR group (3.2 fold change) compared to 
the DCR (1.7 fold change) (Figure 7-6). miR-224 expression was lower in the non-
DCR group (-6.3 fold change) in comparison to the DCR group (1.8 fold change) 
(Figure 7-6). miR-9 expression was higher in the non-DCR group compared to the 
DCR group (Figure 7-6). However, statistical testing using a Mann Whitney test 
yielded no significance between the DCR and non-DCR groups for miR-221 (p=0.74), 
miR-222 (p=0.74), miR-224 (p=0.51) and miR-9 (p=0.79). 
 
Table 7-7: Mean miRNA expression values (range) for miR-221, -222, -224 and -9 in 
DCR (n=6) and non-DCR (n=10) cohort. Fold changes were calculated relative to 
normal FFPE breast tissue. 
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Figure 7-6: miRNA expression analysis for miR-221 (A), -222 (B), -224 (C) and -9 (D) 
in DCR     (n=6) and non-DCR     (n=10) cohort. Fold changes were calculated relative 
to normal FFPE breast tissue. The average fold change for each group is plotted as a 
black line. 
 
7.4 Conditioned media study 
CmiRNAs are potential non-invasive biomarkers of disease [285, 286], clinical outcome 
[287] and resistance [288]. To determine if the miRNAs identified in Chapter 4 may be 
detected in patient sera, we initially analysed miRNAs in conditioned media from cell 
lines.  
7.4.1. miRNA analysis from conditioned media  
miRNA was extracted from conditioned media from the SKBR3-P, SKBR3-T and 
SKBR3-L cell lines as previously described [255] and extracts were analysed using the 
Nanodrop (Table 7-8). We observed high variability in the A260/230 values. We carried 
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out qRT-PCR analysis for the miRNAs using 100 ng RNA (instead of 10 ng) for the 
RT-PCR step and RNU48 endogenous control. The standard deviations between the 
biological replicates were quite high (Table 7-9) which could be due to the variability 
seen in the A260/230. The endogenous control RNU48 also had variable Ct values 
suggesting it is not an appropriate control for this experiment (Table 7-9). We observed 
detectable Ct values for all miRNAs tested in this study qRT-PCR analysis (Table 7-9) 
(Figure 7-7). Fold changes were calculated using the comparative Ct method using the 
SKBR3-P CM as a control. No significant alterations were seen in the miRNAs tested 
(Table 7-10) but this possibly due to the high deviations between the samples. 
 
Table 7-8: Quantification of concentration (ng/ µL), total RNA (µg) and assessment of 
RNA purity by A260/280 and A260/230 ratios of RNA extracts from conditioned media from 
SKBR3, SKBR3-T and SKBR3-L cell lines. 
 
 
 
 
Sample Conc (ng/µL) 
Total RNA 
(µg) 
A260/280 A260/230 
SKBR3-P #1 67.7 2.0 2.0 6.9 
SKBR3-P #2 69.8 2.1 2.0 0.5 
SKBR3-P #3 66.0 2.0 2.0 1.0 
SKBR3-T #1 64.3 1.9 2.0 4.5 
SKBR3-T #2 72.6 2.2 2.0 5.7 
SKBR3-T #3 70.2 2.1 2.0 0.5 
SKBR3-L #1 63.6 1.9 2.0 3.7 
SKBR3-L #2 67.8 2.0 2.0 5.1 
SKBR3-L #3 68.5 2.1 2.0 1.0 
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Replicate 1 Replicate 2 Replicate 3 AVG std dev
SKBR3-P-CM 
miR-9 38.9 38.7 39.7 39.1 0.5
miR-221 34.0 29.0 30.5 35.3 2.6
miR-222 29.4 28.6 30.3 38.4 0.9
miR-224 32.2 32.4 32.7 31.2 0.3
RNU48 30.5 31.0 32.8 31.6 1.2
SKBR3-T-CM
miR-9 34.0 34.1 38.0 32.5 2.3
miR-221 30.5 32.6 31.7 29.4 1.1
miR-222 28.1 29.7 30.0 29.3 1.0
miR-224 28.9 30.2 32.4 28.9 1.8
RNU48 26.4 29.6 31.7 32.4 2.7
SKBR3-L-CM
miR-9 36.4 38.9 40.0 30.5 1.8
miR-221 33.1 32.6 31.7 32.0 0.7
miR-222 29.1 28.3 29.4 31.4 0.6
miR-224 31.0 32.6 32.4 29.3 0.9
RNU48 29.6 29.8 31.7 30.4 1.2
Table 7-9: miR-9, -221, -222, -224 and RNU48 Ct values for each biological replicate 
for the SKBR3-P, SKBR3-T and SKBR3-L conditioned media. Average Ct values 
(AVG) and standard deviations (std dev) for each cell line.  
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miR-9 miR-221 miR-222 miR-224
SKBR3-T 3.0  1.4 -6.1  2.3 -4.1  1.2 -1.2  0.9
SKBR3-L -1.3  1.7 -5.2  2.5 -1.5  0.5 -1.6  0.9
A B
C D
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7-7: Amplification plots for (A) miR-221, (B) -222, (C) -224 (D) RNU48 for the 
SKBR3-P-CM, SKBR3-T-CM and SKBR3-L-CM. 
 
Table 7-10: Expression analysis of miRNA in conditioned media from SKBR3-T and 
SKBR3-L cell line compared to the parental cell line. Fold changes were calculated 
using the comparative Ct method. 
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Sample ng/ul A260/280 A260/230 
082 pre 4.8 0.7 0.1
082 post 4.7 0.7 0.1
09 pre 3.6 0.9 0.2
09 post 3.9 0.9 0.2
7.5 miRNA analysis from serum samples  
As shown previously, miRNAs are stable and can be successfully extracted from 
conditioned media. Using pre- and post-treatment serum samples from the TCHL trial 
(outlined in Section 2.27) (neoadjuvant trial comparing trastuzumab and/or lapatinib 
with chemotherapy in HER2 positive breast cancer), we extracted miRNAs using the 
miRCURY RNA Isolation Kit - Biofluids (Exiqon). We initially extracted two samples; 
patient #09 from the TCH arm A and patient #082 from the TCHL arm B (Table 7-11). 
miR-9, -221 and -222 were detectable in both sets of patient sera, however, miR-224 
was not detectable (Table 7-12) (Figure 7-8). RNU48 was undetermined for patient 
#082 and quite variable for patient #09 (Table 7-12). We calculated the fold change 
differences between pre- and post-treatment in patient no 09 and determined the miR-9, 
-221 and -222 expression are elevated post treatment (Table 7-13). 
 
Table 7-11: Nanodrop analysis of serum extracted from pre and post TCHL samples 
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Table 7-12: Ct values for TCHL serum samples, pre- and post-surgery, for miR-9, -221, 
-222, -224 and the endogenous control RNU48. Ct values are represented ± standard 
deviation of technical triplicates. Undet represents undetermined values i.e.> 40 cycle 
thresholds. 
09 Pre 09 Post 082 Pre 082 Post
miR-9 38.1  0.6 37.8  0.9 39.2   0.1 38.9  0.8
miR-221 28.1  0.0 28.7  0.1 29.9  0.0 29.5  0.1
miR-222 27.2  0.1 29.0  0.1 28.2  0.1 30.0  0.2
miR-224 Undet Undet Undet Undet
RNU48 33.7  0.4 39.6  0.5 Undet Undet
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A B
C D
E
Patient #09 Fold Change  Std Dev
miR-9 74.5   0.9
miR-221 39.8  0.1
miR-222 17.0  0.1
 
 
 
 
 
Figure 7-8: Amplification plots for (A) miR-221, (B) -222, (C) -224 (D) -9 and (E) 
RNU48 in TCHL serum samples (Patient #082 and #09).  
 
Table 7-13: Expression analysis of miR-9, -221 and -222 in serum from Patient #09 
(complete response) after treatment on the TCH arm A. Fold changes were calculated 
using the comparative Ct method. 
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7.6 Summary 
In this study, we optimised the extraction of miRNA from FFPE derived tissues. 
Analysis of miRNA extracted from HER2 positive tumour tissues in FFPE patient 
samples by Nanodrop, Bioanalyzer and qRT-PCR shows that intact miRNA was 
successfully extracted and is suitable for use in down-stream expression analysis. Using 
this information, we examined miRNA expression of miR-221, -222,-224 and -9 in a 
cohort of HER2 positive breast cancer patients who either achieved a DCR or who 
relapsed (non-DCR). Interestingly, we observed the same trends in expression of miR-
221, -222,-224 and -9 as observed in the acquired resistant cell lines. miR-221, -222 and 
-9 expression is elevated in the non-DCR cohort compared to the DCR cohort and miR-
224 is decreased in the non-DCR cohort compared to the DCR cohort. With regards 
innate trastuzumab resistance, the results seen in the non-DCR cohort follow the same 
elevated trend observed in miR-221 and -224 expression. These preliminary results 
confirm the trends in miRNA expression seen in the acquired trastuzumab resistant cell 
lines and in two of the miRNAs in the innate trastuzumab resistant cell lines. However 
the differences in expression levels were not statistically significant. This may be due to 
the small number (n = 16) of samples in this study and a larger patient study would be 
required to confirm that these miRNAs may have potential as biomarkers of 
trastuzumab resistance.  
 
We also successfully extracted miRNAs from conditioned media. The A260/280 ratio of 
2.0 suggest ‘pure’ RNA [289]. However, the A260/230 ratios were extremely variable 
between samples and this suggests contamination from the extraction procedure or the 
starting material. Low A260/230 ratios are related to phenol carryover from the extraction 
procedure which may account for the low ratio seen in SKBR3-P #2, SKBR3-T #3, 
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SKBR3-P #3 and SKBR3-L #3. High A260/230 ratios are generally associated with 
problems in the measurement e.g.: a dirty pedestal or using a different pH solution to 
blank the samples initially. However, the samples were eluted in nuclease free H2O and 
the Nanodrop was blanked using the same so this does not account for the high ratios 
observed in the SKBR3-P #1, SKBR3-T #1, SKBR3-T #2, SKBR3-L #1 and SKBR3-L 
#2. We also collected the conditioned media in media with added serum. The protein in 
serum may have carried through the reaction. The variability in the samples may 
account for the variability seen downstream in the Ct values and the high standard 
deviations in the qRT-PCR analysis.  Despite this, all four miRNAs were successfully 
detected in the conditioned medium which suggests that they are secreted and thus may 
have potential as extracellular biomarkers that may be detected in patient sera. 
 
We initially examined 2 patient serum samples from the TCHL trial. Similar to the 
conditioned media RNU48 does not appear to be a suitable endogenous control for these 
studies. However, 3 of the 4 miRNAs tested were successfully detected.  
 
This provides proof in principle that miR-221, -222 and -9 can be detected in patient 
sera. Further work using a more appropriate endogenous control, one that is stable in 
normal healthy sera, will be required to determine their predictive biomarker potential 
and the possibility of looking at miRNAs in serum samples as predictive biomarkers for 
trastuzumab treatment. 
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8.1. Introduction 
Trastuzumab is a monoclonal antibody approved for the treatment of HER2 positive 
breast cancer. It has become a standard of care for the treatment of HER2 positive 
tumours in both the metastatic and adjuvant settings. Lapatinib, a dual HER2/EGFR 
tyrosine kinase inhibitor, in combination with capecitabine is an approved treatment for 
HER2 positive advanced or metastatic breast cancer that has previously been treated 
with anthracyclines, taxanes and trastuzumab. However, some patients do not respond 
initially (de novo or innate resistance), and those who initially respond frequently 
develop resistance within 1-2 years (acquired resistance). Resistance to HER2 targeted 
therapies has been extensively investigated [145, 247, 290, 291]. However, biomarkers 
of resistance and strategies to overcome resistance have yet to be approved. miRNAs 
are potential biomarkers that may possess valuable information regarding resistance and 
prognosis [292]. In recent years, their expression and alterations have been linked with 
diseases including breast cancer [184, 293]. As access to fresh tissues is difficult the 
most common patient material is archived FFPE tumour blocks [283]. The process of 
formalin fixation and paraffin embedding has degradative effects upon tissue 
components including DNA and RNA; however, miRNAs remain stable after this 
process [294]. Therefore miRNAs may hold potential as predictive biomarkers of 
resistance to trastuzumab and lapatinib. They may also lead to the identification of new 
targets to overcome resistance.  
 
Initially in this study, a panel of previously generated acquired resistant cell lines were 
characterised with regard to drug sensitivities, doubling times and migratory potential. 
Furthermore, identification of miRNAs associated with acquired trastuzumab and 
lapatinib resistance in HER2 positive breast cancer cells and determination if these 
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miRNAs are also involved in innate resistance. In parallel, a number of FFPE miRNA 
extraction methods were investigated to identify optimal extraction of miRNA from 
these precious tissue sources. Expression analysis was carried out of the miRNAs 
identified from the cell lines in a cohort of FFPE samples from HER2 positive breast 
cancer patients who are classified as durable complete responders (DCR > 36 months in 
remission) and non-DCR (progression < 12 months) to trastuzumab-based therapy. 
Preliminary miRNA expression analysis in patient sera was carried out using samples 
obtained from a neoadjuvant clinical trial (TCHL). 
 
8.2. Characterisation of acquired trastuzumab and lapatinib resistant 
cell lines 
An acquired trastuzumab resistant cell line SKBR3-T and lapatinib resistant cell line, 
SKBR3-L were previously created by continuous exposure to trastuzumab or lapatinib 
for 6 months (Figure 2-1). The SKBR3-T cell line was confirmed as resistant to 
trastuzumab treatment (Figure 3-1) compared to the parental and the SKBR3-L cell line 
is resistant to both lapatinib and trastuzumab (Figure 3-1) (Figure 3-3). One of the 
issues encountered while working with the resistant cell lines was instability of the 
resistant phenotype. A potential explanation is culturing in difference sera. The resistant 
cell line models were tested in two different batches of serum and a significant 
difference in resistance was determined (Figure 3-2). Serum is a vital ingredient for the 
growth of cells in vitro and is an extremely complex mixture. It is comprised of growth 
factors, transport proteins, trace elements and hormones which are essential for active 
cellular proliferation [295]. Proteomic analysis by Zheng et al. identified that protein 
concentrations and abundance were relatively stable among all sera tested, however, the 
levels of growth factors varied between samples. Interestingly, serum which promoted 
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cell proliferation contained the highest levels of growth factors [296]. Previously, 
growth factors such as transforming growth factor 1 (TGF1) [297] and insulin-like 
growth factor binding protein 2 (IGFBP2) [298] have been implicated in multidrug and 
chemotherapy resistance respectively. The significant loss of resistance in the acquired 
resistant cell lines is potentially due to the levels growth factors present in different 
batches of serum. Future proteomic analysis of the serum the cells were conditioned in 
compared to the new batches of serum may identify the main growth factor that is 
causative in the loss of the resistant phenotype. 
 
One way to avoid this issue would be to work with the same batch of serum that the cell 
lines were conditioned in, however, this is difficult to achieve. Another option would be 
to culture in batchless ‘chemically defined’ serum. This serum contains no proteins, 
hydroslyates or components of unknown composition and is animal origin free [299]. 
Each component in this serum is known and this eliminates the variability seen between 
batches of serum. Another option is to use a defined growth factor composition such as 
those used for primary culture. Chemically defined serum or primary culture growth 
factors may be advantageous but would need to be tested with respect growth, 
morphology, doubling times, miRNA, mRNA and protein expression profiles and drug 
sensitivity to determine if they cause any significant alterations in the cell lines. 
 
The doubling times of our panel of acquired resistant SKBR3 cell lines was investigated 
and lapatinib conditioning of the SKBR3 was determined to significantly increase the 
doubling time of the SKBR3-L compared to the SKBR3-P cells (Table 3-1) (Figure 3-
4). This suggests lapatinib resistance is associated with a slower growth rate which is 
later discussed in relation to CDKN1A expression in 8.3.3. The migratory properties of 
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the cell lines were also investigated by wound scratch assay [253], using two time 
points, 24 and 48 h. The SKBR3-T cell line was significantly more migratory than the 
parental after 48 h (Figure 3-5). Interestingly, the SKBR3-L cell line is significantly 
more migratory than the SKBR3-P and SKBR3-T cell lines at 48 h (Figure 3-5). 
Therefore, although the SKBR3-L cells have a slower growth rate they are highly 
migratory. It has previously been reported that lapatinib treatment in triple negative cell 
lines increases the aggressive phenotype of these cells through down-regulation of miR-
7 [212]. Enhancement of migration and invasion in the TNBC cells was due to over-
expression of cyclooxygenase-2 (COX2) and EGFR and down-regulation of miR-7. 
Interestingly, the SKBR3-L cell lines have increased levels of EGFR and pEGFR 
compared to the SKBR3-P [300]. This may contribute to the increased migratory 
potential of these cells compared to the parental cells. Further work would be required 
to determine if this increase in the EGFR pathway is associated with increased 
migration. 
 
Another acquired trastuzumab resistant cell line, BT-474-Tr and its parental BT474-P 
were generously gifted from UCLA [123] and another lapatinib acquired resistant cell 
line, HCC1954-L was previously created by Dr. Mc Dermott [247]. The BT-474-Tr cell 
line was confirmed as resistant to trastuzumab treatment (Figure 3-6) but extremely 
sensitive to lapatinib inhibition (Figure 3-7). The HCC-1954-P and HCC-1954-L cell 
lines are both innately resistant to trastuzumab treatment (Figure 3-8) and the HCC-
1954-L cells were confirmed as resistant to lapatinib inhibition (Figure 3-9). Previously, 
microarray analysis of the SKBR3-P, SKBR3-T and SKBR3-L cell lines was carried out 
in UCLA (one replicate each). This data was used for potential target gene 
identification. Previously, breast cancer stem cells (BCSCs) have been reported as 
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chemo-resistant [301, 302] and therefore a panel of stem cell markers were examined in 
our microarray data and significantly altered stem cell markers were identified in the 
SKBR3-T (Table 3-2) and SKBR3-L (Table 3-3) cell lines. Interestingly, ALDH1A1 
was altered in both resistant cell lines. Consistent with the microarray data, ALDH1A1 
protein expression is slightly decreased in the SKBR3-T and is significantly increased 
in the SKBR3-L cell line (Figure 3-10). The ALDH1 enzyme family is comprised of 
ALDH1A1, ALDH1A2 and ALDH1A3. It was previously assumed that ALDH1A1 was 
the primary determinant of ALDEFLUOR activity, however; other ALDH family 
members including ALDH1A3, ALDH2, ALDH4A1, ALDH5A1, ALDH6A1 and 
ALDH7A1 also determine activity [303]. Duru et al. have previously shown that HER2 
positive breast cancer stem cells are associated with increased ALDH activity and 
aggressiveness [304].  
 
A collaboration with Dr. Gallagher’s ‘Stemness’ group in Trinity College Dublin 
examined the ALDH activity of the SKBR3-P and SKBR3-L cell lines. This assay can 
identify stem and progenitor cells as the enzyme ALDH is highly expressed in these cell 
types [305]. ALDH positivity identifies a stem cell population and using the 
fluorescence nature of this assay ALDH+ cells can be identified and sorted from 
ALDH- cells. Initially the ALDH expression of the SKBR3-P and SKBR3-L cell lines 
was examined. A high population of ALDH+ cells in the SKBR3-P cell line was 
identified and a significantly lower population in the SKBR3-L cell line (Figure 3-11) 
(Table 3-4). This conflicts with the results observed in the microarray and 
immunoblotting. However, as the ALDEFLUOR assay detects activity of a number of 
different isoforms and the immunoblotting focused on ALDH1A1 expression this may 
account for the difference in results. The microarray data also suggests that there are 
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alterations in multiple members of the ALDH family including, ALDH2, ALDH5A1, 
ALDH6A1, and ALDH7A1 which have also been associated with ALDEFLUOR 
activity [303]. However, the ALDEFLUOR results suggest that an increase in a stem 
cell population is not likely to play a causative role in the resistant phenotype of the 
SKBR3-L cells. 
  
8.3. microRNA expression analysis 
8.3.1.  Cell line analysis 
miRNA profiling was carried out on the acquired trastuzumab and lapatinib resistant 
SKBR3 breast cancer cells. Analysis of TLDA identified ten (Table 4-1) and thirteen 
(Table 4-2) miRNAs that were altered in the acquired trastuzumab and lapatinib 
resistant cell lines, respectively. Validation of these miRNAs by individual qRT-PCR 
confirmed that miR-221, miR-222 and miR-9 were significantly up-regulated in the 
SKBR3-T cell line (Table 4-3). miR-224 was included in the validation due to its 
position on the same chromosome as miR-221 and -222 and observed it was 
significantly down-regulated (Table 4-3). Validation in the SKBR3-L cell line 
determined miR-30a-3p and miR-9 were significantly up-regulated and miR-221, miR-
224, miR-375, miR-550 and miR-92a were down-regulated (Table 4-4). However, miR-
30a-3p was excluded as it followed an opposite trend from the TLDA analysis. miR-221 
and -222 were selected for validation in the SKBR3-L despite miR-222 not being 
altered in the TLDA data. As miR-221 and -222 are clustered genes located which 
contain identical seed sequences suggesting that these miRNA are expressed together 
and function on the same target mRNAs (356).   
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To determine that these alterations were not specific to the SKBR3 cell line, expression 
of these miRNAs in other cell line models of acquired trastuzumab (BT474-Tr) and 
lapatinib (HCC-1954-L) resistance was investigated. miR-9 expression was unaltered 
and miR-224 expression was turned off in the acquired trastuzumab resistant BT-474-Tr 
cells compared to the parental cells (Table 4-5). miR-221 and miR-222 were 
significantly up-regulated in the BT-474-Tr cells (Table 4-5). miR-9 was significantly 
up-regulated and miR-222 was significantly down-regulated in the HCC-1954-L cell 
line (Table 4-6).  
 
The miRNA profiles for each drug were different as miR-221, -222, -224 and -9 are 
associated with acquired trastuzumab resistant cell lines. miR-222 and -9 are associated 
with acquired lapatinib resistance. However, miR-222 is a common alteration in both 
the acquired trastuzumab and lapatinib cell lines. 
 
The expression of the altered miRNAs was also investigated in a panel of innately 
sensitive and resistant HER2 positive cell lines. The trastuzumab sensitive cell lines 
(SKBR3 and BT-474) were used for the comparative calculations. miR-221 expression 
was significantly higher in 5/6 innately resistance cell lines tested and miR-222 was 
higher only in 3/6 of the innately resistant cell lines compared to the sensitive cell lines 
(Table 4-7). miR-224 was lower in 5/6 of the innately resistant cell lines compared to 
the sensitive cell lines. miR-9 expression was lower in 5/6 of the innately resistant cell 
lines in contrast with the up-regulated expression in the acquired resistant cell lines 
(Table 4-7). These results show that altered expression of miR-221 and miR-224 is not 
only seen in the acquired resistant cell lines but also in the innate resistant cell lines and 
suggest that these miRNAs could be possible biomarkers of trastuzumab resistance. 
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Low expression of miR-9 may be a predictive biomarker of specifically innate 
trastuzumab resistance. miR-222 is not a marker of innate trastuzumab resistance but 
could be used as an indicator of acquired trastuzumab resistance. 
 
miR-221, miR-224 and miR-9 expression was also investigated in the innate lapatinib 
resistant cell lines. The SKBR3, BT-474, HCC-1419 and HCC-1954 cell lines are 
classed as sensitive cell lines and were used for the comparative calculations. miR-221 
expression was lower in 2/4 innately resistant cell lines, miR-224 was lower in all 4 
innately lapatinib resistant cell lines and miR-9 expression was higher in 1/4 innately 
resistant cell lines (Table 4-8). Low expression of miR-224 maybe an indicator of innate 
lapatinib resistance. 
 
Ye et al. determined that miR-221 expression may promote trastuzumab resistance by 
targeting PTEN [207], which has been previously reported as a mechanism of 
trastuzumab resistance [103].  They also observed that miR-221 over-expression in the 
SKBR3 cell lines conferred trastuzumab resistance and increased the migratory and 
invasive properties of this cell line. This is the only reported miRNA involved in 
trastuzumab and/or lapatinib resistance from our panel of miRNAs identified. 
 
The effect of a short term treatment of trastuzumab and lapatinib on the SKBR3-P cells 
was investigated. This experiment also investigated if the miRNA alterations are caused 
by long term exposure or also occur following short-term exposure of drug.  No changes 
were seen in the expression of the miRNAs after 24 and 48 h treatment with 
trastuzumab (10 µg/mL) (Table 4-9). A significant down-regulation of miR-221, miR-
222 and miR-224 was observed in the SKBR3-P cell lines after lapatinib treatment (24 
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h) (Table 4-10). Thus, the miRNAs identified in the trastuzumab acquired resistant 
SKBR3-T cell line are specifically associated with long term exposure and not short 
term drug treatment. The short term treatment with lapatinib however, has a significant 
effect on the miRNAs after 24 h but these changes are reversed after 48 hours. This 
reversal in miRNA expression needs to be explored further.  
8.3.2. Comparison of FFPE miRNA extraction kits 
During the FFPE process, from collection and fixation and to the dehydration and 
embedding process each step can impact the quality of the final embedded sample. 
Integrity of DNA and RNA from FFPE samples is affected by the fixation length and 
cross-linking that can occur from formalin [306]. Other factors that may result in 
fragmented DNA and RNA are the temperature at which the sample is embedded and 
the length of storage [306]. RNA can become oxidised at the exposed surface of the 
FFPE sample [306]. The optimal storage conditions for FFPE after one year was 4°C as 
intact RNA was still detectable [306]. Formalin and the chemical modifications it has 
upon RNA negatively impact on RT-PCR. The degree of formalin modifications on 
RNA is dependent on fixation time and the RNA isolation procedure. Cross-linking 
occurs at the 5’ and 3’ ends of RNA and efficiency of PCR is greatly reduced. PCR 
amplification of FFPE RNA samples is best suited to short targets [306] which is why 
miRNAs are suitable for investigation. Gene expression analysis utilises TaqMan PCR 
which can be carried out on as little as 1 ng of starting material [307]. This overcomes 
one of the problems frequently encountered in FFPE as the RNA yields can be quite 
low.  
 
Recent improvements in RNA extraction kits include a proteinase K step which 
solubilised the FFPE tissue completely, promoting breakdown of the formalin cross-
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links, inhibiting RNases that may still be stable and successfully extracting RNA [307, 
308]. Extraction methods with a column DNase digestion step were found to yield 
detectable RNA from FFPE samples [307]. Increasing the temperature of the formalin 
free buffer removed the methlyol groups from the bases which restored template activity 
to RNA from FFPE samples [308]. FFPE sections were susceptible to RNA degradation 
by light and air, however, storage of the FFPE blocks in the open or protected from both 
light and air did not affect the RNA quality if the sample for extraction was not taken 
directly from the top of the block [306].  
 
FFPE extraction kits were assessed; firstly using CCDB generated using SKBR3-P 
cells. Three commercially available kits that are most commonly used for miRNA 
extraction were used; RecoverAll (Ambion), miRNeasy (Qiagen) and High Pure FFPE 
RNA Micro Kit (Roche). A previous comparison of these 3 kits showed that miRNA 
extracted from FFPE tissues is more stable and easily recovered than mRNA and the 
RecoverAll kit was the preferred extraction kit for miRNA [294]. Another important 
criterion for extraction of miRNA is the specimen size. Previous investigations into the 
optimal thickness of sections for miRNA extraction from FFPE samples suggested that 
the optimal section thickness was 10 µM or greater for optimal miRNA analysis. In 
addition to testing 10 µM sections we also investigated cores of 1.0 mm and 1.5 mm. 
The reasoning for isolating cores from tissue samples is disease specific areas e.g.: 
HER2 positive can be isolated areas of tumour as sections which should minimise the 
amount of normal tissue in the sample. In comparison with Doleshal et al., we found 
that the RecoverAll kit had good overall yields of RNA as did the RNeasy kit (Table 7-
1). The Roche kit had high variability in yields of RNA (Table 7-1). When comparing 
the sections (10 µM) and cores, sections produced greater yields. As the cores focus on 
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a smaller more specific area of FPPE block than a section, it is not surprising to find 
smaller yields in our core samples. 
 
 Bioanalyser analysis of all samples in comparison to a cell line positive control showed 
that the RecoverAll and miRNeasy kit yielded small peaks at the small RNA positions 
but no evidence of 18S and 28S peaks for total RNA (Figure 7-2). As the RNA is 
degraded from the embedding process, RIN values tend to be lower in FFPE samples 
even as low as 1.4 [309]. In this study, the RIN values ranged from 1.1-1.8 suggesting 
the RNA has been degraded in the overall embedding process but is acceptable for 
acceptable for downstream qRT-PCR analysis. The RIN value has been suggested as 
superior over the A260/280 ratio in breast cancer samples [310] so it is best to focus on 
Bioanalyser (Agilent) analysis for determination of intact RNA and the Nanodrop 
(Thermo scientific) for determination of concentration. The conclusion from this study 
was sufficient miRNA could be extracted from two 1.0 mm cores in HER2 positive 
specific areas using the miRNeasy kit.  
8.3.3.  miRNA analysis in the HER2 positive FFPE tumour samples 
In collaboration with Dr. Giuseppe Gullo and ICORG, access was obtained to a cohort 
of patients (n=16) from St. Vincent’s Hospital, Dublin. The study consists of two 
cohorts of HER2 positive metastatic breast cancer patients who received trastuzumab-
based treatment; cohort one includes patients who are classed trastuzumab sensitive 
(durable complete responders, DCR as defined by RECIST 1.0 [311]) (n=6) and cohort 
two included patients who are classed trastuzumab resistant (non-durable complete 
responders, non-DCR) (n=10).  Approximately, 9% of patients who received first line 
chemotherapy and trastuzumab achieved DCR lasting for more than 36 months [101]. 
DCR was more frequently observed in ER negative patients (DCR-14%) and in those 
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with liver metastases [101]. The DCR rate for patients who received trastuzumab with 
first line chemotherapy was 16 %, however, DCR was completely absent in patients 
who received trastuzumab in second line of chemotherapy. These patient samples were 
chosen for miRNA investigation as a follow up of the previous cell line work as they 
may lead to potential biomarkers of response to trastuzumab based therapy and early 
identification of responders or patients who are likely to achieve DCR. The tumour 
sample available are FFPE specimens and the RNA extraction procedure described in 
section 2.24 was used. 
 
Initially, the miRNAs identified in Chapter Four were examined in this FFPE study. 
HER2 staining was used to identify the HER2 positive areas in the tumour specimens 
from normal tissue. miRNA was successfully extracted from these difficult tissue 
specimens. Interestingly, the miRNA expression profiles followed the same trend as 
observed seen in the acquired trastuzumab resistant cell line (Figure 7-6). miR-221, -
222 and -9 expression is higher and miR-224 is lower in the non-DCR tumours 
compared to the DCR tumours. Although this is a very small cohort these preliminary 
data suggest that these miRNAs maybe predictive biomarkers of trastuzumab resistance. 
Recently, miR-221 has been associated with PTEN expression and trastuzumab 
resistance in HER2 breast cancer cell lines [207]. The authors suggest that miR-221 
may be a biomarker of progression and poor overall survival in HER2 positive breast 
cancer. miR-222 expression is reportedly involved in resistance to adriamycin and 
docetaxel in breast cancer [312]. Both miR-221 and -222 have been associated with 
tamoxifen resistance [274]. miR-9 has previously been shown to predict nasopharyngeal 
carcinoma (NPC) metastasis in plasma samples [313] and is a potential biomarker for 
local recurrence in ER positive breast cancer [314]. miR-224 expression has been 
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associated with cisplatin resistance in lung adenocarcinomas [315] and ovarian papillary 
serous carcinoma [316]. Further miRNA microarrays and microarrays should be carried 
out on these two cohorts to identify other key miRNAs or mRNAs that are involved in 
trastuzumab resistance. 
 
In summary, elevated levels of miR-221, -222 and decreased levels of miR-224 maybe 
predictive of acquired trastuzumab resistance. Elevated levels of miR-221 and low 
levels of miR-224 may be potential predictive biomarkers of both innate and acquired 
trastuzumab resistance. Elevated levels of miR-9 and low levels of miR-222 may be 
predictive of acquired lapatinib resistance. Lower levels of miR-221 and -222 are 
predictive of innate lapatinib resistance. Further exploration of these miRNA signatures 
in a larger cohort of trastuzumab responders and non-responders is needed to confirm 
their predictive potential. To the best of our knowledge, this is the first report of miR-9, 
miR-222 and miR-224 and their potential roles as predictive biomarkers of trastuzumab 
resistance in HER2 positive metastatic disease. 
 
8.3.4. miRNA analysis in conditioned media 
Circulating miRNAs have come to the fore-front of translational research as non-
invasive biomarkers of disease. As we identified potentially novel biomarkers of 
resistance in patient tumours, we decided to investigate miRNA expression in patient 
sera samples from the TCHL trial. To determine if these miRNAs are potentially 
secreted from HER2 positive breast cancer cells we initially tested conditioned media 
from cell lines. We successfully isolated RNA from conditioned media and carried out 
miRNA analysis for the 4 miRNAs (miR-221,-222,-224 and -9) (Table 7-8). We 
observed high variability within the A260/230 values for the RNA extracted from the 
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conditioned media which may account for the variability observed in the Ct values 
obtained in the qRT-PCR (Table 7-9). This suggests that further optimisation of the 
miRNA extraction of conditioned media is required to eliminate potential sources of 
contamination such as protein or phenol. Another potential contaminant is serum and 
further experiments should be carried out under serum reduced conditions to examine 
the serum affects on conditioned media miRNAs. Despite the variation in the Ct values 
obtained, all 4 miRNAs were detected in the conditioned media, providing evidence that 
they are indeed secreted from the HER2 positive breast cancer cells and thus may be 
potential circulating biomarkers in HER2 positive breast cancer patients. 
 
8.3.5. miRNA analysis in patient sera 
Utilising a new miRNA extraction kit specific for biofluids, we extracted miRNAs from 
two pre- and post- neoadjuvant treatment (TCH or TCHL) serum samples. Nanodrop 
analysis of the miRNA extracts showed low ratios for both A260/280 and A260/230 (Table 7-
11). miR-9, -221 and -222 were detectable, however miR-224 was undetected in both 
patient sera (Table 7-12). miR-221 has previously been identified in prostate cancer 
[317], malignant melanoma [318] and together with miR-222 in hepatocellular 
carcinoma [319] patients serum samples. miR-222 was one of three altered miRNAs in 
case samples compared to controls within the Sister Study cohort in breast cancer serum 
samples [320]. Previously, miR-224 serum expression was identified as down-regulated 
in prostate cancer serum samples [321] and was correlated with predicting survival and 
reflects stage in hepatocellular carcinoma [322]. miR-9 has been reported as a potential 
prognostic and diagnostic serum miRNA in osteosarcoma [323] and is associated with 
prediction of metastases in NPC [324]. RNU48 was detected in only one patient sample. 
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We observed the same variability in RNU48 expression as seen in the conditioned 
media samples.  
 
The endogenous control used in the previous miRNA analysis RNU48, may not be 
ideally suited to the conditioned media and patient sera studies as we saw large 
variation between the replicates and the Ct values ranged from 26.4-32.8. RNU48 is a 
small nucleolar non-coding RNA (snoRNAs) approximately 70 nucleotides in length 
[325]. It has also been show that U6, another endogenous control is not suitable for 
circulating miRNAs [326]. However, there are 19 human control miRNA assays 
available [327] and further optimisation studies should be performed to identify an 
appropriate control for extracellular miRNAs. From this pilot experiment we can 
conclude that 3 of the 4 miRNAs are detectable in patient serum and following 
optimisation of the control further analysis of their expression in the pre- and post-
treatment samples should be performed to determine if they are predictive of response 
to HER2 targeted therapies in the neoadjuvant setting. 
 
8.4. Evidence of miRNA value in resistance 
A meta- analysis of all previously published data for miR-221 and -222 in PubMed, 
Embase, Cochrane, and CNKI databases which included 17 studies involving 1,204 
subjects analysed their prognostic potential for OS and DFS [328]. Elevated expression 
of miR-221 and -222 was associated with poor OS in cancer patients when stratified by 
ethnicity, cancer type, statistical methodology, sample, and quality assessment.  
 
Previously, miR-224 has been identified in cisplatin resistant lung adenocarcinomas and 
CDKN1A is a direct target [315]. They determined that miR-224 is up-regulated in 
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cisplatin resistant lung cancer cell and it regulates the G1/S phase transition of the cell 
cycle.
 
They concluded that the miR-224:CDKN1A signalling pathway could be a 
potential target in overcoming cisplatin resistance in lung cancer. Cyclin-dependent 
kinase inhibitor 1A (CDKN1A/p21
Cip1
) is an important factor in cell cycle progression 
and is up-regulated in both the SKBR3-T and SKBR3-L cell lines. CDKN1A inhibits 
cyclin-dependent kinase 2 and/or cyclin dependent kinase 4 (CDK2/CDK4) and inhibits 
progression of the cell cycle at the G1 phase and is also involved in cellular senescence 
[329]. The increase in CDKN1A may contribute to the increase in doubling time in the 
SKBR3-L cell lines (Table 3-1). In our cell lines, miR-224 expression is down-
regulated in the SKBR3-T and –L cells and turned off in the BT-474-Tr cell line. This 
would indicate that if miR-224 was a direct target for CDKN1A, then its expression 
would be increased therefore having a higher level of cell cycle arrest and senescence. 
This could potentially account for the increased doubling time seen in the SKBR3-L 
cells (Figure 3-4). Altered CDKN1A expression could contribute to the slower growth 
rate we see in the SKBR3-L cell line. Zhu et al. determined that decreased miR-224 
expression is a potentially diagnostic and prognostic tool in non-small cell lung cancer 
(NSCLC) cell lines and primary tissues [330]. 
 
 miR-9 expression has been identified as a prognostic marker in osteosarcoma in both 
tissue [331] and serum [323] samples. More recently, miR-9 has been associated with 
epithelial-mesenchymal transition (EMT) and breast cancer stem cell (BCSC) 
phenotypes [332]. Gwak et al. observed higher expression levels of miR-9 in HER2 
positive and triple negative breast cancer subtypes. miR-9 was associated with higher 
stage and grade, p53 over-expression and a high proliferation index. Interestingly, high 
levels of miR-9 was found in tumours exhibiting CD44+/CD24- phenotype, vimentin 
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expression and E-cadherin loss which are involved in the EMT pathway. In a study by 
Liu et al., they determined that erbin (Erbb2 Interacting Protein) was down-regulated in 
HER2 over-expressing breast cancer cell lines [333]. They also concluded that erbin 
mediates trastuzumab resistance by activation of AKT and that it is essential for the 
regulation of migration. Interestingly, utilising miRWalk miR-9 is predicted to target 
erbin which could be a potential miRNA:mRNA interaction that could be a key player 
in trastuzumab resistance. 
 
The miRNAs which were identified in the innate trastuzumab (miR-221 and miR-224) 
and lapatinib (miR-224) resistant cell lines have predictive potential and could be used 
to screen HER2 positive breast cancer patients prior to therapy to determine innate 
resistance. In the clinic, carrying out miRNA analysis on biopsy specimens could 
identify a subset of patients who will not respond or go on to relapse on trastuzumab 
based therapy. These patients could be placed on a different regimen of alternative 
HER2 targeted therapies.  
 
Biomarkers of acquired resistance may be of value in the neoadjuvant setting. An 
increase in miR-221,-222 and -9 and /or decreased levels of miR-224 in a surgical 
tumour specimen following neoadjuvant therapy could be indicative of acquired 
resistance and suggest that alternative therapies should be administered post-surgery 
rather than continuing trastuzumab therapy as is the current practice. Similarly these 
biomarkers could also be used to monitor disease progression in patients with metastatic 
disease. 
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8.5. Target prediction for miRNAs 
Utilising the miRWalk database potential gene targets were identified for the altered 
miRNAs (miR-221, -222, -224, -9). Cross comparison of the miRWalk results with the 
UCLA microarray dataset narrowed down the potential targets specific to the resistant 
cell lines. miR-221 and miR-222 belong to a miRNA cluster located on chromosome X 
[334]. A common target was identified for miR-221 and -222; angiogenin (ANG) which 
is up-regulated in the SKBR3-T cell lines according to the microarray data (Table 4-11). 
ANG is a pro-angiogenic secreted protein which has been previously associated with 
invasion and metastasis in breast cancer [335]. Chemokine (C-C motif) ligand 2 (CCL2) 
is a potential target for miR-221 in the SKBR3-L cell lines (Table 4-12). CCL2 is a 
chemokine that has stimulatory and migratory effects on mononuclear cells [336] and 
elevated expression has been previously associated with poor prognosis in breast cancer 
patients [337]. miR-224 has reported roles in cellular migration, invasion [338], and 
metastasis in breast cancer cells [339]. In a study by Zhu et al., they found that down-
regulation of miR-224 (anti-miR-224) in MDA-MB-231 cells (triple negative breast 
cancer cells) that over-express Ubc9 (E2-conjugating enzyme that promotes cell 
invasion and metastasis) enhanced their invasive potential [340]. miR-224 targets 
included FBJ murine osteosarcoma viral oncogene homolog B (FOSB) in the acquired 
trastuzumab SKBR3 cell line (Table 4-15) and jun B proto-oncogene (JUNB) in the 
acquired lapatinib SKBR3 cell line (Table 4-16). FOSB has previously been associated 
with poor differentiation of breast carcinomas [341] and JUNB expression has been 
negatively correlated with tumour stage in breast cancer [342].  
 
In the acquired trastuzumab SKBR3 cell line retinoic acid receptor alpha (RARΑ) was 
identified as a potential target for miR-9. RARα is mainly associated with acute 
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promyelocytic leukemia (APL) [343]. Interestingly, HER2 and RARα are located on the 
same chromosome, 17q12-q21. Co-amplification of RARΑα was identified in 23-32% 
of HER2 positive breast cancers [344]. Combination treatment with lapatinib and 
ATRA caused synergistic growth inhibition and apoptosis. In 2013, Alsafadi et al., 
reported that RARα is amplified in 27 % of HER2 positive breast cancers and in the 
SKBR3 cell line [345]. RARα was selected in this study as a potentially druggable 
target for further evaluation in the resistant cells. 
 
8.5.1 miR-9 and Retinoic acid receptor alpha  
miR-9 has reported roles in epithelial and breast carcinoma cells. It has been associated 
with induction of epithelial mesenchymal transition (EMT) by targeting E-cadherin 
[346] and increased motility and migration in breast cancer cells by activation of MYC 
and MYCN [346]. Thus miR-9 may play a role in the increased migration we see in the 
SKBR3-L acquired resistant cell line. It also plays a role in: (i) metastases and 
promotion of cell motility [347], (ii) induction of VEGF and tumour angiogenesis [346], 
(iii) cell growth [348] and (iv) negative regulation of NFkB-1 [349]. Recent studies have 
also identified miR-9 as a potential marker of local recurrence in ER positive breast 
cancer patients [350]. Hyper-methylation of miR-9 can be used as an independent 
prognostic factor for DFS in acute lymphoblastic leukaemia [351].  
 
RARα was identified as an altered target gene in SKBR3-T cells and a potential target 
for miR-9 from miRWalk database cross compared with the microarray (UCLA) (Table 
5-1). RARα was included as a validated target for miR-9, however, the reference cited 
does not specifically link miR-9 and RARα [352]. According to that study RARα is a 
potential target for miR-27a.  
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Initially, the effect of ATRA treatment was investigated in the SKBR3-P, SKBR3-T and 
SKBR3-L cell lines. ATRA is an active metabolite of vitamin A and is also a 
differentiating agent of cancer stem cells [353]. It is primarily and routinely used in the 
treatment of acute promyelocytic leukemia [354]. The SKBR3-P and SKBR3-L were 
sensitive to ATRA treatment; however, interestingly the SKBR3-T cell line was 
insensitive to ATRA inhibition (Figure 5-1) (Table 5-2). The other cell line models of 
resistance were also investigated and determined the BT-474-P, BT-474-Tr, HCC-1954-
P, HCC-1954-L are insensitive to ATRA treatment (Figure 5-2). The EFM-192A cell 
lines are moderately sensitive to ATRA treatment (Figure 5-2).  
 
Combination treatment of these cell lines with ATRA and trastuzumab was also 
investigated further. Combination treatment was significantly more effective than either 
ATRA or trastuzumab treatment alone in the SKBR3-P, -L and –T cell lines despite the 
SKBR3-T cells displaying acquired resistance to ATRA alone (Figure 5-3). Combined 
treatment in the BT-474 (Figure 5-4) and HCC-1954 (Figure 5-5) cell lines showed no 
significant enhancement on growth inhibition. The EFM-192A cells showed an 
enhanced growth inhibition upon combined treatment with ATRA and trastuzumab 
(Figure 5-6).  
 
The effect of combined treatment of ATRA with lapatinib was investigated in our cell 
line models of acquired resistance. We identified that the combination treatment in the 
SKBR3-P, -T and –L cell lines was significantly more effective than either agent alone 
(Figure 5-7). Combined treatment in the BT474 (Figure 5-8), HCC-1954 (Figure 5-9) 
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and EFM-192A (Figure 5-10) cell lines showed no enhanced growth inhibition 
compared to lapatinib treatment alone. 
 
These results suggest that combination treatment with ATRA and anti-HER2 therapies 
is only effective in HER2 positive breast cancer cells that show some sensitivity to 
single agent ATRA. The results also suggest that combined treatment may overcome 
trastuzumab and/or lapatinib resistance in some cases as we see enhanced growth 
inhibition in the acquired trastuzumab and lapatinib SKBR3 cell lines. 
 
mRNA expression of RARα was examined in the SKBR3-T and SKBR3-L cell lines; 
however RARα mRNA is not significantly altered in these cell lines (Table 5-3). RARα 
protein expression is also unaltered in these cell lines (Figure 5-11). Thus we see no 
significant change in the mRNA or protein expression of RARα. As the expression of 
RARα is unaltered it therefore does not account for the ATRA insensitivity observed in 
the SKBR3-T cell line, we investigated further into predicted targets of miR-9 from 
miRWalk. RARβ, RARγ, RxRα and RxRβ are listed as predicted targets for miR-9 and 
cross comparison with the UCLA dataset for the SKBR3-T cell line showed alterations 
in these proteins (Table 5-5). However RARβ (Figure 5-12), RARγ (Figure 5-13) and 
RxRα (Figure 5-14) protein expression is unaltered in the SKBR3-T and BT-474-Tr cell 
lines compared to the parental cell lines. Thus none of these receptors account for the 
difference in sensitivity in the SKBR3-T cell line.  
 
To identify potential alterations that may contribute to the reduced ATRA sensitivity in 
SKBR3-T cells, we examined the retinoic acid receptor signalling pathway. We 
identified significantly altered mRNAs in the SKBR3-T and SKBR3-L cell line 
218 
 
SKBR3-T microarray SKBR3-L microarray
Gene Name Fold Change p-value Gene Name Fold Change p-value
RARA 2.0 7.09E-06 PRAME 3.3 2.06E-11
CDKN1A 1.6 0.00003 PPARG 2.6 1.15E-17
RARA 1.5 0.00532 PRAME 2.0 0.00001
AKR1B1 -1.5 0.00609 RARA 1.8 0.00011
AKR1B10 -1.9 0.00004 RARG 1.6 0.00086
AKR1B10 -2.3 1.93E-07 CDKN1A 1.5 0.00012
CRABP2 -2.3 2.09E-07 RXRB 1.5 0.00349
RARA -2.8 2.13E-09 RARA -1.5 0.01031
AKR1B1 -1.6 0.00154
RARRES3 -2.0 9.65E-06
STRA8 -2.0 0.00001
RXRA -2.2 7.18E-07
AKR1B10 -3.0 3.22E-10
AKR1B10 -3.5 6.43E-12
CRABP2 -4.0 3.62E-13
microarrays (Table 8-1). There were overlapping targets between the cell lines; however 
we did not identify any unique targets that were altered in the SKBR3-T cell line 
compared to the SKBR3-L cell line that could account for the difference in ATRA 
sensitivities. 
 
Table 8-1: Significantly altered genes of the retinoic acid receptor pathway in the 
SKBR3-T and SKBR3-L cell line microarray data. 
 
 
 
219 
 
8.5.2 ATRA response, estrogen receptor status and RARα amplification 
ATRA resistance has been previously linked with lack of ERα expression and low 
expression of RARs [355, 356]. This is supported by Rishi et al. who discovered that 
RARα is significantly increased in ER positive cell lines [357]. In the cell lines we have 
tested, the SKBR3 and HCC-1954 cell lines are ER negative and show different 
sensitivities to ATRA inhibition. Details of the cell lines examined in this study 
regarding their origin, receptor status and sensitivities to the drugs tested are provided in 
Table 8-2. The SKBR3-P and SKBR3-L cell line are sensitive to ATRA inhibition 
alone. The HCC-1954 and HCC-1954-L cells are ER negative and ATRA resistant. The 
BT-474 and EFM-192A cells are ER positive and resistant to ATRA inhibition. This 
disagrees with the findings of van der Leede et al. regarding the association between ER 
status and ATRA sensitivity [356].  
 
Examination of HER2 and RARA co-amplification, in 5 ER negative and 5 ER positive 
cell lines showed that all cell lines with HER2 over-expression showed amplification of 
RARα [344]. All ER positive cell lines contained more RARα than the ER negative cell 
lines and SKBR3 was the only ER negative cell line that has HER2/RARα co-
amplification. This agrees with the findings that SKBR3 cell lines are more sensitive to 
ATRA inhibition than the BT474 cells. Alsafadi et al., determined the SKBR3 cell lines 
as HER2 and RARα co-amplified and the BT-474 cell line as HER2 amplified and 
RARα non-amplified [345]. The SKBR3 cell line was more sensitive to ATRA 
inhibition than the BT-474 cell line, which is consistent with our results. The HCC-1954 
cell line is also RARα non-amplified and was insensitive to ATRA inhibition alone or 
combined treatments. The EFM-192A cell line, which was moderately sensitive to 
ATRA inhibition is also RARα amplified which suggests the differences in sensitivities 
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Cell line
Original 
tissue
Cancer type
HER2 
status
ER/PR 
status
p53 
status
RARA 
amplification
Trast Lap ATRA
ATRA
+ Trast
ATRA 
+ Lap
SKBR3
Pleural 
effusion
Metastatic 
invasive ductal
carcinoma
+ - +
S S S + +
SKBR3-T + R S R + +
SKBR3-L R R S + +
BT474
Primary 
tumour
Invasive ductal
carcinoma
+ + + -
S S R - -
BT-474-Tr R S R - -
HCC1954
Primary 
tumour
Ductal carcinoma + - ± -
R S R - -
HCC-1954-L R R R - -
EFM192A
Pleural 
effusion
Invasive ductal
carcinoma
+ + + + R S M + -
could be due to differences in co-amplification of RARα in our cell lines. This co-
amplification warrant further investigation in our resistant cell line models. 
 
Table 8-2: Summary of cell lines used in this study. The origin of tissue, cancer type, 
receptor and RARA amplification status (±) and sensitivity (S), moderate sensitivity 
(M) or resistance (R) to trastuzumab (trast), lapatinib (lap) and all-trans retinoic acid 
(ATRA) and enhancement (±) with combined treatment is detailed. 
 
Koay et al., examined the levels of apoptosis upon single and combination treatments 
with trastuzumab and ATRA and determined that only the combination induced 
apoptosis in the BT-474 cells [358]. However, in the SKBR3 cells apoptosis was 
induced upon single ATRA treatment and only a small apoptotic induction with the 
combination treatment. They also investigated the effect of single and combined 
treatment on the retinoic acid receptors. They identified a small decrease in RARα in 
the BT-474 upon ATRA, trastuzumab and combination treatment. They also identified a 
slight decrease in RARβ expression upon trastuzumab and combination treatment. No 
alterations in RARα or RARβ expression were determined after 24 h trastuzumab 
treatment in the SKBR3-P and SKBR3-T cell line (Figure 5-15) or in the BT-474-P and 
BT-474-Tr cell line (Figure 5-16). They also investigated ATRA response in a 
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trastuzumab resistant BT-474 variant and found these cells were resistant to ATRA 
growth inhibition alone or in combination with trastuzumab. This agrees with the 
observations for ATRA alone in the BT-474-Tr cell line, however we did see a 
significant response in combined treatment with trastuzumab compared to ATRA 
treatment alone (Figure 5-8).  
 
These results suggest that although miR-9 is up-regulated, expression of retinoic acid 
receptors is not altered in the resistant cell lines. However, sensitivity to ATRA is 
significantly reduced in the SKBR3-T cells. Further analysis of signalling pathways 
altered in response to ATRA in both the SKBR3-P and SKBR3-T would be required to 
elucidate the mechanism of cross resistance to ATRA alone in the SKBR3-T cells. 
 
However, from a clinical perspective the SKBR3-T cells remain sensitive to combined 
trastuzumab and ATRA treatment suggesting that this may be a rationale combination 
to overcome resistance, perhaps in RARα co-amplified HER2 positive tumours. 
 
8.5.3 miR-221 and -222 expression 
miR-221 and -222 are both up-regulated in both of the acquired trastuzumab resistant 
cell lines, SKBR3-T (Table 4-3) and BT-474-T (Table 4-5). This up-regulation appears 
to be specific to acquired trastuzumab resistance as miR-221 is down-regulated and 
miR-222 is unaltered in the SKBR3-L (Table 4-4) and HCC-1954-L cell lines (Table 4-
6).  
 
miR-221 expression has previously been associated with triple negative breast cancer 
(TNBC) [359]. Nassirpour et al. identified that miR-221 is an oncogene and functions in 
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cell proliferation, apoptosis, cell migration, invasion and tumour progression by its 
target p27
kip1
. They found that miR-221 expression is down-regulated and p27
kip1
 
mRNA expression is up-regulated in the SKBR3 cell line compared to normal breast 
tissue. Upon knockdown of miR-221 in the TNBC, they identified an induction of 
apoptosis, decrease in proliferation and suppression of tumourigencity in mice. Li et al., 
determined that miR-221 and miR-222 promote cellular migration in basal-like breast 
cancer (BLBC) cells [278]. They focused on this subtype of breast cancer and found 
that miR-221 and -222 expressions were higher in the highly invasive BLBC compared 
to non-invasive cell lines. They also determined that miR-221 and -222 inhibition slows 
down would closure in the three BLBC cell lines.  
 
The role of miR-221 and -222 was investigated in the acquired trastuzumab resistance 
setting. Initially, transient transductions were carried out to examine the functionality of 
these miRNAs but they were unsuccessful due to increased growth with the scrambled 
controls. In collaboration with Dr. Mulrane, stably transduced cell lines were 
established. The SKBR3-P cell line was used as the model to determine if over-
expression of these miRNAs induced resistance to trastuzumab. The morphology of the 
cell lines after transduction was similar to the non-transduced SKBR3-P (Figure 6-2). 
Over-expression of the miRNAs does not have any effect on the doubling time of the 
cell lines, however, upon trastuzumab treatment the doubling times were significantly 
increased in the SKBR3-P, SKBR3-P-Scrm, SKBR3-P-221 and SKBR3-P-221-222 
(Table 6-2). The resistance profile of these cells was examined by proliferation assays 
and the stably transfected cell lines showed slightly reduced sensitivity to trastuzumab, 
however this was not a statistically significant difference compared to the SKBR3-P cell 
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line. Therefore, these results suggest that miR-221 and miR-222 on their own do not 
cause a resistant phenotype in the SKBR3 cells. 
 
miR-221 and -222 have been previously reported to be involved in migration [278, 
360]. Using the wound scratch assay, an increase in migration was observed in the 
SKBR3-P-Scrm at both 24 and 48 h time points suggesting the stable transduction has 
an effect (Figure 6-6). Over-expression of miR-221 significantly increased the 
migration potential at both 24 and 48 h. miR-222 over-expression did not have a 
significant effect on migration. The co-transfected cell line SKBR3-P-221-222 also 
showed a significant increase in migration after 48 h (Figure 6-6). No significant effect 
of miR-222 was observed on migration; however this could be due to the large standard 
deviations. Migration is an important feature in the ability of cancer cells to spread from 
the primary tumour and metastasise [361]. Although miR-221 does not appear to confer 
trastuzumab resistance in 2D proliferation assays, it enhances migration which could 
contribute to a more aggressive tumour phenotype in breast cancers that progress on 
trastuzumab. Thus targeting miR-221 or relevant downstream targets may be beneficial 
to prevent further metastatic spread. 
 
To identify potential targets for miR-221 and -222, a freely accessible microarray data 
set (n=3) of over-expression of miR-221 and -222 in MCF-7 cells was utilised [279]. 
Bioinformatic analysis of this data identified a number of potential targets and cross 
comparison with the SKBR3-T microarray yielded seven potential targets (Table 6-5). 
Cyclin-dependent kinase inhibitor 1B (CDKN1B/p27
kip1
) was identified and expression 
was examined in our panel of transfected cell lines. CDKN1B expression was 
confirmed as significantly down-regulated in the SKBR3-P-222 and SKBR3-P-221-222 
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B
cell lines (Figure 6-8). This miRNA:mRNA interaction is also supported by a previous 
study that identified this relationship by sequence alignment (Figure 8-1) and luciferase 
reporter assay [278]. This study also led to the investigation of expression in suppressor 
of cytokine signalling (SOCS1) as they also confirmed direct target interaction with 
miR-221 and -222. However, no differences in SOCS1 expression were observed in our 
stable cell lines (Figure 6-9). 
 
 
 
 
 
 
 
Figure 8-1: The binding sites of miR-221 and -222 seed sequences in (A) CDKN1B 
and (B) SOCS1 3’ UTR [278]. 
 
p27
kip1
 is a cell cycle regulator and can exert its function by halting the G1 phase 
progression [362]. It has been previously shown that knockdown of miR-221 has the 
ability to increase the levels of p27
kip1
 and cause a subsequent increase in apoptosis in 
hepatocellular carcinoma [363]. HER2 over-expression in breast tumours correlated 
with low levels of p27
kip1
 [364]. HER2 exerts its suppressive abilities on p27
kip1
 through 
enhanced degradation of p27
kip1
 by the Grb2/MAPK pathway [365]. Nahta et al., have 
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previously reported that decreased levels of p27
kip1 
are associated with trastuzumab 
resistance [290]. More recently, knockdown of a p27 phosphatase; protein phosphatase, 
Mg2+/Mn2+ dependent, 1H (PPM1H) confers resistance to trastuzumab by decreasing 
levels of p27
kip1
[366]. Lee-Hoeflich et al. also determined that in HER2 positive 
tumours low levels of PPM1H is a poor prognostic marker in this subtype treated with 
trastuzumab. In the miR-221 and -222 over-expressing SKBR3-T cell line, p27
kip1
 
mRNA expression is down-regulated (-1.5, p=0.06). miR-221 and -222 mediated down-
regulation of p27
kip1 
levels may occur in trastuzumab resistant cells, although the fact 
that trastuzumab resistance is not induced in the 221/222 transfected cells suggests that 
down-regulation of p27
kip1 
does not play a causative role in the development of 
resistance, at least in this cell line model. 
 
8.5.4 miR-221 and -222 expression and ‘stemness’ 
As miR-221 and -222 have previously been implicated in cancer stem cells [367], the 
mammosphere assay was used to investigate the stem cell potential of our cell lines. 
Mammosphere forming efficiency (MFE) is an important property of cancer stem cells 
that posses tumour regeneration properties [368]. The stemness potential of the SKBR3-
P, SKBR3-T and the stably transfected cell lines was investigated. Unfortunately, the 
SKBR3-L cell lines were not tested due to difficulties encountered with the stability of 
the resistant phenotype. There were no significant differences in the MFE of the 
SKBR3-T cell line compared to its parental (Figure 6-10). Over-expression of miR-221 
significantly increased the MFE of the SKBR3-P cell line (Figure 6-10). We also 
investigated the effect of trastuzumab and lapatinib treatment on the MFE. Lapatinib 
(50 nM) treatment on the SKBR3-T mammospheres significantly decreased the MFE of 
this cell line (Figure 6-11). Trastuzumab treatment had no effect on the MFE of any of 
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the cell lines tested. This appears to suggest that trastuzumab is unable to block 
mammosphere formation. The fold change of miR-221 in the SKBR3-T cells is lower 
than the over-expression levels achieved in the SKBR3-P-221 cell line. This may 
account for the lack of an increase in MFE in the SKBR3-T cells. Also, as the SKBR3 
cell lines are mostly a homogenous population, it is perhaps difficult to identify putative 
cancer stem cells in an in vitro situation.  
 
Breast cancer stem cells (BCSCs) have been characterised by the expression of stem 
cell surface markers CD44, epithelial surface antigen (ESA), epithelial cell adhesion 
molecule (EpCAM) and integrin subunit α6 (CD49f) and the absence of CD24 (Figure 
8-2A). Liu et al., described two stem cell states that breast cancer stem cells can exist in. 
Firstly an epithelial to mesenchymal transition (EMT)-like state which is characterised 
by CD24-/CD44+ expression and secondly a mesenchymal to epithelial transition 
(MET)-like state which is ALDH positive. EMT is characterised by a loss of E-
cadherin, increased expression of transcription factors; slug, snail and twist and an 
increase in mesenchymal proteins such as vimentin [369]. EMT is a key player in cell 
metastasis and invasion of breast cancer [370]. Liu et al. proposed that the two stem cell 
states are inter-convertable and this is regulated by miRNA expression (Figure 8-2 B). 
Interestingly, miR-221 and miR-9 are suggested to induce the EMT-like stem cell state 
in association with miR-100 and miR-155. With regard to the trastuzumab acquired 
resistant cell line, miR-9 and miR-221 expression is up-regulated which could suggest 
the acquired cells are driven toward a more EMT stem cell state. The SKBR3-P cell line 
may be driven towards a MET-stem cell state due to the high levels of ALDH+ cells. 
Potentially, the driver behind acquired trastuzumab resistance is a shift towards an EMT 
stem cell state. This would also suggest the SKBR3-T cell line should be more 
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migratory and invasive. In our assays they showed enhanced migration but not invasion 
(Figure 3-5). To investigate this hypothesis further, future work involving other markers 
of the EMT and MET-like stem cell phenotypes would need to be explored in these 
cells lines. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8-2: Illustration of two stem cell states breast cancer stem cells (BSCS) can exist 
in. (A) BCSC EMT-like state which is EpCAM-CD49f+ and CD24-/CD44+ and a 
MET-like state which is EpCAM+ and ALDH+ (B) The two stem cell states are 
interconvertable which are governed by miRNA expression; miR-9,-100,-221 and -155 
can promote EMT-like stem cells and miR-200, -205 and -93 can induce MET-like stem 
cells [367].  
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8.6. Summary and conclusions 
miRNA expression is altered within the acquired trastuzumab and lapatinib resistant cell 
lines. We identified a miRNA profile of increased miR-221 and -222 expression with 
decreased miR-224 expression is associated with acquired trastuzumab resistance. 
Altered miR-9 expression is relevant to both acquired trastuzumab and lapatinib 
resistance in the SKBR3-T, SKBR3-L and HCC-1954-L cell line models. The miRNA 
profile of decreased miR-221 and -224 expression with increase miR-9 expression is 
associated with acquired lapatinib resistance. These miRNAs may be used as predictive 
markers of resistance. Elevated expression of miR-221 and decreased expression of 
miR-224 is also associated with innate trastuzumab resistance and could be potentially 
used as predictive biomarkers of response to trastuzumab. Through analysis of potential 
targets of miR-9, we identified that ATRA treatment enhances response to trastuzumab 
treatment and overcomes trastuzumab resistance in selected HER2 positive breast 
cancer cell lines. RARα co-amplification may be a potential predictive biomarker of 
response to ATRA to identify the patients who might benefit from this combination 
treatment. Preliminary analysis of the miRNAs identified in the cell line models of 
resistance, in patient samples, suggest that they may have potential as biomarkers of 
resistance in HER2 positive tumours or as circulating biomarkers in serum specimens.  
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